US20070009442A1 - Macrocyclic metal complexes and their use for the production of conjugates with biomolecules - Google Patents
Macrocyclic metal complexes and their use for the production of conjugates with biomolecules Download PDFInfo
- Publication number
- US20070009442A1 US20070009442A1 US11/390,472 US39047206A US2007009442A1 US 20070009442 A1 US20070009442 A1 US 20070009442A1 US 39047206 A US39047206 A US 39047206A US 2007009442 A1 US2007009442 A1 US 2007009442A1
- Authority
- US
- United States
- Prior art keywords
- tris
- tetraazacyclododecane
- carboxymethyl
- oxo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 15
- 239000002184 metal Substances 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 108
- 239000007983 Tris buffer Substances 0.000 claims description 79
- -1 C1-4-alkyl radicals Chemical class 0.000 claims description 74
- 239000000126 substance Substances 0.000 claims description 51
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 48
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 45
- 150000003254 radicals Chemical class 0.000 claims description 41
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 31
- 230000002378 acidificating effect Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 125000006239 protecting group Chemical group 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 18
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 16
- 229910006069 SO3H Inorganic materials 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 150000005840 aryl radicals Chemical class 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 229910021645 metal ion Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 230000005298 paramagnetic effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 229920001222 biopolymer Polymers 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000002540 isothiocyanates Chemical class 0.000 claims description 5
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229910044991 metal oxide Inorganic materials 0.000 claims description 4
- 150000004706 metal oxides Chemical class 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 150000004032 porphyrins Chemical class 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- 229910052770 Uranium Inorganic materials 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- ILOMQDLIPOMYJN-UHFFFAOYSA-N 2-[2-[2,5,8,11-tetramethyl-4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetic acid Chemical compound OC(=O)CNC(=O)C(C)N1CC(C)N(CC(=O)OC(C)(C)C)CC(C)N(CC(=O)OC(C)(C)C)CC(C)N(CC(=O)OC(C)(C)C)CC1C ILOMQDLIPOMYJN-UHFFFAOYSA-N 0.000 claims description 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 claims description 2
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 claims description 2
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 claims description 2
- 102000052052 Casein Kinase II Human genes 0.000 claims description 2
- 108010010919 Casein Kinase II Proteins 0.000 claims description 2
- 108010078140 Cation Transport Proteins Proteins 0.000 claims description 2
- HBBOZFUQJDYASD-UHFFFAOYSA-N Cis-1,3-Dioxide-1,3-Dithiane Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1NC(C)=O HBBOZFUQJDYASD-UHFFFAOYSA-N 0.000 claims description 2
- 102000018832 Cytochromes Human genes 0.000 claims description 2
- 108010052832 Cytochromes Proteins 0.000 claims description 2
- 239000012625 DNA intercalator Substances 0.000 claims description 2
- 102000002045 Endothelin Human genes 0.000 claims description 2
- 108050009340 Endothelin Proteins 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 108010070675 Glutathione transferase Proteins 0.000 claims description 2
- 102000005720 Glutathione transferase Human genes 0.000 claims description 2
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 2
- 108010022901 Heparin Lyase Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 108090000189 Neuropeptides Proteins 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920000388 Polyphosphate Polymers 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 claims description 2
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000003388 anti-hormonal effect Effects 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 150000001576 beta-amino acids Chemical class 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 230000000035 biogenic effect Effects 0.000 claims description 2
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 229940020356 folic acid and derivative as antianemic Drugs 0.000 claims description 2
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 claims description 2
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000000771 oncological effect Effects 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 239000001205 polyphosphate Substances 0.000 claims description 2
- 235000011176 polyphosphates Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004185 ester group Chemical group 0.000 claims 2
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 1
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- RPDJEKMSFIRVII-UHFFFAOYSA-N oxomethylidenehydrazine Chemical compound NN=C=O RPDJEKMSFIRVII-UHFFFAOYSA-N 0.000 claims 1
- 125000001174 sulfone group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 1
- 125000000464 thioxo group Chemical group S=* 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000002872 contrast media Substances 0.000 abstract description 26
- 229940039231 contrast media Drugs 0.000 abstract description 16
- 238000003745 diagnosis Methods 0.000 abstract description 14
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract description 11
- 238000001959 radiotherapy Methods 0.000 abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 474
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 273
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 203
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 160
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 132
- 238000004458 analytical method Methods 0.000 description 113
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 106
- 239000000843 powder Substances 0.000 description 99
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 97
- 239000000741 silica gel Substances 0.000 description 97
- 229910002027 silica gel Inorganic materials 0.000 description 97
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 94
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 89
- 239000000047 product Substances 0.000 description 88
- 239000002904 solvent Substances 0.000 description 86
- 229910021529 ammonia Inorganic materials 0.000 description 78
- 239000012074 organic phase Substances 0.000 description 78
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
- 239000003054 catalyst Substances 0.000 description 62
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 53
- 235000019341 magnesium sulphate Nutrition 0.000 description 53
- 238000001704 evaporation Methods 0.000 description 52
- 230000008020 evaporation Effects 0.000 description 52
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 45
- 229940098773 bovine serum albumin Drugs 0.000 description 45
- 239000000706 filtrate Substances 0.000 description 39
- 239000000243 solution Substances 0.000 description 39
- 229940075613 gadolinium oxide Drugs 0.000 description 37
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 37
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 32
- 229910052763 palladium Inorganic materials 0.000 description 31
- 238000010992 reflux Methods 0.000 description 30
- 239000003446 ligand Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 230000000536 complexating effect Effects 0.000 description 27
- 238000005341 cation exchange Methods 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 239000013067 intermediate product Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 108091006905 Human Serum Albumin Proteins 0.000 description 13
- 102000008100 Human Serum Albumin Human genes 0.000 description 13
- 244000309464 bull Species 0.000 description 13
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 12
- 0 [1*]C(C)N1CC(C)N(*C)CC(C)N(C([2*])C)CC(C)N(C([3*])C)CC1C Chemical compound [1*]C(C)N1CC(C)N(*C)CC(C)N(C([2*])C)CC(C)N(C([3*])C)CC1C 0.000 description 12
- OCZJJSVVVXDQQC-UHFFFAOYSA-N benzyl 2-(trifluoromethylsulfonyloxy)propanoate Chemical compound FC(F)(F)S(=O)(=O)OC(C)C(=O)OCC1=CC=CC=C1 OCZJJSVVVXDQQC-UHFFFAOYSA-N 0.000 description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 11
- 150000001735 carboxylic acids Chemical class 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- PRDNZVJNZCYXHK-UHFFFAOYSA-N benzyl 3-methyl-2-(trifluoromethylsulfonyloxy)butanoate Chemical compound FC(F)(F)S(=O)(=O)OC(C(C)C)C(=O)OCC1=CC=CC=C1 PRDNZVJNZCYXHK-UHFFFAOYSA-N 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- UVSKKLILRRMKTK-UHFFFAOYSA-N benzyl 2-cyclohexyl-2-(trifluoromethylsulfonyloxy)acetate Chemical compound C=1C=CC=CC=1COC(=O)C(OS(=O)(=O)C(F)(F)F)C1CCCCC1 UVSKKLILRRMKTK-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000010668 complexation reaction Methods 0.000 description 6
- 238000011022 operating instruction Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- MLTSBKJUUBAWGA-UHFFFAOYSA-N benzyl 2-(2-bromopropanoylamino)acetate Chemical compound CC(Br)C(=O)NCC(=O)OCC1=CC=CC=C1 MLTSBKJUUBAWGA-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229910003440 dysprosium oxide Inorganic materials 0.000 description 5
- NLQFUUYNQFMIJW-UHFFFAOYSA-N dysprosium(iii) oxide Chemical compound O=[Dy]O[Dy]=O NLQFUUYNQFMIJW-UHFFFAOYSA-N 0.000 description 5
- 230000000269 nucleophilic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- RSSMGVSCJWTWNT-UHFFFAOYSA-N CC(C)C(C)C(=O)N(C)C(C)C Chemical compound CC(C)C(C)C(=O)N(C)C(C)C RSSMGVSCJWTWNT-UHFFFAOYSA-N 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
- HKVLOZLUWWLDFP-UHFFFAOYSA-M hydron;tetrabutylazanium;carbonate Chemical compound OC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC HKVLOZLUWWLDFP-UHFFFAOYSA-M 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- QPUQGGYVBPEAFL-UHFFFAOYSA-N methyl 4-(1,4,7,10-tetrazacyclododec-1-ylmethyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1CCNCCNCCNCC1 QPUQGGYVBPEAFL-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- PTXAGLHJWPSGNR-UHFFFAOYSA-N 2,5,8,11-tetramethyl-1,4,7,10-tetrazacyclododecane Chemical compound CC1CNC(C)CNC(C)CNC(C)CN1 PTXAGLHJWPSGNR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- ACRDZZXVIHGVED-UHFFFAOYSA-N CC(C)C1CCCN(C(C)C)C1=O Chemical compound CC(C)C1CCCN(C(C)C)C1=O ACRDZZXVIHGVED-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- ITATYELQCJRCCK-UHFFFAOYSA-N Mandelic Acid, Methyl Ester Chemical compound COC(=O)C(O)C1=CC=CC=C1 ITATYELQCJRCCK-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- CMQMATVWWLXQIO-UHFFFAOYSA-N benzyl 2-[(2-bromoacetyl)amino]acetate Chemical compound BrCC(=O)NCC(=O)OCC1=CC=CC=C1 CMQMATVWWLXQIO-UHFFFAOYSA-N 0.000 description 3
- KYMCIUJHFWRWGC-UHFFFAOYSA-N benzyl 2-[2-(1,4,7,10-tetrazacyclododec-1-yl)propanoylamino]acetate Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(C)N1CCNCCNCCNCC1 KYMCIUJHFWRWGC-UHFFFAOYSA-N 0.000 description 3
- VNGPFUOVGGKVLP-UHFFFAOYSA-N benzyl 2-[2-oxo-3-(1,4,7,10-tetrazacyclododec-1-yl)piperidin-1-yl]acetate Chemical compound C=1C=CC=CC=1COC(=O)CN(C1=O)CCCC1N1CCNCCNCCNCC1 VNGPFUOVGGKVLP-UHFFFAOYSA-N 0.000 description 3
- DYPNGJPWBWUHRW-UHFFFAOYSA-N benzyl 4-[2-oxo-3-(1,4,7,10-tetrazacyclododec-1-yl)piperidin-1-yl]benzoate Chemical compound C=1C=C(N2C(C(N3CCNCCNCCNCC3)CCC2)=O)C=CC=1C(=O)OCC1=CC=CC=C1 DYPNGJPWBWUHRW-UHFFFAOYSA-N 0.000 description 3
- LCKCTMSZINZHSQ-UHFFFAOYSA-N benzyl 4-[2-oxo-3-(1,4,7,10-tetrazacyclododec-1-yl)pyrrolidin-1-yl]benzoate Chemical compound C=1C=C(N2C(C(N3CCNCCNCCNCC3)CC2)=O)C=CC=1C(=O)OCC1=CC=CC=C1 LCKCTMSZINZHSQ-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229940087646 methanolamine Drugs 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000012217 radiopharmaceutical Substances 0.000 description 3
- 230000003439 radiotherapeutic effect Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YNHKVOGCDPODMT-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCCN1C(=O)C=CC1=O YNHKVOGCDPODMT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- WYZLYWUZERABRL-UHFFFAOYSA-N 2,4-dibromobutanoyl chloride Chemical compound ClC(=O)C(Br)CCBr WYZLYWUZERABRL-UHFFFAOYSA-N 0.000 description 2
- OUADIZVZFBYKSK-UHFFFAOYSA-N 2,5-dibromopentanoyl chloride Chemical compound ClC(=O)C(Br)CCCBr OUADIZVZFBYKSK-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OTDJAMXESTUWLO-FTWQFJAYSA-N 2-amino-9-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OTDJAMXESTUWLO-FTWQFJAYSA-N 0.000 description 2
- ZUDYUQOEAQPQDS-UHFFFAOYSA-N 2-aminopurine-2-thiol Chemical compound NC1(S)N=CC2=NC=NC2=N1 ZUDYUQOEAQPQDS-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- QFQNZYLVKGVGTP-UHFFFAOYSA-N C=CC(C)=O.CCC(C)=O.CN1C(=O)C=CC1=O Chemical compound C=CC(C)=O.CCC(C)=O.CN1C(=O)C=CC1=O QFQNZYLVKGVGTP-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N CC(C)C Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
- RYKMJNPXVYETAR-UHFFFAOYSA-N benzyl 2-(3-bromo-2-oxopiperidin-1-yl)acetate Chemical compound O=C1C(Br)CCCN1CC(=O)OCC1=CC=CC=C1 RYKMJNPXVYETAR-UHFFFAOYSA-N 0.000 description 2
- KKIOCXPSGRAIDD-UHFFFAOYSA-N benzyl 2-(3-bromo-2-oxopiperidin-1-yl)benzoate Chemical compound O=C1C(Br)CCCN1C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 KKIOCXPSGRAIDD-UHFFFAOYSA-N 0.000 description 2
- SPSBPRYNQCDKNK-UHFFFAOYSA-N benzyl 2-(3-bromo-2-oxopyrrolidin-1-yl)acetate Chemical compound O=C1C(Br)CCN1CC(=O)OCC1=CC=CC=C1 SPSBPRYNQCDKNK-UHFFFAOYSA-N 0.000 description 2
- APROLBCJDAAFMZ-UHFFFAOYSA-N benzyl 2-(3-bromo-2-oxopyrrolidin-1-yl)benzoate Chemical compound O=C1C(Br)CCN1C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 APROLBCJDAAFMZ-UHFFFAOYSA-N 0.000 description 2
- XKNGLVLWTPFXJH-UHFFFAOYSA-N benzyl 2-[2-oxo-3-(1,4,7,10-tetrazacyclododec-1-yl)pyrrolidin-1-yl]acetate Chemical compound C=1C=CC=CC=1COC(=O)CN(C1=O)CCC1N1CCNCCNCCNCC1 XKNGLVLWTPFXJH-UHFFFAOYSA-N 0.000 description 2
- HFJFWEIZLDVWGJ-UHFFFAOYSA-N benzyl 2-[[2-(1,4,7,10-tetrazacyclododec-1-yl)acetyl]amino]acetate Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)CN1CCNCCNCCNCC1 HFJFWEIZLDVWGJ-UHFFFAOYSA-N 0.000 description 2
- GLVRCRBEAFARDL-UHFFFAOYSA-N benzyl 2-phenyl-2-(trifluoromethylsulfonyloxy)acetate Chemical compound C=1C=CC=CC=1C(OS(=O)(=O)C(F)(F)F)C(=O)OCC1=CC=CC=C1 GLVRCRBEAFARDL-UHFFFAOYSA-N 0.000 description 2
- WJKJXKRHMUXQSL-UHFFFAOYSA-N benzyl glycinate 4-methylbenzenesulfonate salt Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCC(=O)OCC1=CC=CC=C1 WJKJXKRHMUXQSL-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000004697 chelate complex Chemical class 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- XLXMYMNBHSMTEB-UHFFFAOYSA-N dibenzyl 1,4,7,10-tetrazacyclododecane-1,7-dicarboxylate Chemical compound C1CNCCN(C(=O)OCC=2C=CC=CC=2)CCNCCN1C(=O)OCC1=CC=CC=C1 XLXMYMNBHSMTEB-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- SZCCZBJDRILSGI-UHFFFAOYSA-N methyl 2-bromo-2-[4-(2-ethoxy-2-oxoethoxy)phenyl]acetate Chemical compound CCOC(=O)COC1=CC=C(C(Br)C(=O)OC)C=C1 SZCCZBJDRILSGI-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- CAOMWSBJFZDBBI-UHFFFAOYSA-N tert-butyl 2-[(2-bromo-2-phenylacetyl)amino]acetate Chemical compound CC(C)(C)OC(=O)CNC(=O)C(Br)C1=CC=CC=C1 CAOMWSBJFZDBBI-UHFFFAOYSA-N 0.000 description 2
- NTTHNPZBRZRXRD-UHFFFAOYSA-N tert-butyl 2-[[2-phenyl-2-(1,4,7,10-tetrazacyclododec-1-yl)acetyl]amino]acetate Chemical compound C=1C=CC=CC=1C(C(=O)NCC(=O)OC(C)(C)C)N1CCNCCNCCNCC1 NTTHNPZBRZRXRD-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- XWRZKLKALVJDDS-REOHCLBHSA-N (2r)-2-(diaminomethylideneamino)-3-sulfanylpropanoic acid Chemical compound NC(N)=N[C@@H](CS)C(O)=O XWRZKLKALVJDDS-REOHCLBHSA-N 0.000 description 1
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- AEGSIYIIMVBZQU-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxy-2-sulfanylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AEGSIYIIMVBZQU-CIUDSAMLSA-N 0.000 description 1
- OXXJRPSXRKVBAC-AKKDPBBWSA-N (4S,5R,6R)-3-acetyl-5-amino-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical class C(C)(=O)C1C(C(O)=O)(O)O[C@H]([C@@H]([C@H]1O)N)[C@H](O)[C@H](O)CO OXXJRPSXRKVBAC-AKKDPBBWSA-N 0.000 description 1
- WNDXUFDJFGKDLM-RBWOKHCDSA-N (4s)-4-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4h-imidazol-4-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2s,3s)-1-amino-3-methyl-1-oxopentan-2-yl]amino]-5-ox Chemical compound CC[C@H](C)[C@@H](C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)CC1C=NC=N1 WNDXUFDJFGKDLM-RBWOKHCDSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- RRFHMCFQWRQMCZ-UHFFFAOYSA-N 2-[2-[4,7,10-tris(carboxymethyl)-2,5,8,11-tetramethyl-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetic acid Chemical compound OC(=O)CNC(=O)C(C)N1CC(C)N(CC(O)=O)CC(C)N(CC(O)=O)CC(C)N(CC(O)=O)CC1C RRFHMCFQWRQMCZ-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical group OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical class OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical group C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- SMRZXQLPBYIIND-UHFFFAOYSA-N 4-sulfanyl-1h-pyrimidine-6-thione Chemical compound SC1=CC(=S)NC=N1 SMRZXQLPBYIIND-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
- 108010038638 ACTH (1-17) Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- SHKGHIFSEAGTNL-DLOVCJGASA-N Ala-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 SHKGHIFSEAGTNL-DLOVCJGASA-N 0.000 description 1
- IGVYYYIGRZRCKV-UHFFFAOYSA-N Albuminamide Natural products CCC(C)C(C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CC1=CN=CN1 IGVYYYIGRZRCKV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- CJGOOOUAWBXYCM-UHFFFAOYSA-N CC(NC(=O)C(C)C1=CC=CC=C1)C1=CC=CC=C1.CC1=CC=C(N2CCC(C)C2=O)C=C1.CCC1=CC(C)=CC=N1.CCC1=CC=C(C)C=C1.CCCCCCCCCCCC.CCCCCCCCCCCOC1=CC=C(C(C)C(=O)O)C=C1.CCCCOC1=CC=C(C(C)C(=O)O)C=C1.CCNC(=O)CC.CCOC1=CC=C(C(C)C(=O)O)C=C1.CCOC1=CC=C(CC)N=C1.CCOC1CCC(C(C)C(=O)O)CC1.[H]N(C(=O)C(C)C1=CC=C(OCCCCCCCCCCCC)C=C1)C1=CC=C(C)C=C1.[H]N(C(=O)C(C)C1=CC=CC=C1)C1=CC=C(C)C=C1.[H]N(C(=O)CC)C1=CC=C(C)C=C1.[H]N(CC)C(=O)C(C)C.[H]N(CC)C(=O)C(C)C1=CC=CC=C1 Chemical compound CC(NC(=O)C(C)C1=CC=CC=C1)C1=CC=CC=C1.CC1=CC=C(N2CCC(C)C2=O)C=C1.CCC1=CC(C)=CC=N1.CCC1=CC=C(C)C=C1.CCCCCCCCCCCC.CCCCCCCCCCCOC1=CC=C(C(C)C(=O)O)C=C1.CCCCOC1=CC=C(C(C)C(=O)O)C=C1.CCNC(=O)CC.CCOC1=CC=C(C(C)C(=O)O)C=C1.CCOC1=CC=C(CC)N=C1.CCOC1CCC(C(C)C(=O)O)CC1.[H]N(C(=O)C(C)C1=CC=C(OCCCCCCCCCCCC)C=C1)C1=CC=C(C)C=C1.[H]N(C(=O)C(C)C1=CC=CC=C1)C1=CC=C(C)C=C1.[H]N(C(=O)CC)C1=CC=C(C)C=C1.[H]N(CC)C(=O)C(C)C.[H]N(CC)C(=O)C(C)C1=CC=CC=C1 CJGOOOUAWBXYCM-UHFFFAOYSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N CCC(=O)ON1C(=O)CCC1=O Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- ODGLVFYGHDQFLG-UHFFFAOYSA-J CCCCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+] Chemical compound CCCCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+] ODGLVFYGHDQFLG-UHFFFAOYSA-J 0.000 description 1
- GFNYITSGRAPEEG-UHFFFAOYSA-K CCCCCNC(=O)CNC(=O)C(C)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3] Chemical compound CCCCCNC(=O)CNC(=O)C(C)N1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3] GFNYITSGRAPEEG-UHFFFAOYSA-K 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 241000448280 Elates Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HKBNQXMLSMKLJV-BQBZGAKWSA-N L-gamma-glutamyl-L-cysteinyl-beta-alanine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCCC(O)=O HKBNQXMLSMKLJV-BQBZGAKWSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PWFXCKSJTXMSMO-MVNLRXSJSA-N NC1=NC(=NC(=C1N)S)S.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=O)N=C(N)N=C1 Chemical compound NC1=NC(=NC(=C1N)S)S.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=O)N=C(N)N=C1 PWFXCKSJTXMSMO-MVNLRXSJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- JCZMLBFDBDEWDS-UHFFFAOYSA-N [H]N(C(=O)C(C)C)C1=CC=C(C)C=C1.[H]N(CCC)C(=O)CN([H])C(=O)C(C)C.[H]N(CCCCCC)C(=O)C(C)C Chemical compound [H]N(C(=O)C(C)C)C1=CC=C(C)C=C1.[H]N(CCC)C(=O)CN([H])C(=O)C(C)C.[H]N(CCCCCC)C(=O)C(C)C JCZMLBFDBDEWDS-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108010027149 albuminamide Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- CUNSGVAZYOCGMB-UHFFFAOYSA-N benzyl 2-[2-(2,5,8,11-tetramethyl-1,4,7,10-tetrazacyclododec-1-yl)propanoylamino]acetate Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(C)N1CC(C)NCC(C)NCC(C)NCC1C CUNSGVAZYOCGMB-UHFFFAOYSA-N 0.000 description 1
- SPDJMGTURTUPBD-UHFFFAOYSA-N benzyl 2-[2-[2,5,8,11-tetramethyl-4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetate Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(C)N1CC(C)N(CC(=O)OC(C)(C)C)CC(C)N(CC(=O)OC(C)(C)C)CC(C)N(CC(=O)OC(C)(C)C)CC1C SPDJMGTURTUPBD-UHFFFAOYSA-N 0.000 description 1
- DAOPOOMCXJPWPK-UHFFFAOYSA-N benzyl 4-aminobenzoate Chemical compound C1=CC(N)=CC=C1C(=O)OCC1=CC=CC=C1 DAOPOOMCXJPWPK-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- IOIFRTZBJMZZFO-UHFFFAOYSA-N dysprosium(3+) Chemical compound [Dy+3] IOIFRTZBJMZZFO-UHFFFAOYSA-N 0.000 description 1
- MLFJHYIHIKEBTQ-IYRKOGFYSA-N endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- JHFPQYFEJICGKC-UHFFFAOYSA-N erbium(3+) Chemical compound [Er+3] JHFPQYFEJICGKC-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- MTPSPELUOGZYFU-UHFFFAOYSA-N ethyl 11-[4-(1-bromo-2-methoxy-2-oxoethyl)phenoxy]undecanoate Chemical compound CCOC(=O)CCCCCCCCCCOC1=CC=C(C(Br)C(=O)OC)C=C1 MTPSPELUOGZYFU-UHFFFAOYSA-N 0.000 description 1
- HEWLEJOZZXKHQZ-UHFFFAOYSA-N ethyl 11-[4-(2-methoxy-2-oxoethyl)phenoxy]undecanoate Chemical compound CCOC(=O)CCCCCCCCCCOC1=CC=C(CC(=O)OC)C=C1 HEWLEJOZZXKHQZ-UHFFFAOYSA-N 0.000 description 1
- RTRQVORXLUFHAS-UHFFFAOYSA-N ethyl 4-[4-(1-bromo-2-methoxy-2-oxoethyl)phenoxy]butanoate Chemical compound CCOC(=O)CCCOC1=CC=C(C(Br)C(=O)OC)C=C1 RTRQVORXLUFHAS-UHFFFAOYSA-N 0.000 description 1
- VLXTWNNVQLXTIU-UHFFFAOYSA-N ethyl 4-[4-(2-methoxy-2-oxoethyl)phenoxy]butanoate Chemical compound CCOC(=O)CCCOC1=CC=C(CC(=O)OC)C=C1 VLXTWNNVQLXTIU-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- HKBNQXMLSMKLJV-UHFFFAOYSA-N gamma-L-glutamyl-L-cysteinyl-beta-alanine Natural products OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCCC(O)=O HKBNQXMLSMKLJV-UHFFFAOYSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 229940103893 gliotoxin Drugs 0.000 description 1
- 229930190252 gliotoxin Natural products 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- SCKNFLZJSOHWIV-UHFFFAOYSA-N holmium(3+) Chemical compound [Ho+3] SCKNFLZJSOHWIV-UHFFFAOYSA-N 0.000 description 1
- 108700020537 homoglutathione Proteins 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- FJLLNEDPVRELGR-UHFFFAOYSA-N methyl 2-[4-(2-ethoxy-2-oxoethoxy)phenyl]acetate Chemical compound CCOC(=O)COC1=CC=C(CC(=O)OC)C=C1 FJLLNEDPVRELGR-UHFFFAOYSA-N 0.000 description 1
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000012011 nucleophilic catalyst Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940078497 paramagnetic contrast media Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 1
- 229920003228 poly(4-vinyl pyridine) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- WCWKKSOQLQEJTE-UHFFFAOYSA-N praseodymium(3+) Chemical compound [Pr+3] WCWKKSOQLQEJTE-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- NDJBHBQUEAGIOB-UHFFFAOYSA-N propan-2-yl trifluoromethanesulfonate Chemical compound CC(C)OS(=O)(=O)C(F)(F)F NDJBHBQUEAGIOB-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- HKCRVXUAKWXBLE-UHFFFAOYSA-N terbium(3+) Chemical compound [Tb+3] HKCRVXUAKWXBLE-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- AWSFICBXMUKWSK-UHFFFAOYSA-N ytterbium(3+) Chemical compound [Yb+3] AWSFICBXMUKWSK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Definitions
- the invention relates to the subjects that are characterized in the claims, i.e., macrocyclic metal complexes as well as their use for the production of conjugates with biomolecules.
- the conjugates are suitable for the production of contrast media for NMR diagnosis and radiodiagnosis as well as agents for radiotherapy.
- a prerequisite for a specific and successful therapy is an exact diagnosis.
- the possibilities have very greatly increased in recent years, whereby, for example, NMR diagnosis is able to visualize virtually any anatomical detail selectively and with great accuracy.
- the corresponding structures are visible only by the application of contrast media, however.
- the image intensity in the proton NMR is basically determined by the water protons. It depends on the nuclear relaxation times. Complexes of paramagnetic transition metals and lanthanoids shorten the relaxation times of adjacent protons by dipolar interactions.
- the paramagnetic contrast media are not directly detected, but rather an indirect detection is carried out based on the fact that the contrast media can change relaxation times of adjacent protons, such as water protons. Based on their high magnetic moments and relaxation efficiency, Gd 3+ , Fe 3+ and Mn 2+ are preferred paramagnetic metal cations in NMR diagnosis.
- T 1 An important physical value, which describes the relaxation behavior of protons, is longitudinal relaxation time T 1 . Tissues with short relaxation times T 1 generally yield images of higher intensity than those with longer relaxation times. If the reciprocal value of measured relaxation time T 1 based on concentration c is applied to a specific paramagnetic ion, straight lines of rise R are obtained. This rise is also named relaxivity, which is a measurement of the capacity of the corresponding paramagnetic ion to shorten the relaxation time of the adjacent protons.
- radiopharmaceutical agents for diagnostic and therapeutic purposes has also been known for a long time in the area of biological and medical research.
- radiopharmaceutical agents are used to visualize specific structures such as, for example, the skeleton, organs or tissues.
- the diagnostic application requires the use of such radioactive agents, which accumulate after administration specifically in the structures in patients that are to be examined. These locally accumulating radioactive agents can then be traced, plotted or scintigraphed using suitable detectors, such as, for example scintillation cameras or other suitable recording processes.
- suitable detectors such as, for example scintillation cameras or other suitable recording processes.
- the dispersion and relative intensity of the detected radioactive agent identifies the site of a structure in which the radioactive agent is found and can visualize the presence of anomalies in structures and functions, pathological changes, etc.
- Radiopharmaceutical agents can be used in a similar way as therapeutic agents to irradiate pathological tissues or areas. Such treatment requires the production of radioactive therapeutic agents that accumulate in certain structures, organs or tissues.
- the required ions are normally not administered in the form of water-soluble salts, but rather in the form of chelate complexes.
- the latter can be eliminated virtually unchanged from the body.
- the relaxivity thus increases with the molecular mass of the entire complex.
- a high molecular mass can be achieved by binding to macromolecules.
- a good NMR contrast medium is distinguished, i.a., in that it has a large value for the relaxivity.
- WO 01/08712 proposes a contrast medium that comprises at least two metal chelate units as image-improving groups and at least two “target binding units” for binding the contrast medium molecule to the desired target molecule or target organ in the body.
- Tetraazacyclododecanetetraacetic acid derivatives of high stability and good solubility based on deficient charge that are suitable for binding to biomolecules are described in EP-A-0 565 930.
- An object of this invention thus consists in making available improved contrast media for NMR diagnosis and radiodiagnosis as well as agents for radiotherapy.
- these NMR contrast media are to have as high a relaxivity as possible and are to accumulate as selectively as possible at a desired site in the body.
- This invention thus relates to compounds of formula I in which
- a corresponding macrocyclic compound in which the four nitrogen atoms of the macrocyclic ring are substituted in each case with the substituent —CH(CO 2 H)CH 2 CH 2 —CO 2 H is disclosed in P. Caravan et al., Chem. Rev. 1999, 99, 2293-2352. A possible use of this compound for the production of conjugates with biomolecules is not disclosed, however.
- WO 97/02051 discloses macrocyclic compounds, in which A is a radical —CH(R 7 )—CO—NR 5 —U 6 , as intermediate compounds for the production of cascade polymers.
- EP-A-0-565 930 discloses macrocyclic compounds, in which A is a radical —CH(R 6 )—C(O)—NH—(CH 2 ) 1-6 —NH-D-. An increase in relaxivity by certain substituents is not disclosed. These compounds are consequently excluded in the definition of the compound of formula I in claim 1 .
- alkyl radical is defined here as a saturated or unsaturated, straight-chain or branched or cyclic alkyl radical with the indicated number of carbon atoms. If this radical can contain other groups or atoms, it is understood here that the other groups or atoms in addition to the already existing atoms of the radical are present and can be introduced at any position of the radical including the terminal positions.
- Aryl is defined here preferably as phenyl, bisphenyl, pyridyl, furanyl, pyrrolyl and imidazolyl. Especially preferred is phenyl.
- Hydrocarbon chain which can be arranged completely or partially concentrically, is defined here preferably as a hydrocarbon chain such as, for example, an alkyl chain, which can comprise, for example, an aliphatic or aromatic, optionally heterocyclic 5- or 6-ring (e.g., phenyl(ene), pyridyl(ene) or cyclohexyl(ene)) or consists of the latter.
- the acetic acid or carboxylate methyl radicals at three of the nitrogen atoms of the macrocyclic ring in addition can have substituents R 1 , R 2 and R 3 .
- the macrocyclic ring can have substituents B 1 , B 2 , B 3 and B 4 at four of its carbon atoms.
- a special feature of the compounds according to the invention consists in that at least one of the B 1 , B 2 , B 3 , B 4 , R 1 , R 2 and R 3 does not represent a hydrogen atom, i.e., the macrocyclic ring must have additional substituents either directly on its ring atoms and/or on the acetic acid or carboxylate methyl substituents of its nitrogen atoms.
- B 1 , B 2 , B 3 and B 4 can be hydrogen atoms or C 1-4 -alkyl radicals.
- Preferred C 1-4 -alkyl radicals are methyl, ethyl and iso-propyl.
- R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen atoms, straight, branched and/or cyclic, saturated or unsaturated C 1-10 -alkyl (preferably C 5-10 -alkyl) or aryl radicals, which optionally are substituted with a carboxyl group, —SO 3 H or —PO 3 H 2 , and whereby the alkyl chains of the C 1-10 -alkyl radicals optionally contain an aryl group and/or 1-2 oxygen atoms, provided that at least one of the radicals R 1 , R 2 and R 3 does not represent a hydrogen atom.
- alkyl radicals straight-chain or branched, preferably saturated C 1-10 - and especially C 1-4 -alkyl radicals, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl, as well as cyclohexyl, are preferred.
- straight-chain, branched or cyclic, preferably saturated C 5-10 -alkyl radicals such as pentyl, hexyl, cyclohexyl, heptyl, octyl, nonyl and decyl, are preferred.
- the C 1-10 -alkyl radicals for R 1 , R 2 and R 3 can optionally be substituted with a carboxyl group, —SO 3 H or —PO 3 H 2 .
- Preferred examples of such substituted alkyl groups are —CH 2 —COOH and —C(CH 3 ) 2 —COOH.
- the alkyl chain of the C 1-10 -alkyl radicals can contain an aryl group and/or 1-2 oxygen atoms.
- the aryl group and the oxygen atoms can be present at any position within the alkyl chain.
- the aryl group moreover, can also be arranged in terminal position on the alkyl chain and can form an aryloxy group together with an oxygen atom.
- a phenyl group is suitable as an aryl group.
- Preferred alkyl chains for R 1 , R 2 and R 3 which optionally contain an aryl group and 1-2 oxygen atoms, are radicals of formula —(CH 2 ) m —(O) n -(phenylene) p -Y, in which m is an integer from 1-5, n is 0 or 1, p is 0 or 1 and Y is a hydrogen atom, a methoxy radical, a carboxyl group, —SO 3 H or —PO 3 H 2 .
- Substituent Y is preferably in para-position in this case.
- the aryl radicals for R 1 , R 2 and R 3 are preferably phenyl radicals, which are optionally substituted with a carboxyl group, —SO 3 H or —PO 3 H 2 .
- R 1 , R 2 and R 3 are preferably independently selected from the group consisting of hydrogen atoms, isopropyl, isobutyl, tert-butyl, a straight-chain or branched C 5-10 -alkyl radicals, cyclohexyl, —CH 2 —COOH, —C(CH 3 ) 2 —COOH, phenyl radicals or radicals of formula —(CH 2 ) m —(O) n -(phenylene) p -Y, in which m is an integer from 1 to 5, n is 0 or 1, p is 0 or 1, and Y represents a hydrogen atom, a methoxy radical, a carboxyl group, —SO 3 H or —PO 3 H 2 , and R 1 , R 2 and R 3 are especially preferably independently selected from the group consisting of hydrogen atoms, isopropyl, cyclo
- the substituted macrocyclic ring of the compound of formula I can be bonded via a spacer A to a biomolecule using a group X, which can participate in a reaction with a biomolecule.
- spacer A represents a straight or branched, saturated or unsaturated C 1-30 hydrocarbon chain, which optionally contains 1-5 oxygen atoms, 1-5 nitrogen atoms and/or 1-5 —NR′ radicals, in which R′ is defined as R 1 , R 2 and R 3 above but can be selected independently, which optionally is substituted with 1-3 carboxyl groups, 1-3 —SO 3 H, 1-3 —PO 3 H 2 and/or 1-3 halogen atoms, in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically and which is configured in such a way that X is connected via at least 3 atoms to the nitrogen atom to which A is bonded.
- the spacer is to have at least three atoms and preferably at least four atoms in a chain between the nitrogen atom of the macrocyclic ring and X.
- a chain of atoms is defined in this case as the shortest connection between the nitrogen atom of the macrocyclic ring and X via a ring as well.
- a para-phenylene group would be regarded as a spacer with four atoms in a chain
- a meta-phenylene group would be regarded as a spacer with three atoms in a chain.
- carbon, nitrogen and oxygen atoms are simultaneously counted in each case as an atom. Substituents in these atoms or side chains are not part of the number of atoms inside the chain.
- -A-X is preferably selected to be different from the substituents —CH(R 1 )—CO 2 Z, —CH(R 2 )—CO 2 Z and —CH(R 3 )—CO 2 Z.
- Spacer A preferably can be represented as a radical A′-U, in which A′ is bonded to the nitrogen atom of the macrocyclic ring and U is bonded to X.
- A′ is preferably
- Q is preferably a linear or branched C 1-10 radical, especially a C 1-4 -alkyl radical, such as methyl, ethyl or isopropyl, or a cyclohexyl radical. These radicals can optionally be substituted with a carboxyl group, whereby a carboxymethyl radical is preferred.
- the preferred aryl radical for Q is phenyl. This aryl radical can be substituted with a carboxyl group, a C 1-15 -alkoxy group, an aryloxy group, such as especially a phenoxy group, or a halogen atom, such as fluorine, chlorine, bromine or iodine, and especially fluorine or chlorine.
- aryl radical is a phenyl radical
- the latter is preferably substituted in para-position with one of the above-mentioned groups.
- Especially preferred groups for Q are methyl, phenyl and p-dodecanoxyphenyl.
- R′ is defined as R 1 , R 2 and R 3 above, but can be selected independently from R 1 , R 2 and R 3 .
- R′ is especially preferably a hydrogen atom.
- A′ is preferably selected from a bond, —CH(CO 2 H)—, —C(CH 3 )H—CO—NH—, —C(phenyl)H—CO—NH—, —C(p-dodecanoxyphenyl)H—CO—NH—, in which R 4 is —OCH 3 , —CO 2 H, —SO 3 H or —PO 3 H 2 .
- spacer A is represented as a radical A′-U, and A′ has the meaning defined above, U is preferably a straight or branched, saturated or unsaturated C 1-30 -hydrocarbon chain, which optionally contains 1-3 oxygen atoms, 1-3 nitrogen atoms and/or 1-3 —NR′′ radicals, in which R′′ is defined as R 1 , R 2 and R 3 above, but can be selected independently, and in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically.
- U is especially preferably an aryl radical or a C 1-20 -alkyl radical (preferably straight-lined or at least partially cyclic and saturated) that optionally contains 1-3 oxygen atoms, 1-3 NR′′ radicals, 1-2 phenylene radicals and/or a pyridylene radical, in which optionally 1-3 carbon atoms are present as carbonyl groups, and which optionally is substituted with an aryl radical (e.g., phenyl).
- A′ and U together must be configured in such a way that X is connected by at least three atoms to the nitrogen atom to which A′ is bonded.
- the chain of at least three atoms is defined as above in A.
- the aryl radical for U is preferably a phenyl radical.
- the C 1-20 -alkyl radical for U is preferably a linear, saturated C 1-10 -alkyl radical, cyclohexyl radical or cyclohexyl-C 1-5 -alkyl radical.
- the alkyl radicals of these radicals can optionally be interrupted by 1 oxygen atom, 1 phenylene radical and/or 1 pyridylene radical or can contain a —CO—NR′′ radical or can be substituted with phenyl.
- U is preferably selected from —CH 2 —, —(CH 2 ) 5 —, —(CH 2 ) 10 —, -phenylene-O—CH 2 —, -phenylene-O—(CH 2 ) 3 —, -phenylene-O—(CH 2 ) 10 —, —CH 2 -phenylene-, -cyclohexylene-O—CH 2 —, -phenylene-, —C(phenyl)H—, —CH 2 -pyridylene-O—CH 2 —, —CH 2 -pyridylene- and —CH 2 —CO—NH—CH 2 —CH 2 —.
- the phenylene groups are preferably substituted in para-position
- the pyridylene groups are preferably pyrid-2,5-ylene groups or pyrid-2,4-ylene groups.
- Preferred groups for the spacer A are:
- a group X is bonded to the macrocyclic ring in the compounds of formula I.
- This group X is a group that can participate in a reaction with a biomolecule.
- carboxyl —COOH
- activated carboxyl amino (—NH 2 ), isocyanate (—NCO), isothiocyanate (—NCS)
- hydrazine —NHNH 2
- semicarbazide —NHCONHNH 2
- thiosemicarbazide —NHCSNHNH 2
- chloroacetamide —NHCOCH 2 Cl
- bromoacetamide —NHCOCH 2 Br
- iodoacetamide —NHCOCH 2 I
- acylamino such as, for example acetylamino (—NHCOCH 3 ), mixed anhydrides, azide, hydroxide, sulfonyl chloride, carbodiimide or a group of formulas in which Hal represents a halogen atom
- Activated carboxyl groups are defined above as those carboxyl groups that can be derivatized in such a way that they facilitate the reaction with a biomolecule. Which groups can be used for activation is known, and reference can be made to, for example, M. and A. Bodanszky, “The Practice of Peptide Synthesis,” Springerverlag 1984. Examples are aducts of carboxylic acid with carbodiimides or activated esters, such as, e.g., hydroxybenzotriazole esters. Especially preferred is the activated carboxyl group for X that is selected from
- Z stands for a hydrogen atom or a metal ion equivalent.
- Which metal ion in the compound according to the invention is to be complexed here depends on the intended use of the conjugates that are produced with the inventions according to the invention with a biomolecule.
- Corresponding conjugates are suitable, for example, for NMR diagnosis, radiodiagnosis and radiotherapy and neutron capture therapy.
- the conjugates in NMR diagnosis are especially preferably used as contrast media.
- the production of complexes for NMR diagnosis can be carried out as was disclosed in Patents EP 71564, EP 130934 and DE-OS 34 01 052.
- the metal oxide or a metal salt for example a chloride, nitrate, acetate, carbonate or sulfate
- the metal oxide or a metal salt for example a chloride, nitrate, acetate, carbonate or sulfate
- water and/or a lower alcohol such as methanol, ethanol or isopropanol
- the production of the complexes from the complexing agents can be carried out according to the methods that are described in “Radiotracers for Medical Applications,” Vol. I, CRC Press, Boca Raton, Fla.
- Suitable ions are, for example, the chromium(III), ion(II), cobalt(II), nickel(II), copper(II), praseodymium(III), neodymium(III), samarium(III) and ytterbium(III) ion. Because of their strong magnetic moment, the gadolinum(II), terbium(III), dysprosium(III), holmium(III), erbium(III), manganese(II) and iron(III) ions are especially preferred for NMR diagnosis.
- the compounds according to the invention and especially their conjugates with biomolecules meet the many different requirements for suitability as contrast media for nuclear spin tomography. After oral or parenteral administration, they are thus extremely well suited for enhancing the informational value of the image that is obtained with the aid of a nuclear spin tomograph by increasing the signal intensity. They also show the high effectiveness that is necessary to load the body with the smallest possible amounts of foreign substances and the good compatibility that is necessary to maintain the non-invasive nature of the studies.
- the good water solubility and low osmolality of the compounds according to the invention and their conjugates with biomolecules allow for the production of highly concentrated solutions so as to keep the volume burden of the circulatory system within reasonable limits and to offset the dilution by bodily fluids, i.e., NMR diagnostic agents have to be 100 to 1000 times more water-soluble than for NMR spectroscopy.
- the compounds according to the invention have not only a high stability in vitro but also a surprisingly high stability in vivo, so that a release or an exchange of the ions, which are inherently toxic and not covalently bonded in the complexes, is carried out only extremely slowly within the time that it takes for the new contrast media to be completely excreted again.
- the complex compounds according to the invention can also be used advantageously as susceptibility reagents and as shift reagents for in vivo NMR spectroscopy.
- the compounds according to the invention and their conjugates with biomolecules are also suitable as radiodiagnostic agents and radiotherapeutic agents based on their advantageous radioactive properties and the good stability of the complex compounds that are contained therein. Details of their use and dosage are described in, e.g., “Radiotracers for Medical Applications,” CRC Press, Boca Raton, Fla. 1983, as well as in Eur. J. Nucl. Med. 17 (1990) 346-364 and Chem. Rev. 93 (1993) 1137-1156.
- the complexes with isotopes 111 In and 99m Tc are suitable.
- positron-emission tomography Another imaging method with radioisotopes is the positron-emission tomography, which uses positron-emitting isotopes such as, e.g., 43 Sc, 44 Sc, 52 Fe, 55 Co, 68 Ga, 64 Cu, 86 Y and 94m Tc (Heiss, W. D.; Phelps, M. E.; Positron Emission Tomography of Brain, Springer Verlag Berlin, Heidelberg, New York 1983).
- positron-emitting isotopes such as, e.g., 43 Sc, 44 Sc, 52 Fe, 55 Co, 68 Ga, 64 Cu, 86 Y and 94m Tc
- the compounds according to the invention and their conjugates with biomolecules are also suitable, surprisingly enough, for differentiating malignant and benign tumors in areas without blood-brain barriers.
- the compounds according to the invention and especially their conjugates with biomolecules accumulate in malignant tumors (no diffusion in healthy tissue, but high permeability of tumor vessels), they can also support the radiation therapy of malignant tumors.
- the latter is distinguished from the corresponding diagnosis only by the amount and type of the isotope that is used.
- the purpose in this case is the destruction of tumor cells by high-energy short-wave radiation with the lowest possible range of action.
- interactions of the metals that are contained in the complexes such as, e.g., iron or gadolinium
- ionizing radiations e.g., x rays
- neutron rays are employed.
- the local radiation dose at the site where the metal complex is found increases significantly.
- radiation exposure for healthy tissue can be considerably reduced and thus burdensome side effects for the patients can be avoided when such metal complexes are used.
- the metal complex conjugates according to the invention are therefore also suitable as radio-sensitizing substances in the radiation therapy of malignant tumors (e.g., exploiting Mossbauer effects or neutron capture therapy).
- Suitable ⁇ -emitting ions are, e.g., 46 Sc, 47 Sc, 48 Sc, 72 Ga, 73 Ga, 90 Y, 67 Cu, 109 Pd, 111 Ag, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re and 188 Re 90 Y, 177 Lu, 72 Ga, 153 Sm and 67 Cu are preferred.
- Suitable ⁇ -emitting ions that have short half-lives are, e.g., 211 At, 211 Bi, 212 Bi, 213 Bi and 214 Bi, whereby 212 Bi is preferred.
- a suitable photon- and electron-emitting ion is 158 Gd, which can be obtained from 157 Gd by neutron capture.
- the central ion must be derived from a Mössbauer isotope, such as, for example, 57 Fe or 151 Eu.
- inorganic bases e.g., hydroxides, carbonates or bicarbonates
- organic bases such as, i.a., primary, secondary and tertiary amines, such as, e.g., ethanolamine, morpholine, glucamine, N-methylglucamine and N,N-dimethylglucamine, as well as basic amino acids, such as, e.g., lysine, arginine and ornithine or amides of originally neutral or acidic amino acids.
- the desired base can be added, for example, into acid complex salts in aqueous solution or suspension so that the neutral point is reached.
- the solution that is obtained can then be evaporated to the dry state in a vacuum.
- the compounds of formula I according to the invention can be produced according to the process that is known to one skilled in the art.
- the compounds of formula I can be obtained by a process in which a compound of formula II in which B 1 , B 2 , B 3 and B 4 are defined as above is optionally reacted after introducing protective groups for the nitrogen atoms with Nu-A-X′ and Nu-CH(R 1 )—CO 2 Z′, Nu-CH(R 2 )—CO 2 Z′ and Nu-CH(R 3 )—CO 2 Z′, whereby A and R 1 , R 2 , and R 3 are defined as above and Nu is a nucleofuge, X′ stands for X or a protected form of X, and X is defined as above and Z′ stands for a hydrogen atom, a metal ion equivalent, preferably an alkali metal or alkaline-earth metal, such as especially sodium or potassium, or a protective group for carboxyl.
- the optionally present protective groups can be removed, and it can be reacted in a way that is known in the art with at least one metal oxide or metal salt of a desired element.
- still present acid hydrogen atoms optionally can be substituted completely or partially by cations of inorganic and/or organic bases, amino acids or amino acid amides.
- B 1 , B 2 , B 3 and B 4 can represent the same residues, whereas R 1 , R 2 , and/or R 3 can represent different residues. Furthermore B 1 , B 2 , B 3 and B 4 can represent different residues in the molecule and R 1 , R 2 , and/or R 3 can represent the same residues. And in the compounds according to the invention B 1 , B 2 , B 3 and B 4 can represent different residues and also R 1 , R 2 , and/or R 3 can represent different residues. Furthermore B 1 , B 2 , B 3 and B 4 can represent the same residues in the molecule and R 1 , R 2 , and/or R 3 can also represent the same residues.
- the macrocyclic compound that is unsubstituted at the nitrogens is first reacted with protected unit AX′.
- group A carries a nucleofuge as a leaving group.
- group A carries a nucleofuge as a leaving group.
- one of the four nitrogen atoms in the macrocyclic compound reacts with group A with the leaving group departing.
- X′ a monofunctionalized macrocyclic compound that contains radical X in protected form
- the remaining three nucleophilic nitrogen atoms of the macrocyclic compound are reacted in each case with a protected carboxylic acid, which carries a nucleofuge in ⁇ -position in the carboxyl group.
- three equivalents of the protected carboxylic acids can be used in the second reaction step. It is possible to use one protected carboxylic acid. In this case, all residues R 1 R 2 and R 3 are the same. Alternatively up to three different protected carboxylic acids can be used in same process. In this case it is possible to introduce different residues R 1 , R 2 and/or R 3 into the molecule, wherein R 1 , R 2 and R 3 are as defined above. Of course the different protected carboxylic acids should add up to about 3 equivalents as a total. The different protected carboxylic acids can be used as a mixture, but it is preferred to add the different protected carboxylic acids in different reaction steps.
- a macrocyclic compound is used as an educt, which carries already suitable protective groups SG on three of the four nitrogen atoms.
- protective groups e.g., tert-butyl-oxycarbonyl (t-BOC), COCF 3 , carbobenzoxy (Cbo) or fluorenyl-methoxycarbonyl (FMOC), etc. are suitable here.
- t-BOC tert-butyl-oxycarbonyl
- COCF 3 carbobenzoxy
- Cbo carbobenzoxy
- FMOC fluorenyl-methoxycarbonyl
- SG Protective group (e.g., BOC, Cbo, COCF 3 , FMOC, etc.)
- first one of the four nitrogen atoms of the macrocyclic compound is blocked by a corresponding protective group SG.
- suitable protective groups are formyl, benzyl, boctrityl, etc.
- the reaction now is carried out on the three remaining nucleophilic nitrogen atoms with correspondingly protected carboxylic acid derivatives, which carry a corresponding nucleofuge in ⁇ -position.
- three equivalents of the protected carboxylic acids can be used in the second reaction step. It is possible to use one protected carboxylic acid. In this case, all residues R 1 , R 2 and R 3 are the same. Alternatively up to three different protected carboxylic acids can be used in same process.
- R 1 , R 2 and/or R 3 are as defined above.
- the different protected carboxylic acids should add up to about 3 equivalents as a total.
- the different protected carboxylic acids can be used as a mixture, but it is preferred to add the different protected carboxylic acids in different reaction steps. With this method it is possible to obtain a well defined chemical compound or a mixture of chemical compounds having different substitution patterns. If a mixture of chemical compounds with different substitution patterns is obtained, this mixture can be seperated by known methods, such as chromatography, after the reaction.
- the reaction is performed in a mixture of water and organic solvents, such as: isopropanol, ethanol, methanol, butanol, dioxane, tetrahydrofuran, dimethylformamide, dimethyl acetamide, formamide or dichloromethane.
- organic solvents such as: isopropanol, ethanol, methanol, butanol, dioxane, tetrahydrofuran, dimethylformamide, dimethyl acetamide, formamide or dichloromethane.
- Ternary mixtures that consist of water, isopropanol and dichloromethane are preferred.
- the reaction is carried out in a temperature range of between ⁇ 10° C. and 100° C., preferably between 0° C. and 30° C.
- C 1 -C 6 -alkyl, C 6 -C 10 -aryl and C 6 -C 10 —Ar(C 1 -C 4 )-alkyl groups as well as trialkylsilyl groups are suitable.
- the methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl and tert-butyl groups are preferred.
- the cleavage of these acid protective groups is carried out according to the processes that are known to one skilled in the art, for example by hydrolysis, hydrogenolysis, alkaline saponification of the esters with alkali in aqueous-alcoholic solution at temperatures from 0 to 50° C., acidic saponification with mineral acids or in the case of tert-butyl esters with the aid of trifluoroacetic acid.
- the NH groups can be protected in a variety of ways and then exposed again.
- the N-trifluoroacetyl derivative is cleaved by potassium or sodium carbonate in water (H. Newman, J. Org. Chem., 30: 287 (1965), M. A. Schwartz et al., J. Am. Chem. Soc., 95 G12 (1973)) or simply by ammonia solution (M. Imazama and F. Eckstein, J. Org. Chem., 44: 2039 (1979)).
- the tert-butyloxycarbonyl derivative is equally easy to cleave: stirring with trifluoroacetic acid suffices (B. F. Lundt et al., J. Org.
- the group of NH protective groups to be cleaved hydrogenolytically or in a reductive manner is very large: the N-benzyl group can be cleaved easily with hydrogen/Pd—C (W. H. Hartung and R. Rimonoff, Org. Reactions VII, 262 (1953)), which also applies for the trityl group (L. Zervas et al., J. Am. Chem. Soc., 78; 1359 (1956)) and the benzyloxycarbonyl group (M. Bergmann and L. Zervas Ber. 65: 1192 (1932)).
- the activated esters of the above-described compounds are produced as known to one skilled in the art.
- isothiocyanates or ⁇ -haloacetates the corresponding terminal amino precursors are reacted according to methods that are known in the literature with thiophosgene or 2-halo-acetic acid-halides.
- Nu-A-X is preferably synthesized first independently. If the molecule contains an amide group, the latter is produced, for example, by an activated carboxylic acid being reacted with an amine. The activation of the carboxylic acid is carried out according to the commonly used methods.
- activating reagents are dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide-hydrochloride (EDC), benzotriazol-1-yloxytris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU), preferably DCC.
- O-nucleophilic catalysts such as, e.g., N-hydroxysuccinimide (NHS) or N-hydroxybenzotriazole, is also possible.
- group X is a carboxylic acid function
- the latter can be used in protected form (e.g., in the form of benzyl ester), and the cleavage of the protective group can then be carried out hydrogenolytically.
- esters that are activated to this end are preferably produced at an intermediate stage, and said esters are then attacked by a nucleophilic group of the biomolecule. In this way, a covalent linkage between the biomolecule and the compound of formula I according to the invention is produced.
- Preferred activated esters are the esters of the N-hydroxysuccinimide, the esters of paranitrophenol or the esters of pentafluorophenol. If group X in the form of an isothiocyanate is linked to the biomolecule, a terminal amine is preferably first used which, if necessary, can be provided with a suitable protective group.
- Suitable protective groups are known from peptide chemistry. After the protective group is cleaved off, the isothiocyanate can be produced by reaction of the primary terminal amine with thiophosgene. Nucleophilic groups of the biomolecule can be added to the latter.
- group X represents a maleinimide, which can react, e.g., selectively with thiol functions of the biomolecule.
- group X is a nucleophile (NH 2 , SH), which affects a suitable functionality of the biomolecule (activated ester, maleinimide, etc.).
- a suitable functionality of the biomolecule activated ester, maleinimide, etc.
- Numerous biomolecules that are functionalized with maleinimides are commercially available.
- This invention moreover, relates to the use of the above-described compounds of formula I for the production of conjugates with a biomolecule.
- the synthesis of the conjugates is generally carried out in such a way that first a derivatized and functionalized chelate complex is produced that then is linked to the biomolecule. It is also possible, however, that if synthetically produced biomolecules are used, the chelate complex according to the invention is incorporated in the latter during the synthesis of the biomolecule. This can be carried out, for example, during the sequential synthesis of oligopeptides in the synthesizing robot. If necessary, the protective groups that are commonly used in the synthesis of the corresponding biomolecule can be introduced into the compound according to the invention. The latter are then cleaved again in the synthesizer in line with the usual synthesis algorithm.
- Biomolecule is defined here as any molecule that either occurred naturally, for example in the body, or was produced synthetically with an analogous structure. Moreover, among the latter, those molecules are defined that can occur in interaction with a biological molecule that occurs, for example, in the body or a structure that occurs there, in such a way, for example, that the conjugates accumulate at specific desired spots of the body. “Body” is defined here as any plant or animal body, whereby animal and especially human bodies are preferred.
- Biomolecules are especially the molecules that occur in living creatures that as products of an evolutionary selection by orderly and complex interactions meet specific objects of the organism and constitute the basis of its vital functions (changes in material and shape, reproduction, energy balance).
- simple building blocks amino acids, nucleobases, monosaccharides, fatty acids, etc.
- proteins proteins, nucleic acids, polysaccharides, lipids, etc.
- biopolymers are also referred to as biopolymers.
- the biomolecule advantageously can have, for example, a polypeptide skeleton that consists of amino acids with side chains that can participate in a reaction with reactive group X of the compounds of formula I according to the invention.
- side chains include, for example, the carboxyl groups of aspartic acid and glutamic acid esters, the amino groups of lysine radicals, the aromatic groups of tyrosine and histidine radicals and the sulfhydryl groups of cysteine radicals.
- biomolecules are especially suitable:
- Biopolymers proteins, such as proteins that have a biological function, HSA, BSA, etc., proteins and peptides, which accumulate at certain spots in the organism (e.g., in receptors, cell membranes, at ducts, etc.), peptides that can be cleaved by proteases, peptides with predetermined synthetic sites of rupture (e.g., labile esters, amides, etc.), peptides that are cleaved by metalloproteases, peptides with photocleavable linkers, peptides with oxidative agents (oxydases) and cleavable groups, peptides with natural and unnatural amino acids, glycoproteins (glycopeptides), signal proteins, antiviral proteins and apoctosis, synthetically modified biopolymers such as biopolymers that are derivatized with linkers, modified metalloproteases and derivatized oxydase, etc., carbohydrates (mono- to polysaccharides
- biomolecules are commercially available from, for example, Merck, Aldrich, Sigma, Calibochem or Bachem.
- the number of compounds of formula I according to the invention per biomolecule is random in principle, but a molecular ratio of 0.1:1 to 10:1, especially 0.5:1 to 7:1, is preferred.
- the compounds according to the invention are also suitable for conjugation on all molecules that are reacted with fluorescence dyes in the prior art to determine, for example, their location by epifluorescence microscopy within the cell.
- the compounds with, in principle, any medications can also be conjugated to then track the transport within the organism, for example by the NMR technique.
- the conjugates from the compounds according to the invention and the biomolecules contain other additional molecules, which had been conjugated on the biomolecules.
- biomolecule in terms of this invention thus encompasses all molecules that occur in the biological systems and all molecules that are biocompatible.
- the conjugates that are obtained with the compounds according to the invention are preferably used as contrast media in NMR diagnosis.
- the conjugates should therefore be water-soluble.
- they are preferably dosed in an amount of 0.0001-5 mmol/kg of body weight and especially preferably in an amount of 0.005-0.5 mmol/kg of body weight. Details of use are discussed in, e.g., H.-J. Weinmann et al., Am. J. of Roentgenology 142, 619 (1984).
- the latter can be especially low-dosed, for example, to detect tumors.
- radiotherapeutic agents are discussed in, e.g., R. W. Kozak et al. TIBTEC, October 1986, 262 (see above Bioconjugate Chem. 12 (2001) 7-34).
- Example 1a 26.3 g (30 mmol) of the title compound of Example 1a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Example 3a 32.5 g (30 mmol) of the title compound of Example 3a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Example 4a 27.2 g (30 mmol) of the title compound of Example 4a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Example 6c 28.1 g (30 mmol) of the title compound of Example 6c is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Example 7c 31.1 g (30 mmol) of the title compound of Example 7c is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Fnd. C, 49.56; H, 6.10; Gd, 17.52; N, 6.63.
- Fnd. C, 48.87; H, 6.01; Gd, 20.22; N, 7.59.
- Fnd. C, 43.90; H, 6.40; Gd, 20.80; N, 9.33.
- Example 14a 32.1 g (30 mmol) of the title compound of Example 14a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Example 15a 893 mg (1.0 mmol) of the title compound of Example 15a is dissolved in 10 ml of isopropanol, and a spatula tip full of palladium catalyst (10% Pd/C) is added. It is hydrogenated overnight at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state. The residue is recrystallized from dioxane.
- Example 15b 803 mg (1.0 mmol) of the title compound of Example 15b is dissolved in 5 ml of trifluoroacetic acid and stirred for 3 hours at room temperature. It is evaporated to the dry state, the residue is taken up in 300 ml of water, and the solution is added to a column, filled with Reillex® 425 PVP. It is eluted with water. The product-containing fractions are combined and evaporated to the dry state (446 mg; 0.84 mmol) and again dissolved in 4 ml of water. 152 mg (0.42 mmol) of gadolinium oxide is added, and it is heated for 3 hours to 90° C. It is evaporated to the dry state (vacuum), and the residue is crystallized from 90% aqueous ethanol. The crystals are suctioned off, washed once with ethanol, then with acetone and finally with dimethyl ether and dried in a vacuum furnace at 130° C. (24 hours).
- Fnd. C, 40.06; H, 5.75; N, 10.43; Gd, 22.40.
- Fnd. C, 50.34; H, 4.44; N, 4.41.
- Example 18b 26.7 g (30 mmol) of the title compound of Example 18b is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Fnd. C, 39.99; H, 5.55; Gd, 22.93; N, 10.45.
- the Dy complex of 10-[1-(carboxymethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7- ⁇ , ⁇ ′, ⁇ ′′-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is obtained analogously with use of 12.3 g (20 mmol) of the ligand that is described in Example 19b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Fnd. C, 45.45; H, 5.11; Gd, 20.78; N, 9.40.
- the Dy complex of 10-[1-(4-carboxyphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7- ⁇ , ⁇ ′, ⁇ ′′-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is analogously obtained with use of 13.5 g (20 mmol) of the ligand that is described in Example 22b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- gadolinium oxide 3.6 g (10 mmol) is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Fnd. C, 54.66; H, 6.57; Gd, 16.32; N, 7.32.
- Example 24b 27.1 g (30 mmol) of the title compound of Example 24b is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- the DY complex of 10-[1-(carboxymethyl)-2-oxo-piperidin-3-yl]-1,4,7- ⁇ , ⁇ ′, ⁇ ′′-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is analogously obtained with use of 12.6 g (20 mmol) of the ligand that is described in Example 25b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Fnd. C, 49.99; H, 6.17; Gd, 18.51; N, 8.21.
- the Dy complex of 10-[1-(4-carboxyphenyl)-2-oxo-piperidin-3-yl]-1,4,7- ⁇ , ⁇ ′, ⁇ ′′-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is analogously obtained with use of 13.8 g (20 mmol) of the ligand that is described in Example 28b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Example 29a 35.1 g (30 mmol) of the title compound of Example 29a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state.
- the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum.
- the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- the dysprosium complex is obtained analog to this by using 559 mg (1.5 mmol) dysprosium oxide instead of gadolinium oxide:
- the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum.
- the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- the residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5.543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished, the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H + -form). The acidic eluate is freeze-dried.
- the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum.
- the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum.
- the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- gadolinium oxide is added and it is refluxed for 3 hours.
- pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H + -form). The acidic eluate is freeze-dried.
- the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum.
- the residue is chromatographed on a silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum.
- the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- the residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5.543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished, the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H + -form). The acidic eluate is freeze-dried.
- Examples 36-108 describe conjugates of the above-described gadolinium complexes with biomolecules.
- the conjugates were produced according to the following general operating instructions I-IV. The results are summarized in Table 1.
- AAV stands for general operating instructions
- ACTH stands for adrenocorticotropic hormone
- RP-18 refers to a “reversed phase” stationary chromatography phase.
- the number of complexes per biomolecule was determined by means of ICP (inductively coupled plasma atomic emission spectroscopy).
- the batch solution is filtered, the filtrate is ultrafiltered with an AMICON® YM30 (cut-off 30,000 Da), the retentate is chromatographed on a Sephadex® G50-column, and the product fractions are freeze-dried.
- 3 mmol of the Gd-complex acid is dissolved in 15 ml of DMF, mixed with 380 mg (3.3 mmol) of N-hydroxysuccinimide and 681 mg of dicyclohexylcarbodiimide while being cooled with ice, and preactivated for 1 hour in ice.
- the active ester mixture is added in drops to a solution of 2.5 mmol of amine components in 15-150 ml of DMF and stirred overnight at room temperature.
- the batch solution is filtered and chromatographed on silica gel.
- the relaxivities of the conjugates from Examples 36-38 and 97-108 were compared with the relaxivities of two comparison substances.
- comparison substances Gd-DTPA (1) with the formula: and Gd-GlyMeDOTA (2) with the formula: which were reacted in each case with bovine serum albumin (BSA), were used.
- BSA bovine serum albumin
Abstract
The invention relates to macrocyclic metal complexes and their production and use for the production of conjugates with biomolecules. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of the relaxivity is made possible.
Description
- The invention relates to the subjects that are characterized in the claims, i.e., macrocyclic metal complexes as well as their use for the production of conjugates with biomolecules. The conjugates are suitable for the production of contrast media for NMR diagnosis and radiodiagnosis as well as agents for radiotherapy.
- A prerequisite for a specific and successful therapy is an exact diagnosis. Specifically in the diagnostic field, the possibilities have very greatly increased in recent years, whereby, for example, NMR diagnosis is able to visualize virtually any anatomical detail selectively and with great accuracy. In many cases, the corresponding structures are visible only by the application of contrast media, however. Moreover, the possibility exists of configuring the contrast media in such a way that they selectively accumulate in the desired target structures. To this end, the accuracy of the imaging can be increased with simultaneous reduction of the required amount of contrast medium.
- As contrast media for NMR diagnosis, chelate complexes of paramagnetic metals are suitable. The theory and application of gadolinium(III) chelates as NMR contrast media are explained in detail in a survey article by P. Caravan et al. in Chem. Rev. 1999, 99, 2293-2352.
- The image intensity in the proton NMR is basically determined by the water protons. It depends on the nuclear relaxation times. Complexes of paramagnetic transition metals and lanthanoids shorten the relaxation times of adjacent protons by dipolar interactions. The paramagnetic contrast media are not directly detected, but rather an indirect detection is carried out based on the fact that the contrast media can change relaxation times of adjacent protons, such as water protons. Based on their high magnetic moments and relaxation efficiency, Gd3+, Fe3+ and Mn2+ are preferred paramagnetic metal cations in NMR diagnosis.
- An important physical value, which describes the relaxation behavior of protons, is longitudinal relaxation time T1. Tissues with short relaxation times T1 generally yield images of higher intensity than those with longer relaxation times. If the reciprocal value of measured relaxation time T1 based on concentration c is applied to a specific paramagnetic ion, straight lines of rise R are obtained. This rise is also named relaxivity, which is a measurement of the capacity of the corresponding paramagnetic ion to shorten the relaxation time of the adjacent protons.
- The use of radiopharmaceutical agents for diagnostic and therapeutic purposes has also been known for a long time in the area of biological and medical research. In particular, radiopharmaceutical agents are used to visualize specific structures such as, for example, the skeleton, organs or tissues. The diagnostic application requires the use of such radioactive agents, which accumulate after administration specifically in the structures in patients that are to be examined. These locally accumulating radioactive agents can then be traced, plotted or scintigraphed using suitable detectors, such as, for example scintillation cameras or other suitable recording processes. The dispersion and relative intensity of the detected radioactive agent identifies the site of a structure in which the radioactive agent is found and can visualize the presence of anomalies in structures and functions, pathological changes, etc.
- Radiopharmaceutical agents can be used in a similar way as therapeutic agents to irradiate pathological tissues or areas. Such treatment requires the production of radioactive therapeutic agents that accumulate in certain structures, organs or tissues.
- Because of their sometimes relatively high toxicity, the required ions are normally not administered in the form of water-soluble salts, but rather in the form of chelate complexes. The latter can be eliminated virtually unchanged from the body. The smaller the complexes in solution are, the lower is their moment of inertia and the faster they rotate in solution (Tumbling Motion Time). The faster a complex rotates, the lower its relaxivity is. The relaxivity thus increases with the molecular mass of the entire complex. A high molecular mass can be achieved by binding to macromolecules. A good NMR contrast medium is distinguished, i.a., in that it has a large value for the relaxivity.
- Conjugates of Gd-DTPA (diethylenetriaminepentaacetic acid) with albumin are described by, for example, M. D. Organ et al. in Invest. Radiol. 1987, 22, 665-671 and U. Schmiedl et al. in Radiology 1987, 162, 205-210. Conjugates of macrocyclic metal complexes and biomolecules are disclosed in WO 95/31444. To improve the selectivity of contrast media, WO 01/08712 proposes a contrast medium that comprises at least two metal chelate units as image-improving groups and at least two “target binding units” for binding the contrast medium molecule to the desired target molecule or target organ in the body.
- Large contrast medium molecules with high molar mass are obtained according to WO 97/02051 by incorporation of macrocyclic metal complexes in cascade polymers.
- Tetraazacyclododecanetetraacetic acid derivatives of high stability and good solubility based on deficient charge that are suitable for binding to biomolecules are described in EP-A-0 565 930.
- The binding of macrocyclic metal complexes to biomolecules that is described above makes possible both an increase of relaxivity and selectivity of the contrast medium. The higher the relaxivity of the contrast medium, the smaller amount of contrast medium must be administered to the patient and the greater the opacification in the image. For this reason, it is additionally desirable to make available NMR contrast media with the highest possible relaxivity.
- An object of this invention thus consists in making available improved contrast media for NMR diagnosis and radiodiagnosis as well as agents for radiotherapy. In particular, these NMR contrast media are to have as high a relaxivity as possible and are to accumulate as selectively as possible at a desired site in the body.
- It has now been found that this object can be achieved, surprisingly enough, in that a 1,4,7,10-tetraazacyclododecane macrocyclic compound with special ligands is provided. The new qualities of the compounds according to the invention are evident if they are bonded to biomolecules. By the special liganding of the macrocyclic compound, the relaxivity of the contrast medium that is obtained is increased, and in addition a fine-tuning of the relaxivity for a desired use is possible.
-
-
- Z represents a hydrogen atom or at least two Z's represent a metal ion equivalent,
- B1, B2, B3, B4 are independently selected from the group consisting of hydrogen atoms and C1-4-alkyl radicals,
- R1, R2, R3 are independently selected from the group consisting of hydrogen atoms and straight, branched or cyclic, saturated or unsaturated C1-10-alkyl or aryl radicals, which optionally are substituted with a carboxyl group —SO3H or —PO3H2, and whereby the alkyl chains of the C1-10-alkyl radicals optionally contain an aryl group and/or 1-2 oxygen atoms, provided that at least one of the radicals B1, B2, B3, B4, R1, R2 and R3 does not represent a hydrogen atom,
- A represents a straight or branched, saturated or unsaturated C1-30-hydrocarbon chain that optionally contains 1-5 oxygen atoms, 1-5 nitrogen atoms and/or 1-5 —NR′ radicals, in which R′ is defined as R1, R2 and R3 but can be selected independently, which optionally is substituted with 1-3 carboxyl groups, 1-3 —SO3H, 1-3 —PO3H2 and/or 1-3 halogen atoms, in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically, and which is configured in such a way that X is connected via at least 3 atoms to the nitrogen to which A is bonded, and
- X represents a group that can participate in a reaction with a biomolecule, as well as their salts and their use for the production of a conjugate with a biomolecule.
- A corresponding macrocyclic compound in which the four nitrogen atoms of the macrocyclic ring are substituted in each case with the substituent —CH(CO2H)CH2CH2—CO2H is disclosed in P. Caravan et al., Chem. Rev. 1999, 99, 2293-2352. A possible use of this compound for the production of conjugates with biomolecules is not disclosed, however. WO 97/02051 discloses macrocyclic compounds, in which A is a radical —CH(R7)—CO—NR5—U6, as intermediate compounds for the production of cascade polymers. EP-A-0-565 930 discloses macrocyclic compounds, in which A is a radical —CH(R6)—C(O)—NH—(CH2)1-6—NH-D-. An increase in relaxivity by certain substituents is not disclosed. These compounds are consequently excluded in the definition of the compound of formula I in claim 1.
- Unless otherwise indicated, “alkyl radical” is defined here as a saturated or unsaturated, straight-chain or branched or cyclic alkyl radical with the indicated number of carbon atoms. If this radical can contain other groups or atoms, it is understood here that the other groups or atoms in addition to the already existing atoms of the radical are present and can be introduced at any position of the radical including the terminal positions.
- “Aryl” is defined here preferably as phenyl, bisphenyl, pyridyl, furanyl, pyrrolyl and imidazolyl. Especially preferred is phenyl.
- “Hydrocarbon chain,” which can be arranged completely or partially concentrically, is defined here preferably as a hydrocarbon chain such as, for example, an alkyl chain, which can comprise, for example, an aliphatic or aromatic, optionally heterocyclic 5- or 6-ring (e.g., phenyl(ene), pyridyl(ene) or cyclohexyl(ene)) or consists of the latter.
- In the compound of formula I according to the invention, three of the four nitrogen atoms of the macrocyclic ring are substituted with optionally substituted acetic acid or carboxylate methyl radicals. These radicals contribute to the coordination or to the charge equalization of a coordinated metal ion. Z therefore stands either for a hydrogen atom or a metal ion equivalent.
- The acetic acid or carboxylate methyl radicals at three of the nitrogen atoms of the macrocyclic ring in addition can have substituents R1, R2 and R3. Moreover, the macrocyclic ring can have substituents B1, B2, B3 and B4 at four of its carbon atoms. A special feature of the compounds according to the invention consists in that at least one of the B1, B2, B3, B4, R1, R2 and R3 does not represent a hydrogen atom, i.e., the macrocyclic ring must have additional substituents either directly on its ring atoms and/or on the acetic acid or carboxylate methyl substituents of its nitrogen atoms. By the suitable selection of these additional substituents, the desired fine-tuning of the relaxivity of a contrast medium that is produced with use of the compound according to the invention is carried out.
- B1, B2, B3 and B4 can be hydrogen atoms or C1-4-alkyl radicals. Preferred C1-4-alkyl radicals are methyl, ethyl and iso-propyl.
- If B1, B2, B3 and B4 are hydrogen atoms in the compounds of formula I according to the invention, R1, R2 and R3 are independently selected from the group consisting of hydrogen atoms, straight, branched and/or cyclic, saturated or unsaturated C1-10-alkyl (preferably C5-10-alkyl) or aryl radicals, which optionally are substituted with a carboxyl group, —SO3H or —PO3H2, and whereby the alkyl chains of the C1-10-alkyl radicals optionally contain an aryl group and/or 1-2 oxygen atoms, provided that at least one of the radicals R1, R2 and R3 does not represent a hydrogen atom. As alkyl radicals, straight-chain or branched, preferably saturated C1-10- and especially C1-4-alkyl radicals, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl, as well as cyclohexyl, are preferred. As an alternative, straight-chain, branched or cyclic, preferably saturated C5-10-alkyl radicals, such as pentyl, hexyl, cyclohexyl, heptyl, octyl, nonyl and decyl, are preferred. The C1-10-alkyl radicals for R1, R2 and R3 can optionally be substituted with a carboxyl group, —SO3H or —PO3H2. Preferred examples of such substituted alkyl groups are —CH2—COOH and —C(CH3)2—COOH. Moreover, the alkyl chain of the C1-10-alkyl radicals can contain an aryl group and/or 1-2 oxygen atoms. The aryl group and the oxygen atoms can be present at any position within the alkyl chain. The aryl group, moreover, can also be arranged in terminal position on the alkyl chain and can form an aryloxy group together with an oxygen atom. Especially a phenyl group is suitable as an aryl group.
- Preferred alkyl chains for R1, R2 and R3, which optionally contain an aryl group and 1-2 oxygen atoms, are radicals of formula —(CH2)m—(O)n-(phenylene)p-Y, in which m is an integer from 1-5, n is 0 or 1, p is 0 or 1 and Y is a hydrogen atom, a methoxy radical, a carboxyl group, —SO3H or —PO3H2. Substituent Y is preferably in para-position in this case.
- The aryl radicals for R1, R2 and R3 are preferably phenyl radicals, which are optionally substituted with a carboxyl group, —SO3H or —PO3H2.
- If B1, B2, B3 and B4 are hydrogen atoms, R1, R2 and R3 are preferably independently selected from the group consisting of hydrogen atoms, isopropyl, isobutyl, tert-butyl, a straight-chain or branched C5-10-alkyl radicals, cyclohexyl, —CH2—COOH, —C(CH3)2—COOH, phenyl radicals or radicals of formula —(CH2)m—(O)n-(phenylene)p-Y, in which m is an integer from 1 to 5, n is 0 or 1, p is 0 or 1, and Y represents a hydrogen atom, a methoxy radical, a carboxyl group, —SO3H or —PO3H2, and R1, R2 and R3 are especially preferably independently selected from the group consisting of hydrogen atoms, isopropyl, cyclohexyl or phenyl radicals, provided that at least one of the radicals R1, R2 and R3 does not represent a hydrogen atom.
- The substituted macrocyclic ring of the compound of formula I can be bonded via a spacer A to a biomolecule using a group X, which can participate in a reaction with a biomolecule.
- In this case, spacer A represents a straight or branched, saturated or unsaturated C1-30 hydrocarbon chain, which optionally contains 1-5 oxygen atoms, 1-5 nitrogen atoms and/or 1-5 —NR′ radicals, in which R′ is defined as R1, R2 and R3 above but can be selected independently, which optionally is substituted with 1-3 carboxyl groups, 1-3 —SO3H, 1-3 —PO3H2 and/or 1-3 halogen atoms, in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically and which is configured in such a way that X is connected via at least 3 atoms to the nitrogen atom to which A is bonded.
- The spacer is to have at least three atoms and preferably at least four atoms in a chain between the nitrogen atom of the macrocyclic ring and X. A chain of atoms is defined in this case as the shortest connection between the nitrogen atom of the macrocyclic ring and X via a ring as well. In terms of this definition, for example, a para-phenylene group would be regarded as a spacer with four atoms in a chain, and a meta-phenylene group would be regarded as a spacer with three atoms in a chain. In determining the length of the atom chain, carbon, nitrogen and oxygen atoms are simultaneously counted in each case as an atom. Substituents in these atoms or side chains are not part of the number of atoms inside the chain.
- -A-X is preferably selected to be different from the substituents —CH(R1)—CO2Z, —CH(R2)—CO2Z and —CH(R3)—CO2Z.
- Spacer A preferably can be represented as a radical A′-U, in which A′ is bonded to the nitrogen atom of the macrocyclic ring and U is bonded to X. Hereinafter, A′ is preferably
-
- a) a bond,
- b) —CH(CO2H)—,
- c) a group of formula
- in which Q represents a hydrogen atom, a C1-10-alkyl radical, which optionally is substituted with a carboxyl group, or Q represents an aryl radical, which optionally is substituted with a carboxyl group, a C1-15-alkoxy group, an aryloxy group or a halogen atom, and R′ is defined as R1, R2 and R3, but can be selected independently, or
- d) a group of formula
- in which o is 0 or 1, and the ring optionally is annellated with a benzene ring, whereby this benzene ring, if present, can be substituted with a methoxy or carboxyl group, —SO3H or —PO3H2. In the groups above under c) and d), the positions that are marked
- are bonded to the adjacent groups, position α is bonded to a nitrogen atom of the macrocyclic ring, and position β is bonded to U.
- In the group of formula
Q is preferably a linear or branched C1-10 radical, especially a C1-4-alkyl radical, such as methyl, ethyl or isopropyl, or a cyclohexyl radical. These radicals can optionally be substituted with a carboxyl group, whereby a carboxymethyl radical is preferred. The preferred aryl radical for Q is phenyl. This aryl radical can be substituted with a carboxyl group, a C1-15-alkoxy group, an aryloxy group, such as especially a phenoxy group, or a halogen atom, such as fluorine, chlorine, bromine or iodine, and especially fluorine or chlorine. If the aryl radical is a phenyl radical, the latter is preferably substituted in para-position with one of the above-mentioned groups. Especially preferred groups for Q are methyl, phenyl and p-dodecanoxyphenyl. - R′is defined as R1, R2 and R3 above, but can be selected independently from R1, R2 and R3. R′ is especially preferably a hydrogen atom.
-
- If spacer A is represented as a radical A′-U, and A′ has the meaning defined above, U is preferably a straight or branched, saturated or unsaturated C1-30-hydrocarbon chain, which optionally contains 1-3 oxygen atoms, 1-3 nitrogen atoms and/or 1-3 —NR″ radicals, in which R″ is defined as R1, R2 and R3 above, but can be selected independently, and in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically. U is especially preferably an aryl radical or a C1-20-alkyl radical (preferably straight-lined or at least partially cyclic and saturated) that optionally contains 1-3 oxygen atoms, 1-3 NR″ radicals, 1-2 phenylene radicals and/or a pyridylene radical, in which optionally 1-3 carbon atoms are present as carbonyl groups, and which optionally is substituted with an aryl radical (e.g., phenyl). A′ and U together must be configured in such a way that X is connected by at least three atoms to the nitrogen atom to which A′ is bonded. The chain of at least three atoms is defined as above in A.
- The aryl radical for U is preferably a phenyl radical. The C1-20-alkyl radical for U is preferably a linear, saturated C1-10-alkyl radical, cyclohexyl radical or cyclohexyl-C1-5-alkyl radical. The alkyl radicals of these radicals can optionally be interrupted by 1 oxygen atom, 1 phenylene radical and/or 1 pyridylene radical or can contain a —CO—NR″ radical or can be substituted with phenyl. U is preferably selected from —CH2—, —(CH2)5—, —(CH2)10—, -phenylene-O—CH2—, -phenylene-O—(CH2)3—, -phenylene-O—(CH2)10—, —CH2-phenylene-, -cyclohexylene-O—CH2—, -phenylene-, —C(phenyl)H—, —CH2-pyridylene-O—CH2—, —CH2-pyridylene- and —CH2—CO—NH—CH2—CH2—. In the above-mentioned preferred groups for U, the phenylene groups are preferably substituted in para-position, and the pyridylene groups are preferably pyrid-2,5-ylene groups or pyrid-2,4-ylene groups.
-
- Via spacer A, a group X is bonded to the macrocyclic ring in the compounds of formula I. This group X is a group that can participate in a reaction with a biomolecule. For this purpose, for example, carboxyl (—COOH), activated carboxyl, amino (—NH2), isocyanate (—NCO), isothiocyanate (—NCS), hydrazine (—NHNH2), semicarbazide (—NHCONHNH2), thiosemicarbazide (—NHCSNHNH2), chloroacetamide (—NHCOCH2Cl), bromoacetamide (—NHCOCH2Br), iodoacetamide (—NHCOCH2I), acylamino, such as, for example acetylamino (—NHCOCH3), mixed anhydrides, azide, hydroxide, sulfonyl chloride, carbodiimide or a group of formulas
in which Hal represents a halogen atom, is suitable. - Activated carboxyl groups are defined above as those carboxyl groups that can be derivatized in such a way that they facilitate the reaction with a biomolecule. Which groups can be used for activation is known, and reference can be made to, for example, M. and A. Bodanszky, “The Practice of Peptide Synthesis,” Springerverlag 1984. Examples are aducts of carboxylic acid with carbodiimides or activated esters, such as, e.g., hydroxybenzotriazole esters. Especially preferred is the activated carboxyl group for X that is selected from
- In formula I, Z stands for a hydrogen atom or a metal ion equivalent. Which metal ion in the compound according to the invention is to be complexed here depends on the intended use of the conjugates that are produced with the inventions according to the invention with a biomolecule. Corresponding conjugates are suitable, for example, for NMR diagnosis, radiodiagnosis and radiotherapy and neutron capture therapy. The conjugates in NMR diagnosis are especially preferably used as contrast media.
- The production of complexes for NMR diagnosis can be carried out as was disclosed in Patents EP 71564, EP 130934 and DE-OS 34 01 052. To this end, the metal oxide or a metal salt (for example a chloride, nitrate, acetate, carbonate or sulfate) of the desired element is dissolved or suspended in water and/or a lower alcohol (such as methanol, ethanol or isopropanol) and reacted with the solution or suspension of the equivalent amount of the complexing agent according to the invention.
- If the complexing agents are to be used for the production of radiodiagnostic agents or radiotherapeutic agents, the production of the complexes from the complexing agents can be carried out according to the methods that are described in “Radiotracers for Medical Applications,” Vol. I, CRC Press, Boca Raton, Fla.
- The compounds according to the invention are used
-
- 1. For NMR diagnosis in the form of their complexes with the ions of the paramagnetic elements with atomic numbers 21-29, 42, 44 and 58-70.
- Suitable ions are, for example, the chromium(III), ion(II), cobalt(II), nickel(II), copper(II), praseodymium(III), neodymium(III), samarium(III) and ytterbium(III) ion. Because of their strong magnetic moment, the gadolinum(II), terbium(III), dysprosium(III), holmium(III), erbium(III), manganese(II) and iron(III) ions are especially preferred for NMR diagnosis.
-
- 2. For radiodiagnosis and radiotherapy in the form of their complexes with the radioisotopes of elements with atomic numbers 26, 27, 29, 31, 32, 37-39, 43, 46, 47, 49, 61, 62, 64, 67, 70, 71, 75, 77, 82 and 83.
- The compounds according to the invention and especially their conjugates with biomolecules meet the many different requirements for suitability as contrast media for nuclear spin tomography. After oral or parenteral administration, they are thus extremely well suited for enhancing the informational value of the image that is obtained with the aid of a nuclear spin tomograph by increasing the signal intensity. They also show the high effectiveness that is necessary to load the body with the smallest possible amounts of foreign substances and the good compatibility that is necessary to maintain the non-invasive nature of the studies.
- The good water solubility and low osmolality of the compounds according to the invention and their conjugates with biomolecules allow for the production of highly concentrated solutions so as to keep the volume burden of the circulatory system within reasonable limits and to offset the dilution by bodily fluids, i.e., NMR diagnostic agents have to be 100 to 1000 times more water-soluble than for NMR spectroscopy. In addition, the compounds according to the invention have not only a high stability in vitro but also a surprisingly high stability in vivo, so that a release or an exchange of the ions, which are inherently toxic and not covalently bonded in the complexes, is carried out only extremely slowly within the time that it takes for the new contrast media to be completely excreted again.
- The complex compounds according to the invention can also be used advantageously as susceptibility reagents and as shift reagents for in vivo NMR spectroscopy.
- The compounds according to the invention and their conjugates with biomolecules are also suitable as radiodiagnostic agents and radiotherapeutic agents based on their advantageous radioactive properties and the good stability of the complex compounds that are contained therein. Details of their use and dosage are described in, e.g., “Radiotracers for Medical Applications,” CRC Press, Boca Raton, Fla. 1983, as well as in Eur. J. Nucl. Med. 17 (1990) 346-364 and Chem. Rev. 93 (1993) 1137-1156.
- For SPECT, the complexes with isotopes 111In and 99mTc are suitable.
- Another imaging method with radioisotopes is the positron-emission tomography, which uses positron-emitting isotopes such as, e.g., 43Sc, 44Sc, 52Fe, 55Co, 68Ga, 64Cu, 86Y and 94mTc (Heiss, W. D.; Phelps, M. E.; Positron Emission Tomography of Brain, Springer Verlag Berlin, Heidelberg, New York 1983).
- The compounds according to the invention and their conjugates with biomolecules are also suitable, surprisingly enough, for differentiating malignant and benign tumors in areas without blood-brain barriers.
- They are distinguished in that they are completely eliminated from the body and thus are well-tolerated.
- Since the compounds according to the invention and especially their conjugates with biomolecules accumulate in malignant tumors (no diffusion in healthy tissue, but high permeability of tumor vessels), they can also support the radiation therapy of malignant tumors. The latter is distinguished from the corresponding diagnosis only by the amount and type of the isotope that is used. The purpose in this case is the destruction of tumor cells by high-energy short-wave radiation with the lowest possible range of action. For this purpose, interactions of the metals that are contained in the complexes (such as, e.g., iron or gadolinium) with ionizing radiations (e.g., x rays) or with neutron rays are employed. By this effect, the local radiation dose at the site where the metal complex is found (e.g., in tumors) increases significantly. To produce the same radiation dose in the malignant tissue, radiation exposure for healthy tissue can be considerably reduced and thus burdensome side effects for the patients can be avoided when such metal complexes are used. The metal complex conjugates according to the invention are therefore also suitable as radio-sensitizing substances in the radiation therapy of malignant tumors (e.g., exploiting Mossbauer effects or neutron capture therapy). Suitable β-emitting ions are, e.g., 46Sc, 47Sc, 48Sc, 72Ga, 73Ga, 90Y, 67Cu, 109Pd, 111Ag, 149Pm, 153Sm, 166Ho, 177Lu, 186 Re and 188Re 90Y, 177Lu, 72Ga, 153Sm and 67Cu are preferred. Suitable α-emitting ions that have short half-lives are, e.g., 211At, 211Bi, 212Bi, 213Bi and 214Bi, whereby 212Bi is preferred. A suitable photon- and electron-emitting ion is 158Gd, which can be obtained from 157Gd by neutron capture.
- If the compound according to the invention or conjugate thereof with a biomolecule is intended for use in the variant of the radiation therapy that is proposed by R. L. Mills et al. [Nature Vol. 336 (1988), p. 787], the central ion must be derived from a Mössbauer isotope, such as, for example, 57Fe or 151Eu.
- The neutralization of optionally still present free carboxy groups is carried out with the aid of inorganic bases (e.g., hydroxides, carbonates or bicarbonates) of, e.g., sodium, potassium, lithium, magnesium or calcium and/or organic bases, such as, i.a., primary, secondary and tertiary amines, such as, e.g., ethanolamine, morpholine, glucamine, N-methylglucamine and N,N-dimethylglucamine, as well as basic amino acids, such as, e.g., lysine, arginine and ornithine or amides of originally neutral or acidic amino acids.
- For the production of natural complex compounds, as much of the desired base can be added, for example, into acid complex salts in aqueous solution or suspension so that the neutral point is reached. The solution that is obtained can then be evaporated to the dry state in a vacuum. It is often advantageous to precipitate the neutral salts that are formed by adding water-miscible solvents, such as, e.g., lower alcohols (methanol, ethanol, isopropanol, etc.), lower ketones (acetone, etc.), polar ethers (tetrahydrofuran, dioxane, 1,2-dimethoyethane, etc.) and thus to obtain easily isolated and readily purified crystallizates. It has proven especially advantageous to add the desired base as early as during the complexing of the reaction mixture and thus to save a process step.
- The compounds of formula I according to the invention can be produced according to the process that is known to one skilled in the art. For example, the compounds of formula I can be obtained by a process in which a compound of formula II
in which B1, B2, B3 and B4 are defined as above is optionally reacted after introducing protective groups for the nitrogen atoms with Nu-A-X′ and Nu-CH(R1)—CO2Z′, Nu-CH(R2)—CO2Z′ and Nu-CH(R3)—CO2Z′, whereby A and R1, R2, and R3 are defined as above and Nu is a nucleofuge, X′ stands for X or a protected form of X, and X is defined as above and Z′ stands for a hydrogen atom, a metal ion equivalent, preferably an alkali metal or alkaline-earth metal, such as especially sodium or potassium, or a protective group for carboxyl. Then, the optionally present protective groups can be removed, and it can be reacted in a way that is known in the art with at least one metal oxide or metal salt of a desired element. Then, in the thus obtained complexes, still present acid hydrogen atoms optionally can be substituted completely or partially by cations of inorganic and/or organic bases, amino acids or amino acid amides. - Three preferred process variants are described in more detail below.
- Further process variants, especially where R1, R2 and R3 do not represent the same radicals, are shown in the examples. The described process variants do not limit the extend of the invention.
- In the compounds according to the invention, B1, B2, B3 and B4 can represent the same residues, whereas R1, R2, and/or R3 can represent different residues. Furthermore B1, B2, B3 and B4 can represent different residues in the molecule and R1, R2, and/or R3 can represent the same residues. And in the compounds according to the invention B1, B2, B3 and B4 can represent different residues and also R1, R2, and/or R3 can represent different residues. Furthermore B1, B2, B3 and B4 can represent the same residues in the molecule and R1, R2, and/or R3 can also represent the same residues.
- In the first variant, the macrocyclic compound that is unsubstituted at the nitrogens is first reacted with protected unit AX′. In this case, group A carries a nucleofuge as a leaving group. By stoichiometric reaction control, one of the four nitrogen atoms in the macrocyclic compound reacts with group A with the leaving group departing. In this way, a monofunctionalized macrocyclic compound that contains radical X in protected form (X′) is obtained. In the second reaction step, the remaining three nucleophilic nitrogen atoms of the macrocyclic compound are reacted in each case with a protected carboxylic acid, which carries a nucleofuge in α-position in the carboxyl group.
- For example three equivalents of the protected carboxylic acids can be used in the second reaction step. It is possible to use one protected carboxylic acid. In this case, all residues R1R2 and R3 are the same. Alternatively up to three different protected carboxylic acids can be used in same process. In this case it is possible to introduce different residues R1, R2 and/or R3 into the molecule, wherein R1, R2 and R3 are as defined above. Of course the different protected carboxylic acids should add up to about 3 equivalents as a total. The different protected carboxylic acids can be used as a mixture, but it is preferred to add the different protected carboxylic acids in different reaction steps. With this method it is possible to obtain a well defined chemical compound or a mixture of chemical compounds having different substitution patterns. If a mixture of chemical compounds with different substitution patterns is obtained, this mixture can be seperated by known methods, such as chromatography, after the reaction. Suitable synthetic approaches for obtaining chemical compounds, in which R1, R2 and R3 are different are shown in the examples and these exemplified processes can easily be adapted by a skilled person to obtain further compounds having different residues R1, R2 and/or R3. These and further synthetic approaches are known in the art and can employ steps of e.g. addition or cleavage of protecting groups in order to selectively choose the substituents for each N-atom independently.
After the protective groups are cleaved off from the carboxylic acid functionalities, the complex that consists of paramagnetic metal ions and chelate ligands is finished by adding metal oxide or metal salt. This process variant is diagrammatically reproduced below, whereby the radicals in the formulas are defined as above: - In a second variant, a macrocyclic compound is used as an educt, which carries already suitable protective groups SG on three of the four nitrogen atoms. As protective groups, e.g., tert-butyl-oxycarbonyl (t-BOC), COCF3, carbobenzoxy (Cbo) or fluorenyl-methoxycarbonyl (FMOC), etc. are suitable here. By the presence of the protective groups, only one of the four nitrogen atoms is nucleophilic and can react with A-X′, which for its part carries a nucleofuge Nu as in the variant above. After linkage of both molecules with the leaving group departing, a cleavage of the three protective groups from the nitrogen atoms is carried out. It follows the derivatization with the aid of the carboxylic acid derivatives, as was already described for the variants above. This second process variant is diagrammatically reproduced below, whereby the radicals in the formulas are defined as above:
- SG=Protective group (e.g., BOC, Cbo, COCF3, FMOC, etc.)
- In the third variant, first one of the four nitrogen atoms of the macrocyclic compound is blocked by a corresponding protective group SG. Examples of suitable protective groups are formyl, benzyl, boctrityl, etc. The reaction now is carried out on the three remaining nucleophilic nitrogen atoms with correspondingly protected carboxylic acid derivatives, which carry a corresponding nucleofuge in α-position. For example three equivalents of the protected carboxylic acids can be used in the second reaction step. It is possible to use one protected carboxylic acid. In this case, all residues R1, R2 and R3 are the same. Alternatively up to three different protected carboxylic acids can be used in same process. In this case it is possible to introduce different residues R1, R2 and/or R3 into the molecule, wherein R1, R2 and R3 are as defined above. Of course the different protected carboxylic acids should add up to about 3 equivalents as a total. The different protected carboxylic acids can be used as a mixture, but it is preferred to add the different protected carboxylic acids in different reaction steps. With this method it is possible to obtain a well defined chemical compound or a mixture of chemical compounds having different substitution patterns. If a mixture of chemical compounds with different substitution patterns is obtained, this mixture can be seperated by known methods, such as chromatography, after the reaction. Suitable synthetic approaches for obtaining chemical compounds, in which R1, R2 and R3 are different are shown in the examples and these exemplified processes can easily be adapted by a skilled person to obtain further compounds having different residues R1, R2 and/or R3. These and further synthetic approaches are known in the art and can employ steps of e.g. addition or cleavage of protecting groups in order to selectively choose the substituents for each N-atom independently.
Then, the cleavage of protective group SG that is first introduced at the first nitrogen atom and derivatizing with AX′, which for its part also carries a nucleofuge, are carried out. This third process variant is diagrammatically reproduced below, whereby the radicals in the formulas are defined as above: - Advantageously used as a nucleofuge are the radicals:
- Cl, Br, I, O-triflate, mesylate and tosylate.
- The reaction is performed in a mixture of water and organic solvents, such as: isopropanol, ethanol, methanol, butanol, dioxane, tetrahydrofuran, dimethylformamide, dimethyl acetamide, formamide or dichloromethane. Ternary mixtures that consist of water, isopropanol and dichloromethane are preferred.
- The reaction is carried out in a temperature range of between −10° C. and 100° C., preferably between 0° C. and 30° C.
- The protection of the above-named groups can be accomplished in numerous ways that are familiar to one skilled in the art. The embodiments that are described below are used to explain these protective group techniques without being limited to these synthesis methods.
- As acid protective groups, C1-C6-alkyl, C6-C10-aryl and C6-C10—Ar(C1-C4)-alkyl groups as well as trialkylsilyl groups are suitable. The methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl and tert-butyl groups are preferred.
- The cleavage of these acid protective groups is carried out according to the processes that are known to one skilled in the art, for example by hydrolysis, hydrogenolysis, alkaline saponification of the esters with alkali in aqueous-alcoholic solution at temperatures from 0 to 50° C., acidic saponification with mineral acids or in the case of tert-butyl esters with the aid of trifluoroacetic acid.
- The NH groups can be protected in a variety of ways and then exposed again. The N-trifluoroacetyl derivative is cleaved by potassium or sodium carbonate in water (H. Newman, J. Org. Chem., 30: 287 (1965), M. A. Schwartz et al., J. Am. Chem. Soc., 95 G12 (1973)) or simply by ammonia solution (M. Imazama and F. Eckstein, J. Org. Chem., 44: 2039 (1979)). The tert-butyloxycarbonyl derivative is equally easy to cleave: stirring with trifluoroacetic acid suffices (B. F. Lundt et al., J. Org. Chem., 43: 2285 (1978)). The group of NH protective groups to be cleaved hydrogenolytically or in a reductive manner is very large: the N-benzyl group can be cleaved easily with hydrogen/Pd—C (W. H. Hartung and R. Rimonoff, Org. Reactions VII, 262 (1953)), which also applies for the trityl group (L. Zervas et al., J. Am. Chem. Soc., 78; 1359 (1956)) and the benzyloxycarbonyl group (M. Bergmann and L. Zervas Ber. 65: 1192 (1932)).
- The activated esters of the above-described compounds are produced as known to one skilled in the art. For the case of isothiocyanates or α-haloacetates, the corresponding terminal amino precursors are reacted according to methods that are known in the literature with thiophosgene or 2-halo-acetic acid-halides. The reaction with correspondingly derivatized esters of N-hydroxysuccinimide, such as, for example:
is also possible (Hal=halogen). - In general, for this purpose, all commonly used activation methods for carboxylic acids that are known in the prior art can be used. The molecule Nu-A-X is preferably synthesized first independently. If the molecule contains an amide group, the latter is produced, for example, by an activated carboxylic acid being reacted with an amine. The activation of the carboxylic acid is carried out according to the commonly used methods. Examples of suitable activating reagents are dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide-hydrochloride (EDC), benzotriazol-1-yloxytris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU), preferably DCC. The addition of O-nucleophilic catalysts, such as, e.g., N-hydroxysuccinimide (NHS) or N-hydroxybenzotriazole, is also possible.
- If group X is a carboxylic acid function, the latter can be used in protected form (e.g., in the form of benzyl ester), and the cleavage of the protective group can then be carried out hydrogenolytically.
- To link this carboxylic acid function to a suitable functional group of a suitable biomolecule, the latter should normally first be activated. Esters that are activated to this end are preferably produced at an intermediate stage, and said esters are then attacked by a nucleophilic group of the biomolecule. In this way, a covalent linkage between the biomolecule and the compound of formula I according to the invention is produced. Preferred activated esters are the esters of the N-hydroxysuccinimide, the esters of paranitrophenol or the esters of pentafluorophenol. If group X in the form of an isothiocyanate is linked to the biomolecule, a terminal amine is preferably first used which, if necessary, can be provided with a suitable protective group. Suitable protective groups are known from peptide chemistry. After the protective group is cleaved off, the isothiocyanate can be produced by reaction of the primary terminal amine with thiophosgene. Nucleophilic groups of the biomolecule can be added to the latter.
- In an embodiment, group X represents a maleinimide, which can react, e.g., selectively with thiol functions of the biomolecule.
- In another embodiment, group X is a nucleophile (NH2, SH), which affects a suitable functionality of the biomolecule (activated ester, maleinimide, etc.). Numerous biomolecules that are functionalized with maleinimides are commercially available.
- This invention, moreover, relates to the use of the above-described compounds of formula I for the production of conjugates with a biomolecule.
- The synthesis of the conjugates is generally carried out in such a way that first a derivatized and functionalized chelate complex is produced that then is linked to the biomolecule. It is also possible, however, that if synthetically produced biomolecules are used, the chelate complex according to the invention is incorporated in the latter during the synthesis of the biomolecule. This can be carried out, for example, during the sequential synthesis of oligopeptides in the synthesizing robot. If necessary, the protective groups that are commonly used in the synthesis of the corresponding biomolecule can be introduced into the compound according to the invention. The latter are then cleaved again in the synthesizer in line with the usual synthesis algorithm.
- “Biomolecule” is defined here as any molecule that either occurred naturally, for example in the body, or was produced synthetically with an analogous structure. Moreover, among the latter, those molecules are defined that can occur in interaction with a biological molecule that occurs, for example, in the body or a structure that occurs there, in such a way, for example, that the conjugates accumulate at specific desired spots of the body. “Body” is defined here as any plant or animal body, whereby animal and especially human bodies are preferred.
- Biomolecules are especially the molecules that occur in living creatures that as products of an evolutionary selection by orderly and complex interactions meet specific objects of the organism and constitute the basis of its vital functions (changes in material and shape, reproduction, energy balance). In biomolecules, simple building blocks (amino acids, nucleobases, monosaccharides, fatty acids, etc.) of large molecules (proteins, nucleic acids, polysaccharides, lipids, etc.) are used in most cases. Corresponding macromolecules are also referred to as biopolymers.
- The biomolecule advantageously can have, for example, a polypeptide skeleton that consists of amino acids with side chains that can participate in a reaction with reactive group X of the compounds of formula I according to the invention. Such side chains include, for example, the carboxyl groups of aspartic acid and glutamic acid esters, the amino groups of lysine radicals, the aromatic groups of tyrosine and histidine radicals and the sulfhydryl groups of cysteine radicals.
- A survey on biomolecules with numerous examples is found in the manuscript “Chemie der Biomoleküle [Chemistry of Biomolecules]” of TU-Graz (H. Berthold et al., Institut für Organische Chemie [Institute for Organic Chemistry], Tu-Graz, 2001), which can also be seen on the Internet under www.orgc.tu-graz.ac.at. The content of this document is integrated by reference in this description.
- To form conjugates with the compounds according to the invention, the following biomolecules are especially suitable:
- Biopolymers, proteins, such as proteins that have a biological function, HSA, BSA, etc., proteins and peptides, which accumulate at certain spots in the organism (e.g., in receptors, cell membranes, at ducts, etc.), peptides that can be cleaved by proteases, peptides with predetermined synthetic sites of rupture (e.g., labile esters, amides, etc.), peptides that are cleaved by metalloproteases, peptides with photocleavable linkers, peptides with oxidative agents (oxydases) and cleavable groups, peptides with natural and unnatural amino acids, glycoproteins (glycopeptides), signal proteins, antiviral proteins and apoctosis, synthetically modified biopolymers such as biopolymers that are derivatized with linkers, modified metalloproteases and derivatized oxydase, etc., carbohydrates (mono- to polysaccharides), such as derivatized sugars, sugars that can be cleaved in the organism, cyclodextrins and derivatives thereof, amino sugars, chitosan, polysulfates and acetylneuraminic acid derivatives, antibodies, such as monoclonal antibodies, antibody fragments, polyclonal antibodies, minibodies, single chains (also those that are linked by linkers to multiple fragments), red blood corpuscles and other blood components, cancer markers (e.g., CAA) and cell adhesion substances (e.g., Lewis X and anti-Lewis X derivatives), DNA and RNA fragments, such as derivatized DNAs and RNAs (e.g., those that were found by the SELEX process), synthetic RNA and DNA (also with unnatural bases), PNAs (Hoechst) and antisense, β-amino acids (Seebach), vector amines for transfer into the cell, biogenic amines, pharmaceutical agents, oncological preparations, synthetic polymers, which are directed to a biological target (e.g., receptor), steroids (natural and modified), prostaglandins, taxol and derivatives thereof, endothelins, alkaloids, folic acid and derivatives thereof, bioactive lipids, fats, fatty acid esters, synthetically modified mono-, di- and triglycerides, liposomes, which are derivatized on the surface, micelles that consist of natural fatty acids or perfluoroalkyl compounds, porphyrins, texaphrines, expanded porphyrins, cytochromes, inhibitors, neuramidases, neuropeptides, immunomodulators, such as FK 506, CAPE and gliotoxin, endoglycosidases, substrates that are activated by enzymes such as calmodulin kinase, casein-kinase II, glutathione-S-transferase, heparinase, matrix-metalloproteases, β-insulin-receptor-kinase, UDP-galactose 4-epimerase, fucosidases, G-proteins, galactosidases, glycosidases, glycosyltransferases and xylosidase, antibiotics, vitamins and vitamin analogs, hormones, DNA intercalators, nucleosides, nucleotides, lectins, vitamin B12, Lewis-X and related substances, psoralens, dienetriene antibiotics, carbacyclins, VEGF (vascular endothelial growth factor), somatostatin and derivatives thereof, biotin derivatives, antihormones, tumor-specific proteins and synthetic agents, polymers that accumulate in acidic or basic areas of the body (pH-controlled dispersion), myoglobins, apomyoglobins, etc., neurotransmitter peptides, tumor necrosis factors, peptides that accumulate in inflamed tissues, blood-pool reagents, anion and cation-transporter proteins, polyesters (e.g., lactic acid), polyamides and polyphosphates.
- Most of the above-mentioned biomolecules are commercially available from, for example, Merck, Aldrich, Sigma, Calibochem or Bachem.
- In addition, all “plasma protein binding groups” or “target binding groups” that are disclosed in WO 96/23526 and WO 01/08712 can be used as biomolecules. The content of these two laid-open specifications is therefore integrated by reference into this description.
- The number of compounds of formula I according to the invention per biomolecule is random in principle, but a molecular ratio of 0.1:1 to 10:1, especially 0.5:1 to 7:1, is preferred.
- The compounds according to the invention are also suitable for conjugation on all molecules that are reacted with fluorescence dyes in the prior art to determine, for example, their location by epifluorescence microscopy within the cell. After the administration of the medication, the compounds with, in principle, any medications can also be conjugated to then track the transport within the organism, for example by the NMR technique. It is also possible that the conjugates from the compounds according to the invention and the biomolecules contain other additional molecules, which had been conjugated on the biomolecules. The term “biomolecule” in terms of this invention thus encompasses all molecules that occur in the biological systems and all molecules that are biocompatible.
- The conjugates that are obtained with the compounds according to the invention are preferably used as contrast media in NMR diagnosis. The conjugates should therefore be water-soluble. If the conjugates that are obtained with the compounds according to the invention are to be used as NMR contrast media, they are preferably dosed in an amount of 0.0001-5 mmol/kg of body weight and especially preferably in an amount of 0.005-0.5 mmol/kg of body weight. Details of use are discussed in, e.g., H.-J. Weinmann et al., Am. J. of Roentgenology 142, 619 (1984). By the surprisingly high relaxivity of the compounds according to the invention with simultaneous target specificity of the conjugates that are obtained with these compounds, the latter can be especially low-dosed, for example, to detect tumors.
- Details of use of radiotherapeutic agents are discussed in, e.g., R. W. Kozak et al. TIBTEC, October 1986, 262 (see above Bioconjugate Chem. 12 (2001) 7-34).
- This invention is explained in more detail by the examples below without being limited thereto.
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
- In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.
- 25 g (81.1 mmol) of 2-bromopropionylglycine-benzyl ester (Example 1e of WO 98/24774) is added to 27.9 g (162.2 mol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[4-(benzyloxycarbonyl)-1-methyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane (19.6 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 32.0 g (73% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 68.39; H, 7.23; N, 7.98.
- Fnd.: C, 67.95; H, 7.41; N, 8.22.
- 26.3 g (30 mmol) of the title compound of Example 1a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 15.7 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 51.05; H, 7.60; N, 13.53.
- Fnd.: C, 50.71; H, 7.83; N, 13.25.
- 10.4 g (20 mmol) of the ligand that is described in Example 1b is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20:1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 10.1 g (69% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.3%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 39.33; H, 5.40; Gd, 23.41; N, 10.42.
- Fnd.: C, 39.21; H, 5.88; Gd, 22.93; N, 10.11.
- 19.6 g (50 mmol) of the 1-[4-(benzyloxy-carbonyl)-1-methyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane that is described in Example 1a as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 68.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 33.7 g (70% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 69.90; H, 7.86; N, 7.28.
- Fnd.: C, 69.77; H, 7.51; N, 7.22.
- 28.9 g (30 mmol) of the title compound of Example 2a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 18.0 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 55.89; H, 8.54; N, 11.64.
- Fnd.: C, 55.63; H, 8.83; N, 11.31.
- 12.0 g (20 mmol) of the ligand that is described in Example 2b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 12.0 g (72% of theory) of a colorless powder.
- Water content (Karl-Fischer): 9.1%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 44.49; H, 6.40; Gd, 20.80; N, 9.26.
- Fnd.: C, 44.21; H, 6.72; Gd, 20.23; N, 9.11.
- 19.6 g (50 mmol) of 1-[4-(benzyloxy-carbonyl)-1-methyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane that is described in Example 1a as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 76.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 41.1 g (76% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 72.13; H, 8.10; N, 6.47.
- Fnd.: C, 71.88; H, 8.21; N, 6.25.
- 32.5 g (30 mmol) of the title compound of Example 3a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 22.0 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 61.56; H, 8.80; N, 9.70.
- Fnd.: C, 61.17; H, 8.98; N, 9.41.
- 14.4 g (20 mmol) of the ligand that is described in Example 3b is dissolved in 150 ml of water and 150 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 12.4 g (65% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 50.72; H, 6.90; Gd 17.95; N, 7.99.
- Fnd.: C, 51.03; H, 7.08; Gd, 17.42; N, 8.11.
- 26.6 g (81.1 mmol) of N-[2-bromo-2-phenylacetyl]-glycine-t-butylester (Example 6a of WO 98/24775) is added to 27.9 g (162.2 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[4-(t-butoxycarbonyl)-1-phenyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane (21.0 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyl-oxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 34.0 g (75% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 68.93; H, 7.45; N, 7.73.
- Fnd.: C, 69.12; H, 7.57; N, 7.60.
- 27.2 g (30 mmol) of the title compound of Example 4a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 17.5 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 55.95; H, 7.13; N, 12.08.
- Fnd.: C, 56.21; H, 6.99; N, 11.83.
- 11.6 g (20 mmol) of the t-butylester that is described in Example 4b is dissolved in a very little trifluoroacetic acid and stirred for 15 minutes at room temperature. After 250 ml of diethyl ether is added, it is stirred for 2 more hours, the precipitate is suctioned off and dried in a vacuum. The thus obtained free ligand is dissolved in 200 ml of water and 80 ml of isopropanol, set at pH 7 with dilute ammonia and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.6 g (72% of theory) of a colorless powder.
- Water content (Karl-Fischer): 9.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 44.19; H, 5.22; Gd 21.43; N, 9.54.
- Fnd.: C, 43.91; H, 5.27; Gd, 21.09; N, 9.77.
- 10 g (60.2 mmol) of hydroxyphenylacetic acid methyl ester (Aldrich) is dissolved in 75 ml of acetone. 18.4 g (133 mmol) of solid potassium carbonate is added. 17.8 ml (123 mmol) of bromoacetic acid ethyl ester is added in drops under reflux within 15 minutes, it is kept at this temperature for another 4 hours, and it is stirred overnight at room temperature. Precipitate is filtered out, the solution is evaporated to the dry state and chromatographed on silica gel (hexane/ethyl acetate 3:1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 14.6 g (96% of theory)
- Elementary analysis:
- Cld.: C, 61.90; H, 6.39.
- Fnd.: C, 61.67; H, 6.50.
- 13.5 g (53.5 mmol) of the title compound of Example 5a is dissolved in 75 ml of carbon tetrachloride. 9.52 g (53.5 mmol) of N-bromosuccinimide and 48 mg of dibenzoyl peroxide are added, refluxed for 5 hours and stirred overnight at room temperature. The suspension is washed twice with sodium bicarbonate solution and once with water, the organic phase is dried with magnesium sulfate, desiccant is suctioned off, and the filtrate is evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (hexane/ethyl acetate 3:1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 15.4 g (87% of theory)
- Elementary analysis:
- Cld.: C, 47.15; H, 4.57; Br, 24.13.
- Fnd.: C, 47.01; H, 4.76; Br, 23.70.
- 26.9 g (81.1 mmol) of the bromine compound that is described in Example 5b above is added to 27.9 g (162.2 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/triethylamine=10/5/0.1). The thus obtained 1-[α-(4-(ethoxycarbonylmethoxy)phenyl)-methoxycarbonylmethyl]-1,4,7,10-tetraazacyclododecane (21.1 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane; and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 34.1 g (75% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 67.38; H, 7.10; N, 6.16.
- Fnd.: C, 67.20; H, 7.33; N, 6.31.
- 27.3 g (30 mmol) of the title compound of Example 5c is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 19.3 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 56.42; H, 7.26; N, 8.77.
- Fnd.: C, 56.21; H, 7.56; N, 8.47.
- 13.3 g (20 mmol) of the title compound of Example 5d is taken up in 250 ml of 2N sodium hydroxide solution and 250 ml of tetrahydrofuran, and it is stirred for 5 days at 40° C. Then, the aqueous phase is set at pH 7 with Amberlite IR-120® (H+ form), 80 ml of isopropanol is added, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinum oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 8.6 g (61% of theory) of a colorless powder.
- Water content (Karl-Fischer): 9.3%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 43.19; H, 4.97; Gd, 20.94; N, 7.46.
- Fnd.: C, 43.22; H, 5.29; Gd, 20.42; N, 7.11.
- 10 g (60.2 mmol) of hydroxyphenylacetic acid methyl ester (Aldrich) is dissolved in 75 ml of acetone. 18.4 g (133 mmol) of solid potassium carbonate is added. 17.8 ml (123 mmol) of 4-bromobutyric acid ethyl ester is added in drops under reflux within 15 minutes, and it is kept at this temperature for another 4 hours and stirred overnight at room temperature. Precipitate is filtered out, the solution is evaporated to the dry state, and it is chromatographed on silica gel (hexane/ethyl acetate 3:1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 16.4 g (97% of theory)
- Elementary analysis:
- Cld.: C, 64.27; H, 7.19.
- Fnd.: C, 64.41; H, 6.92.
- 15.0 g (53.5 mmol) of the title compound of Example 6a is dissolved in 75 ml of carbon tetrachloride. 9.52 g (53.5 mmol) of N-bromosuccinimide and 48 mg of dibenzoyl peroxide are added, and it is refluxed for 5 hours and stirred overnight at room temperature. The suspension is washed twice with sodium bicarbonate solution and once with water, the organic phase is dried with magnesium sulfate, desiccant is filtered out, and the filtrate is evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (hexane/ethyl acetate 3:1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 15.9 g (83% of theory)
- Elementary analysis:
- Cld.: C, 50.16; H, 5.33; Br, 22.24.
- Fnd.: C, 50.33; H, 5.04; Br, 21.94.
- 29.1 g (81.1 mmol) of the bromine compound that is described in Example 6b above is added to 27.9 g (162.2 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/triethylamine=10/5/0.1). The thus obtained 1-[α-(4-(ethoxycarbonylpropoxy)phenyl)methoxycarbonyl methyl]-1,4,7,10-tetraazacyclododecane (22.5 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid-benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is refluxed for 6 hours and then overnight at room temperature. It is extracted three times with 500 ml each of water, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 30.5 g (65% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 67.93; H, 7.31; N, 5.98.
- Fnd.: C, 67.95; H, 7.22; N, 6.13.
- 28.1 g (30 mmol) of the title compound of Example 6c is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 20.0 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 57.64; H, 7.56; N, 8.40.
- Fnd.: C, 57.43; H, 7.77; N, 8.69.
- 13.3 g (20 mmol) of the title compound of Example 6d is taken up in 250 ml of 2N sodium hydroxide solution and 250 ml of tetrahydrofuran, and it is stirred for 5 days at 40° C. Then, the aqueous phase is set at pH 7 with Amberlite IR-120® (H+ form), 80 ml of isopropanol is added, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 9.3 g (55% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 44.72; H, 5.31; Gd, 20.19; N, 7.19.
- Fnd.: C, 44.31; H, 5.88; Gd, 19.93; N, 7.11.
- 10 g (60.2 mmol) of hydroxyphenylacetic acid methyl ester (Aldrich) is dissolved in 75 ml of acetone. 18.4 g (133 mmol) of solid potassium carbonate is added, 36.1 g (123 mmol) of ω-bromoundecanoic acid ethyl ester in 50 ml of acetone is added in drops, refluxed for 8 hours and stirred overnight at room temperature. The undissolved material is filtered out, the solution is evaporated to the dry state and chromatographed on silica gel (hexane/ethyl acetate 3:1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 20.3 g (89% of theory)
- Elementary analysis:
- Cld.: C, 69.81; H, 9.05.
- Fnd.: C, 69.50; H, 8.91.
- 20.2 g (53.5 mmol) of the title compound of Example 7a is dissolved in 75 ml of carbon tetrachloride. 9.52 g (53.5 mmol) of N-bromosuccinimide and 48 mg of dibenzoyl peroxide are added, refluxed for 5 hours and stirred overnight at room temperature. The suspension is washed twice with sodium bicarbonate solution and once with water, the organic phase is dried with magnesium sulfate, desiccant is filtered out, and the filtrate is evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (hexane/ethyl acetate 3:1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 21.0 g (86% of theory)
- Elementary analysis:
- Cld.: C, 57.77; H, 7.27; Br, 17.47.
- Fnd.: C, 57.95; H, 7.41; Br, 17.02.
- 37.1 g (81.1 mmol) of the bromine compound that is described in Example 7b above is added to 27.9 g (162.2 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/triethylamine=10/5/0.1). The thus obtained 1-[α-(4-(ethoxycarbonyldecyloxy)phenyl)-methoxycarbonylmethyl]-1,4,7,10-tetraazacyclododecane (27.4 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mmol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate, and it is evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 33.6 g (65% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 69.61; H, 7.98; N, 5.41.
- Fnd.: C, 69.75; H, 7.88; N, 5.12.
- 31.1 g (30 mmol) of the title compound of Example 7c is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 23.0 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 61.24; H, 8.43; N, 7.32.
- Fnd.: C, 60.96; H, 8.61; N, 7.22.
- 15.3 g (20 mmol) of the title compound of Example 7d is taken up in 250 ml of 2N sodium hydroxide solution and 250 ml of tetrahydrofuran, and it is stirred for 5 days at 40° C. Then, the aqueous phase is set at pH 7 with Amberlite IR-120® (H+ form), 80 ml of isopropanol is added, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.5 g (60% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 49.30; H, 6.32; Gd, 17.93; N, 6.39.
- Fnd.: C, 49.56; H, 6.10; Gd, 17.52; N, 6.63.
- 18.6 g (81.1 mmol) of 4-bromomethyl-benzoic acid methyl ester (Aldrich) in 150 ml of chloroform is added to 27.9 g (162.2 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: methanol/aqueous 25% ammonia=8/1). The thus obtained 1-(p-methoxycarbonylbenzyl)-1,4,7,10-tetraazacyclododecane (21.6 g; 67.3 mmol; 83% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 41.8 g (77% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 69.95; H, 7.24; N, 6.94.
- Fnd.: C, 69.57; H, 7.39; N, 7.12.
- 24.2 g (30 mmol) of the title compound of Example 8a is dissolved in 400 ml of methanol, mixed with 100 ml of 15N sodium hydroxide solution, refluxed for 6 hours and stirred overnight at room temperature. After concentration by evaporation in a vacuum, the residue is dissolved in 200 ml of water and set at pH 7 by adding IR-120® cation exchanger (H+ form). Exchanger is filtered out and evaporated to the dry state in a vacuum. The residue is complexed without being further characterized.
- Thin-layer system: n-butanol/aqueous ammonia/ethanol/water 12/6/3/3
- Yield: 16 g
- 11 g (20 mmol) of the ligand that is described in Example 8b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added and refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 8.9 g (61% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.2%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 44.37; H, 5.21; Gd, 23.23; N, 8.28.
- Fnd.: C, 44.12; H, 5.46; Gd, 22.93; N, 8.51.
- 21.6 g (67.3 mmol) of the 1-(p-methoxycarbonylbenzyl)-1,4,7,10-tetraazacyclododecane that is described in Example 8a as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 85.1 g (0.25 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 48.5 g (81% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 71.43; H, 7.92; N, 6.29.
- Fnd.: C, 71.12; H, 7.79; N, 6.55.
- 26.7 g (30 mmol) of the title compound of Example 9a is dissolved in 400 ml of methanol, mixed with 100 ml of 15N sodium hydroxide solution, refluxed for 6 hours and stirred overnight at room temperature. After concentration by evaporation in a vacuum, the residue is dissolved in 200 ml of water and set at pH 7 by adding IR-120® cation exchanger (H+ form). Exchanger is filtered out, and it is evaporated to the dry state in a vacuum. The residue is complexed without being further characterized.
- Thin-layer system: n-butanol/aqueous ammonia/ethanol/water 12/6/3/3
- Yield: 19 g
- 12.6 g (20 mmol) of the ligand that is described in Example 9b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 10.9 g (65% of theory) of a colorless powder.
- Water content (Karl-Fischer): 9.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 48.93; H, 6.23; Gd, 20.66; N, 7.36.
- Fnd.: C, 48.87; H, 6.01; Gd, 20.22; N, 7.59.
- 21.6 g (67.3 mmol) of the 1-(p-methoxycarbonylbenzyl)-1,4,7,10-tetraazacyclododecane that is described in Example 8a as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 95.1 g (0.25 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 48.3 g (71% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 73.63; H, 8.17; N, 5.54.
- Fnd.: C, 73.42; H, 8.39; N, 5.75.
- 30.3 g (30 mmol) of the title compound of Example 10a is dissolved in 400 ml of methanol, mixed with 100 ml of 15N sodium hydroxide solution, refluxed for 6 hours and stirred overnight at room temperature. After concentration by evaporation in a vacuum, the residue is dissolved in 200 ml of water and set at pH 7 by adding IR-120® cation exchanger (H+ form). Exchanger is filtered out, and it is evaporated to the dry state in a vacuum. The residue is complexed without being further characterized.
- Thin-layer system: n-butanol/aqueous ammonia/ethanol/water 12/6/3/3
- Yield: 22.5 g
- 15.0 g (20 mmol) of the ligand that is described in Example 10b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 11.9 g (63% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 54.52; H, 6.75; Gd, 17.85; N, 6.36.
- Fnd.: C, 54.19; H, 6.83; Gd, 17.61; N, 6.69.
- 21.6 g (67.3 mmol) of 1-(p-methoxycarbonylbenzyl)-1,4,7,10-tetraazacyclododecane that is described in Example 8a as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 93.6 g (0.25 mol) of 2-(trifluoromethanesulfonyloxy)-2-phenylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 50.8 g (76% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 74.98; H, 6.49; N, 5.64.
- Fnd.: C, 75.22; H, 6.61; N, 5.47.
- 29.8 g (30 mmol) of the title compound of Example 11a is dissolved in 400 ml of methanol, mixed with 100 ml of 15N sodium hydroxide solution, refluxed for 6 hours and stirred overnight at room temperature. After concentration by evaporation in a vacuum, the residue is dissolved in 200 ml of water and set at pH 7 by adding IR-120® cation exchanger (H+ form). Exchanger is filtered out, and it is evaporated to the dry state in a vacuum. The residue is complexed without being further characterized.
- Thin-layer system: n-butanol/aqueous ammonia/ethanol/water 12/6/3/3
- Yield: 22.0 g
- 14.6 g (20 mmol) of the ligand that is described in Example 11b is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 13.1 g (70% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.1%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 55.67; H, 4.79; Gd, 18.22; N, 6.49.
- Fnd.: C, 55.33; H, 4.97; Gd, 17.92; N, 6.54.
- 26.6 g (81.1 mmol) of N-[2-bromo-2-phenylacetyl]-glycine-t-butylester (Example 6a of WO 98/24775) is added to 27.9 g (162.2 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[4-(t-butoxycarbonyl)-1-phenyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane (21.0 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 74.9 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-phenylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 30/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 37.7 g (69% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 73.67; H, 6.74; N, 6.41.
- Fnd.: C, 73.44; H, 6.43; N, 6.79.
- 32.8 g (30 mmol) of the title compound of Example 12a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 24.8 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 67.22; H, 6.74; N, 8.52.
- Fnd.: C, 67.00; H, 6.85; N, 8.23.
- 16.4 g (20 mmol) of the t-butylester that is described in Example 12b is dissolved in very little trifluoroacetic acid, and it is stirred for 15 minutes at room temperature. After 250 ml of diethyl ether is added, it is stirred for 2 more hours, the precipitate is suctioned off, and it is dried in a vacuum. The thus obtained free ligand is dissolved in 200 ml of water and 80 ml of isopropanol, set at pH 7 with dilute ammonia and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 25/15/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.7 g (59% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 54.83; H, 4.82; Gd, 17.09; N, 7.61.
- Fnd.: C, 54.91; H, 4.67; Gd, 16.62; N, 7.33.
- 23.2 g (81.1 mmol) of 2-bromoacetylglycine-benzyl ester (Teger-Nilsson et al., WO 93/11152, page 38) is added to 34.4 g (0.2 mol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[4-(benzyloxycarbonyl)-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane (19.6 g; 50 mmol; 62% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 68.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53/43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 37.0 g (78% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 69.67; H, 7.76; N, 7.39.
- Fnd.: C, 69.51; H, 7.88; N, 7.39.
- 28.4 g (30 mmol) of the title compound of Example 13a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 17.7 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 55.18; H, 8.40; N, 11.92.
- Fnd.: C, 54.97; H, 8.70; N, 11.88.
- 11.8 g (20 mmol) of the ligand that is described in Example 13b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 12.1 g (75% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 43.71; H, 6.25; Gd, 21.19; N, 9.44.
- Fnd.: C, 43.90; H, 6.40; Gd, 20.80; N, 9.33.
- 18.9 g (50 mmol) of 1-[4-(benzyloxycarbonyl)-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane that is described in Example 13a as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 76.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 38.5 g (72% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 71.95; H, 8.02; N, 6.56.
- Fnd.: C, 71.90; H, 8.21; N, 6.73.
- 32.1 g (30 mmol) of the title compound of Example 14a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 21.2 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 61.08; H, 8.69; N, 9.89.
- Fnd.: C, 61.27; H, 8.55; N, 9.41.
- 14.2 g (20 mmol) of the ligand that is described in Example 14b is dissolved in 150 ml of water and 150 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 13.5 g (71% of theory) of a colorless powder.
- Water content (Karl-Fischer): 9.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 50.15; H, 6.78; Gd, 18.24; N, 8.12.
- Fnd.: C, 49.92; H, 6.51; Gd, 18.01; N, 8.31.
- 0.50 g (1.67 mmol) of 2-bromo-propionylglycine-benzyl ester (Example 1e of WO 98/24774) is added to 1.14 g (5 mmol) of 2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane (Petrov et al., DE 19608307; Ranganathan et al., WO 95/31444), dissolved in 10 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). 822 mg (4.2 mmol) of bromoacetic acid-tert-butyl ester is added to the thus obtained 1-[4-(benzyloxycarbonyl)-1-methyl-2-oxo-3-azabutyl]-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane (0.70 g; 1.27 mmol; 76% of theory) and 541 mg (5.1 mmol) of sodium carbonate in 5 ml of acetonitrile, and it is stirred for 12 hours at 60° C. It is cooled to 0° C., and salts are filtered out. The filtrate is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: methylene chloride/methanol=20:1).
- Yield: 964 mg (85% of theory) of a colorless solid
- Elementary analysis:
- Cld.: C, 56.49; H, 8.01; N, 7.84; Na, 2.57; Br, 8.95.
- Fnd.: C, 56.37; H, 7.88; N, 7.61; Na, 2.33; Br, 8.59.
- 893 mg (1.0 mmol) of the title compound of Example 15a is dissolved in 10 ml of isopropanol, and a spatula tip full of palladium catalyst (10% Pd/C) is added. It is hydrogenated overnight at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state. The residue is recrystallized from dioxane.
- Yield: 562 mg (70% of theory) of a crystalline solid
- Elementary analysis:
- Cld.: C, 52.36; H, 8.16; N, 8.72; Na, 2.86; Br, 9.95.
- Fnd.: C, 52.51; H, 8.30; N, 8.93; Na, 2.71; Br, 9.44.
- 803 mg (1.0 mmol) of the title compound of Example 15b is dissolved in 5 ml of trifluoroacetic acid and stirred for 3 hours at room temperature. It is evaporated to the dry state, the residue is taken up in 300 ml of water, and the solution is added to a column, filled with Reillex® 425 PVP. It is eluted with water. The product-containing fractions are combined and evaporated to the dry state (446 mg; 0.84 mmol) and again dissolved in 4 ml of water. 152 mg (0.42 mmol) of gadolinium oxide is added, and it is heated for 3 hours to 90° C. It is evaporated to the dry state (vacuum), and the residue is crystallized from 90% aqueous ethanol. The crystals are suctioned off, washed once with ethanol, then with acetone and finally with dimethyl ether and dried in a vacuum furnace at 130° C. (24 hours).
- Yield: 469 mg (65% of theory) of a colorless, crystalline powder
- Water content: 5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 40.28; H, 5.58; N, 10.21; Gd, 22.93.
- Fnd.: C, 40.06; H, 5.75; N, 10.43; Gd, 22.40.
- 2.27 g (3 mmol) of the Gd complex acid that is described in Example 2 is dissolved in 15 ml of DMF, mixed with 380 mg (3.3 mmol) of N-hydroxysuccinimide and 681 mg (3.3 mmol) of dicyclohexylcarbodiimide while being cooled with ice and preactivated for 1 hour in ice. Then, a mixture that consists of 839 mg (3.3 mmol) of N-(2-aminoethyl)maleimide trifluoroacetate salt (Arano et al., J. Med. Chem., 1996, 39, 3458) and 0.7 ml (4 mmol) of N,N-diisopropylethyl-amine in 10 ml of DMF is added and stirred overnight at room temperature. The reaction mixture is cooled again in an ice bath, filtered, and the filtrate is evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 1/1).
- Yield: 997 mg (35% of theory)
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 46.51; H, 6.20; Gd, 17.91; N, 11.17.
- Fnd.: C, 46.28; H, 6.44; Gd, 17.31; N, 11.26.
- 2.63 g (3 mmol) of the Gd complex acid that is described in Example 3 is dissolved in 15 ml of DMF, mixed with 380 mg (3.3 mmol) of N-hydroxysuccinimide and 681 mg (3.3 mmol) of dicyclohexylcarbodiimide while being cooled with ice, and preactivated for 1 hour in ice. Then, a mixture that consists of 839 mg (3.3 mmol) of N-(2-aminoethyl)maleimide trifluoroacetate salt (Arano et al., J. Med. Chem., 1996, 39, 3458) and 0.7 ml (4 mmol) of N,N-diisopropylethylamine in 10 ml of DMF is added and stirred overnight at room temperature. The reaction mixture is cooled again in an ice bath, filtered, and the filtrate is evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 1/1).
- Yield: 1.24 g (39% of theory)
- Water content (Karl-Fischer): 6.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 51.74; H, 6.66; Gd, 15.75; N, 9.82.
- Fnd.: C, 51.77; H, 6.41; Gd, 15.25; N, 10.02.
- 67.7 g (0.2 mol) of glycinebenzyl ester tosylate and 61.2 ml (0.44 mol) of triethylamine are dissolved in 200 ml of methylene chloride and added in drops at 0° C. to a solution of 52.9 g (0.2 mol) of 2,4-dibromobutyric acid chloride (Gramain et al. Synth. Commun. (1997), (27), 1827) in 200 ml of methylene chloride within 45 minutes, and it is stirred for 18 hours at room temperature. The reaction mixture is now added in drops at 0° C. to a solution of 400 ml of aqueous 32% sodium hydroxide and 2 g of tetrabutylammonium hydrogen carbonate (about 15 minutes), and it is stirred for 30 minutes. Then, the phases are separated, and the aqueous phase is extracted three times with 200 ml each of dichloromethane. The organic phases are dried on sodium sulfate, the solution is evaporated to the dry state and chromatographed on silica gel (methylene chloride). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 29.3 g (47% of theory)
- Elementary analysis:
- Cld.: C, 50.02; H, 4.52; N, 4.49.
- Fnd.: C, 50.34; H, 4.44; N, 4.41.
- 20.7 (66.3 mmol) of (3-bromo-2-oxo-pyrrolidin-1-yl)acetic acid benzyl ester is added to 28.7 g (165.8 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[1-(benzyloxycarbonylmethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7,10-tetraazacyclododecane (20.9 g; 51.8 mmol; 78% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 32.7 g (71% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Clod.: C, 68.82; H, 7.13; N, 7.87.
- Find.: C, 68.54; H, 7.28; N, 8.01.
- 26.7 g (30 mmol) of the title compound of Example 18b is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 15.8 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 52.16; H, 7.42; N, 13.22.
- Fnd.: C, 52.32; H, 7.35; N, 13.11.
- 10.6 g (20 mmol) of the ligand that is described in Example 18c is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic elate is freeze-dried.
- Yield: 9.7 g (67% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.3%
- Elementary analysis (relative to anhydrous substance)
- Cld.: C, 40.40; H, 5.31; Gd, 23.00; N, 10.24.
- Fnd.: C, 39.99; H, 5.55; Gd, 22.93; N, 10.45.
- 20.2 g (50 mmol) of 1-[1-(benzyloxycarbonylmethyl)-2-oxo-pyrolidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 18b as an intermediate product and 60 ml (0.35 mmol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 68.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 34.1 g (70% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 70.27; H, 7.76; N, 7.19.
- Fnd.: C, 70.45; H, 7.61; N, 7.11.
- 29.2 g (30 mmol) of the title compound of Example 19a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 18.4 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 56.75; H, 8.38; N, 11.41.
- Fnd.: C, 56.89; H, 8.31; N, 11.37.
- 12.3 g (20 mmol) of the ligand that is described in Example 19b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.9 g (75% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.2%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 45.36; H, 6.30; Gd, 20.48; N, 9.12.
- Fnd.: C, 45.89; H, 6.22; Gd, 20.23; N, 9.01.
- The Dy complex of 10-[1-(carboxymethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is obtained analogously with use of 12.3 g (20 mmol) of the ligand that is described in Example 19b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Yield: 11.4 g (71% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 45.05; H, 6.26; Dy, 21.02; N, 9.06.
- Fnd.: C, 45.35; H, 6.22; Dy, 20.88; N, 9.04.
- 20.2 g (50 mmol) of 1-[1-(benzyloxycarbonylmethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 18b as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 76.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 37.2 g (68% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 72.43; H, 8.01; N, 6.40.
- Fnd.: C, 72.55; H, 7.98; N, 6.35.
- 32.8 g (30 mmol) of the title compound of Example 20a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 22.0 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 62.19; H, 8.65; N, 9.54.
- Fnd.: C, 62.44; H, 8.56; N, 9.46.
- 14.6 g (20 mmol) of the ligand that is described in Example 20b is dissolved in 150 ml of water and 150 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane, and then it is dried in a vacuum until a constant weight is reached.
- Yield: 12.1 g (65% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 51.39; H, 6.81; Gd, 17.70; N, 7.89.
- Fnd.: C, 51.64; H, 6.77; Gd, 17.44; N, 7.77.
- 45.5 g (0.2 mol) of 4-aminobeznoic acid benzyl ester and 30.6 ml (0.22 mol) of triethylamine are dissolved in 200 ml of methylene chloride and added in drops at 0° C. to a solution of 52.9 g (0.2 mol) of 2,4-dibromobutyric acid chloride (Gramin et al. Synth. Commun. (1997), (27), 1827) in 200 ml of methylene chloride within 45 minutes, and it is stirred for 18 hours at room temperature. The reaction mixture is now added in drops at 0° C. to a solution of 400 ml of aqueous 32% sodium hydroxide and 2 g of tetrabutylammonium hydrogen carbonate (about 15 minutes), and it is stirred for 30 minutes. Then, the phases are separated, and the aqueous phase is extracted three times with 200 ml of dichloromethane each. The organic phases are dried on sodium sulfate, the solution is evaporated to the dry state and chromatographed on silica gel (methylene chloride). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 38.2 g (51% of theory)
- Elementary analysis:
- Cld.: C, 57.77; H, 4.31; N, 3.74.
- Fnd.: C, 57.99; H, 4.27; N, 3.66.
- 26.9 g (71.9 mmol) of (3-bromo-2-oxo-pyrrolidin-1-yl)benzoic acid benzyl ester is added to 31.2 g (180 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[1-(4-benzyloxycarbonylphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7,10-tetraazacyclododecane (26.1 g; 56.1 mmol; 78% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 36.3 g (68% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 70.64; H, 6.88; N, 7.36.
- Fnd.: C, 70.89; H, 6.81; N, 7.29.
- 28.6 g (30 mmol) of the title compound of Example 21 b is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 17.7 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 56.84; H, 6.98; N, 11.84.
- Fnd.: C, 57.04; H, 6.91; N, 11.79.
- 11.8 g (20 mmol) of the ligand that is described in Example 21c is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.1 g (71% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 45.09; H, 5.13; Gd, 21.08; N, 9.39.
- Fnd.: C, 45.45; H, 5.11; Gd, 20.78; N, 9.40.
- 23.3 g (50 mmol) of 1-[1-(4-benzyloxycarbonylphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 21b as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 68.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 35.3 g (68% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 71.86; H, 7.49; N, 6.76.
- Fnd.: C, 71.99; H, 7.46; N, 6.71.
- 31.1 g (30 mmol) of the title compound of Example 22a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 20.2 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 60.43; H, 7.90; N, 10.36.
- Fnd.: C, 60.59; H, 7.82; N, 10.31.
- 13.5 g (20 mmol) of the ligand that is described in Example 22b is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 12.4 g (72% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.8%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 49.20; H, 6.07; Gd, 18.94; N, 8.44.
- Fnd.: C, 49.51; H, 6.04; Gd, 18.71; N, 8.45.
- The Dy complex of 10-[1-(4-carboxyphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is analogously obtained with use of 13.5 g (20 mmol) of the ligand that is described in Example 22b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Yield: 13.0 g (75% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 48.89; H, 6.03; Dy, 19.45; N, 8.38.
- Fnd.: C, 49.11; H, 6.04; Dy, 19.22; N, 8.36.
- 23.3 g (50 mmol) of 1-[1-(4-benzyloxycarbonylphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 21b as an intermediate product and 60 ml (0.35 mol) of N-ethylodiisopropylamine in 200 ml of dichloromethane are added to 76.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexyalacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 41.1 g (71% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 73.74; H, 7.76; N, 6.06.
- Fnd.: C, 73.91; H, 7.69; N, 6.01.
- 34.7 g (30 mmol) of the title compound of Example 23a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 23.8 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 64.88; H, 8.23; N, 8.80.
- Fnd.: C, 65.04; H, 8.19; N, 8.70.
- 15.9 g (20 mmol) of the ligand that is described in Example 23b is dissolved in 150 ml of water and 150 ml of isopropanol and acidified by adding 5 ml of acetic acid.
- 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 12.9 g (65% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.0%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 54.35; H, 6.58; Gd, 16.55; N, 7.37.
- Fnd.: C, 54.66; H, 6.57; Gd, 16.32; N, 7.32.
- 67.7 g (0.2 mol) of glycine benzyl ester tosylate and 61.2 ml (0.44 mol) of triethylamine are dissolved in 200 ml of methylene chloride and added in drops at 0° C. to a solution of 55.7 g (0.2 mol) of 2,5-dibromovaleric acid chloride (Okawara et al. Chem. Pharm. Bull. (1982), (30), 1225) in 200 ml of methylene chloride within 45 minutes, and it is stirred for 18 hours at room temperature. The reaction mixture is now added in drops at 0° C. to a solution of 400 ml of aqueous 32% sodium hydroxide and 2 g of tetrabutylammonium hydrogen carbonate (about 15 minutes), and it is stirred for 30 minutes. Then, the phases are separated, and the aqueous phase is extracted three times with 200 ml of dichloromethane each. The organic phases are dried on sodium sulfate, the solution is evaporated to the dry state and chromatographed on silica gel (methylene chloride). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 33.2 g (51% of theory)
- Elementary analysis:
- Cld.: C, 51.55; H, 4.94; N, 4.29.
- Fnd.: C, 51.86; H, 4.91; N, 4.18
- 18.9 g (58 mmol) of (3-bromo-2-oxo-piperidin-1-yl)acetic acid benzyl ester is added to 30.3 g (175 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia=10/5/1). The thus obtained 1-[1-(benzyloxycarbonylmethyl)-2-oxo-piperidin-3-yl]-1,4,7,10-tetraazacyclododecane (20.3 g; 48.6 mol; 84% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, and the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 32.5 g (74% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 69.08; H, 7.25; N, 7.75.
- Fnd.: C, 69.34; H, 7.19; N, 7.66.
- 27.1 g (30 mmol) of the title compound of Example 24b is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 16.3 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 53.03; H, 7.60; N, 12.88.
- Fnd.: C, 53.34; H, 7.54; N, 12.79.
- 10.9 g (20 mmol) of the ligand that is described in Example 24c is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added and refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 9.6 g (65% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.2%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 41.31; H, 5.49; Gd, 22.53; N, 10.04.
- Fnd.: C, 41.67; H, 5.48; Gd, 22.21; N, 9.97.
- 20.9 g (50 mmol) of 1-[1-(benzyloxycarbonylmethyl)-2-oxo-piperidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 24b as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 68.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, and the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 36.2 g (73% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 70.49; H, 7.85; N, 7.09.
- Fnd.: C, 70.61; H, 7.83; N, 7.01.
- 29.6 g (30 mmol) of the title compound of Example 25a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 18.8 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 57.40; H, 8.51; N, 11.16.
- Fnd.: C, 57.64; H, 8.45; N, 11.09.
- 12.6 g (20 mmol) of the ligand that is described in Example 25b is dissolved in 200 ml of water and 80 ml of isopropanol and acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.7 g (71% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.1%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 46.08; H, 6.44; Gd, 20.11; N, 8.96.
- Fnd.: C, 46.34; H, 6.41; Gd, 19.99; N, 8.91.
- The DY complex of 10-[1-(carboxymethyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is analogously obtained with use of 12.6 g (20 mmol) of the ligand that is described in Example 25b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Yield: 10.8 g (66% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.6%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 45.77; H, 6.40; Dy, 20.64; N, 8.90.
- Fnd.: C, 46.01; H, 6.46; Dy, 20.34; N, 8.91.
- 20.9 g (50 mmol) of 1-[1-(benzyloxycarbonylmethyl)-2-oxo-piperidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 24b as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 76.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 39.8 g (72% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 72.60; H, 8.09; N, 6.32.
- Fnd.: C, 72.89; H, 7.98; N, 6.27.
- 33.3 g (30 mmol) of the title compound of Example 26a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 22.4 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 62.63; H, 8.76; N, 9.36.
- Fnd.: C, 62.77; H, 8.71; N, 9.29.
- 14.9 g (20 mmol) of the ligand that is described in Example 26b is dissolved in 150 ml of water and 150 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 12.9 g (68% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.6%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 51.92; H, 6.93; Gd 17.43; N, 7.76.
- Fnd.: C, 52.09; H, 6.88; Gd, 17.21; N, 7.77.
- 45.5 g (0.2 mol) of 4-aminobenzoic acid benzyl ester and 30.6 ml (0.22 mol) of triethylamine are dissolved in 200 ml of methylene chloride and added in drops within 45 minutes at 0° C. to a solution of 55.3 g (0.2 mol) of 2,5-dibromovaleric acid chloride (Okawara et al. Chem. Pharm. Bull. (1982), (30), 1225) in 200 ml of methylene chloride, and it is stirred for 18 hours at room temperature. The reaction mixture is now added in drops at 0° C. to a solution of 400 ml of aqueous 32% sodium hydroxide and 2 g of tetrabutylammonium hydrogen carbonate (about 15 minutes), and it is stirred for 30 minutes. Then, the phases are separated, and the aqueous phase is extracted three times with 200 ml of dichloromethane each. The organic phases are dried on sodium sulfate, the solution is evaporated to the dry state and chromatographed on silica gel (methylene chloride). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 38.8 g (50% of theory)
- Elementary analysis:
- Cld.: C, 58.78; H, 4.67; N, 3.61.
- Fnd.: C, 59.01; H, 4.50; N, 3.59.
- 26.6 g (68.5 mmol) of (3-bromo-2-oxo-piperidin-1-yl)benzoic acid benzyl ester is added to 31.2 g (180 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 300 ml of chloroform, and it is stirred overnight at room temperature. 250 ml of water is added, the organic phase is separated, and it is washed twice in each case with 200 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqueous 25% ammonia 10/5/1). The thus obtained 1-[1-(4-benzyloxycarbonylphenyl)-2-oxo-piperidin-3-yl]-1,4,7,10-tetraazacyclododecane (27.6 g; 57.5 mmol; 84% of theory) and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 62.45 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)propanoic acid benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 39.4 g (71% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 70.86; H, 6.99; N, 7.25.
- Fnd.: C 71.11; H, 6.81; N, 7.17.
- 29.0 g (30 mmol) of the title compound of Example 27b is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 18.1 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 57.51; H, 7.16; N, 11.56.
- Fnd.: C, 57.72; H, 7.11; N, 11.50.
- 12.1 g (20 mmol) of the ligand that is described in Example 27c is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 11.4 g (72% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.1%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 45.84; H, 5.31; Gd, 20.69; N, 9.22.
- Fnd.: C, 45.99; H, 5.26; Gd, 20.55; N, 9.21.
- 24.0 g (50 mmol) of 1-[1-(4-benzyloxycarbonylphenyl)-2-oxo-piperidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 27b as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 68.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 500 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 37.8 g (72% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 72.04; H, 7.58; N, 6.67.
- Fnd.: C, 72.32; H, 7.46; N, 6.59.
- 31.5 g (30 mmol) of the title compound of Example 28a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 20.7 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 60.94; H, 8.04; N, 10.15.
- Fnd.: C, 60.87; H, 8.05; N, 10.11.
- 13.8 g (20 mmol) of the ligand that is described in Example 28b is dissolved in 200 ml of water and 80 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120® cation exchange column (H+ form). The acidic eluate is freeze-dried.
- Yield: 12.0 g (68% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 49.80; H, 6.21; Gd, 18.63; N, 8.30.
- Fnd.: C, 49.99; H, 6.17; Gd, 18.51; N, 8.21.
- The Dy complex of 10-[1-(4-carboxyphenyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane is analogously obtained with use of 13.8 g (20 mmol) of the ligand that is described in Example 28b and 3.73 g (10 mmol) of dysprosium oxide instead of gadolinium oxide.
- Yield: 12.4 g (70% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 49.50; H, 6.17; Dy, 19.13; N, 8.25.
- Fnd.: C, 49.77; H, 6.18; Dy, 18.89; N, 8.27.
- 24.0 g (50 mmol) of 1-[1-(4-benzyloxycarbonylphenyl)-2-oxo-piperidin-3-yl]-1,4,7,10-tetraazacyclododecane that is described in Example 27b as an intermediate product and 60 ml (0.35 mol) of N-ethyldiisopropylamine in 200 ml of dichloromethane are added to 76.1 g (0.2 mol) of 2-(trifluoromethanesulfonyloxy)-2-cyclohexylacetic acid benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 400 ml of dichloromethane, and it is stirred for 6 hours under reflux and then overnight at room temperature. It is extracted three times with 50 ml of water each, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 40.9 g (70% of theory) of a colorless, crystalline powder
- Elementary analysis:
- Cld.: C, 73.88; H, 7.84; N, 5.98.
- Fnd.: C, 74.12; H, 7.69; N, 5.89.
- 35.1 g (30 mmol) of the title compound of Example 29a is dissolved in 400 ml of isopropanol, mixed with 40 ml of water, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state.
- Yield: 24.3 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 65.24; H, 8.34; N, 8.65.
- Fnd.: C, 65.48; H, 8.22; N, 8.60.
- 16.2 g (20 mmol) of the ligand that is described in Example 29b is dissolved in 150 ml of water and 150 ml of isopropanol, and it is acidified by adding 5 ml of acetic acid. 3.6 g (10 mmol) of gadolinium oxide is added, and it is refluxed for 8 hours. After complexing is completed, it is set at pH 7.4 again with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and evaporated to the dry state. The residue is taken up with formic acid and evaporated to the dry state several times with the addition of dichloromethane and then dried in a vacuum until a constant weight is reached.
- Yield: 13.6 g (68% of theory) of a colorless powder.
- Water content (Karl-Fischer): 7.5%
- Elementary analysis (relative to anhydrous substance):
- Cld.: C, 54.81; H, 6.69; Gd, 16.31; N, 7.26.
- Fnd.: C, 55.11; H, 6.57; Gd, 16.09; N, 7.24.
- 13.8 g (100 mmol) potassium carbonate and 15.3 g (55 mmol) 2-(trifluoromethane-sulfonyloxy)propane acid t-butyl ester (Decicco et al., Journal of Organic Chemistry 1995, 60, 4782) are added to 11.01 g (25 mmol) 1,7-bis(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecane (Kovacs et al., Synthesis 1997, 759), dissolved in 150 ml of tetrahydrofurane and 15 ml of water, and it is stirred over night at room temperature. After evaporation to the dry state, the residue is distributed between 100 ml dichloromethane and 100 ml of water, the organic phase is separated and it is washed twice in each case with 50 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqu. 25% ammonia=10/5/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 17.4 g (86% of theory) of a colorless powder
- Elementary analysis:
- Cld.: C, 65.49; H, 8.10; N, 8.04.
- Fnd.: C, 65.22; H, 8.17; N, 8.20.
- 13.9 g (20 mmol) of the title compound of example 30a is dissolved in 250 ml of isopropanol, mixed with 25 ml of water, and 2 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 8.5 g (quantitative) of a colorless powder
- Elementary analysis:
- Cld.: C, 61.65; H, 10.35; N, 13.07.
- Fnd.: C, 61.17; H, 10.55; N, 12.85.
- 8.51 g (25 mmol) 2-(trifluoromethane-sulfonyloxy)-isovaleric acid benzyl ester (Walker et al., Tetrahedron (1997), 53(43), 14591) in 60 ml of dichloromethane is added to 8.5 g (20 mmol) of that in example 30b described 1,7-α,α′-dimethyl-1,7-bis-(t-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane and 6.86 ml (40 mmol) N-ethyldiisopropylamine in 200 ml of dichloromethane and it is stirred for 6 hours under reflux and then over night at room temperature. It is extracted three times in each case with 50 ml of water, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 8.8 g (71% of theory) of a colorless powder
- Elementary analysis:
- Cld.: C, 65.99; H, 9.45; N, 9.05.
- Fnd.: C, 66.08; H, 9.25; N, 8.85.
- 2.5 g (8.11 mmol) 2-bromopropionylglycin-benzyl ester (example 1e of WO 98/24774) is added to 4.33 g (7 mmol) of that in example 30c described 1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-isopropyl-4-benzyloxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, dissolved in 50 ml of chloroform, and it is stirred at 50° C. over night. 50 ml of water are added, the organic phase is separated and it is washed twice in each case with 20 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 3.1 g (53% of theory) of a colorless powder
- Elementary analysis:
- Cld.: C, 65.92; H, 8.54; N, 8.36.
- Fnd.: C, 65.77; H, 8.62; N, 8.20.
- 2.5 g (3 mmol) of the title compound of example 30d is dissolved in 100 ml of isopropanol, mixed with 5 ml of water and after addition of a spatula tip of palladium catalyst (10% Pd/C), it is hydrogenated for 8 hours at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. The residue is dissolved in 25 ml of trifluoroacetic acid without further purification and it is stirred for 2 hours at room temperature. The deprotected product is precipitated by the addition of diethylether, exhausted and dried in a vacuum. The residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5. 543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished, the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H+-form). The acidic eluate is freeze-dried.
- Yield: 1.44 g (62% of theory) of a colorless powder. Water content (Karl-Fischer): 9.3%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 41.19; H, 5.76; Gd, 22.47; N, 10.01.
- Fnd.: C, 40.88; H, 5.88; Gd, 22.11; N, 9.79.
- The dysprosium complex is obtained analog to this by using 559 mg (1.5 mmol) dysprosium oxide instead of gadolinium oxide:
- Yield: 1.44 g (62% of theory) of a colorless powder. Water content (Karl-Fischer): 9.0%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 40.88; H, 5.72; Dy 23.05; N, 9.93
- Fnd.: C, 40.58; H, 5.90; Dy, 22.73; N, 9.86.
- 13.8 g (100 mmol) potassium carbonate and 16.85 g (55 mmol) 2-(trifluoromethane-sulfonyloxy)-isovaleric acid t-butyl ester (Semmelhack et al., Tetrahedron Letters 34, 1395 (1993)) are added to 11.01 g (25 mmol) 1,7-bis(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecane (Kovacs et al., Synthesis 1997, 759), dissolved in 150 ml of tetrahydrofurane and 15 ml of water and it is stirred over night at room temperature. It is evaporated to the dry state in a vacuum and the residue is distributed between 100 ml of dichloromethane and 100 ml of water, the organic phase is separated and washed twice with each 50 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: chloroform/methanol/aqu. 25% ammonia=10/5/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 13.9 g (74% of theory) of a colorless powder.
- Elementary analysis:
- Cld.: C, 66.99; H, 8.57; N, 7.44.
- Fnd.: C, 66.58; H, 8.72; N, 7.22.
- 15.06 g (20 mmol) of the title compound of example 31a is dissolved in 250 ml of isopropanol, 25 ml of water is added and 2 g palladium catalyst (10% Pd/C) are added. It is hydrogenated for 8 hours at 50° C. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
- Yield: 9.7 g (quantitative) of a colorless powder.
- Elementary analysis:
- Cld.: C, 64.43; H, 10.81; N, 11.56.
- Fnd.: C, 64.30; H, 10.94; N, 11.31.
- 8.18 g (25 mmol) 2-(trifluoromethane-sulfonyloxy)propanoic acid-benzyl ester (Kitazaki et al., Chem. Pharm. Bull. (1999), 47(3), 360) in 60 ml of dichloromethane is added to 8.5 g (20 mmol) of that in example 31b described 1,7-α,α′-diisopropyl-1,7-bis(t-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane and 6.86 ml (40 mmol) N-ethyldiisopropylamine in 200 ml of dichloromethane, and it is stirred for 6 hours under reflux and then over night at room temperature. It is extracted three times in each case with 50 ml of water, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 9.8 g (76% of theory) of a colorless powder.
- Elementary analysis:
- Cld.: C, 66.84; H, 9.66; N, 8.66.
- Fnd.: C, 66.58; H, 9.82; N, 8.63.
- 2.5 g (8.11 mmol) 2-bromopropionylglycin-benzyl ester (example 1e of WO 98/24774) is added to 4.53 g (7 mmol) of that in example 31c described 1,7-α,α′-diisopropyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-methyl-4-benzyloxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, dissolved in 50 ml of chloroform, and it is stirred at 50° C. over night. 50 ml of water is added, the organic phase is separated and washed twice in each case with 20 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 3.6 g (59% of theory) of a colorless powder.
- Elementary analysis:
- Cld.: C, 66.56; H, 8.73; N, 8.09.
- Fnd.: C, 66.26; H, 8.98; N, 7.91.
- 2.6 g (3 mmol) of the title compound of example 31d is dissolved in 100 ml of isopropanol, 5 ml of water is added and after addition of a spatula tip of palladium catalyst (10% Pd/C), it is hydrogenated for 8 hours at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. The residue is dissolved in 25 ml of trifluoroacetic acid without further purification and it is stirred for 2 hours at room temperature. The deprotected product is precipitated by addition of diethylether, exhausted and dried in a vacuum. The residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5.543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished, the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H+-form). The acidic eluate is freeze-dried.
- Yield: 1.55 g (64% of theory) of a colorless powder.
- Water content (Karl-Fischer): 10.0%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 42.90; H, 6.09; Gd, 21.60; N, 9.62.
- Fnd.: C, 42.75; H, 5.93; Gd, 21.21; N, 9.54.
- 9.51 g (25 mmol) 2-(trifluoromethane-sulfonyloxy)-2-cyclohexyl acetic acid-benzyl ester (Qabar et al., Tetrahedron Letters (1998), 39(33), 5895) in 60 ml of dichloromethane is added to 8.5 g (20 mmol) of that in example 30b described 1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane and 6.86 ml (40 mmol) of N-ethyldiisopropylamine in 200 ml dichloromethane and it is stirred for 6 hours under reflux and then over night at room temperature. It is extracted three times with in each case 50 ml of water, the organic phase is dried on magnesium sulfate and evaporated to the dry state. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 9.1 g (69% of theory) of a colorless powder.
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 67.44; H, 9.48; N, 8.50.
- Fnd.: C, 67.28; H, 9.66; N, 8.31.
- 2.5 g (8.11 mmol) 2-bromopropionylglycin-benzyl ester (example 1e of WO 98/24774) is added to 4.61 g (7 mmol) of that in example 32a described 1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-cyclohexyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, dissolved in 50 ml of chloroform, and it is stirred over night at 50° C. 50 ml of water is added, the organic phase is separated and it is washed twice in each case with 20 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 3.5 g (57% of theory) of a colorless powder
- Elementary analysis:
- Cld.: C, 67.02; H, 8.61; N, 7.97.
- Fnd.: C, 66.86; H, 8.62; N, 8.11.
- 2.6 g (3 mmol) of the title compound of example 32b is dissolved in 100 ml of isopropanol, 5 ml of water is added and after addition of a spatula tip of palladium catalyst (10% Pd/C), it is hydrogenated for 8 hours at room temperature. Catalyst is filtered off and the filtrate is evaporated to the dry state in a vacuum. The residue is dissolved in 25 ml of trifluoroacetic acid without further purification and it is stirred for two hours at room temperature. The deprotected product is precipitated by addition of diethylether, exhausted and dried in a vacuum. The residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5. 543 mg (1.5 mmol) gadolinium oxide are added and it is refluxed for 3 hours. After the complexation is finished, the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H+-form). The acidic eluate is freeze-dried.
- Yield: 1.56 g (64% of theory) of a colorless powder
- Water content (Karl-Fischer): 9.1%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 43.83; H, 5.99; Gd, 21.25; N, 9.46.
- Fnd.: C, 43.62; H, 6.18; Gd, 21.04; N, 9.31.
- 2.69 g (8.11 mmol) of that in example 5b described α-bromo-4-(ethoxycarbonylmethoxy)-phenylacetic acid methyl ester is added to 4.33 g (7 mmol) of that in example 30c described 1,7-α,α′-dimethyl-1,7-bis-(t-butoxycarbonylmethyl)-4-α-isopropyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, dissolved in 50 ml of chloroform, and it is stirred over night at 50° C. 50 ml of water is added, the organic phase is separated and it is washed twice in each case with 20 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 3.5 g (58% of theory) of a colorless powder
- Elementary analysis:
- Cld.: C, 64.95; H, 8.35; N, 6.45.
- Fnd.: C, 64.73; H, 8.22; N, 6.58.
- 2.6 g (3 mmol) of the title compound of example 33a is dissolved in 100 ml of isopropanol, 5 ml of water is added and after addition of a spatula tip of palladium catalyst (10% Pd/C), it is hydrogenated for 8 hours at 50° C. Catalyst is filtered off, the filtrate is evaporated to the dry state in a vacuum. The residue is treated with 40 ml of a 2N sodium hydroxide solution and 40 ml tetrahydrofuran, without further purification and it is stirred for 5 days at 40° C. Afterwards the pH is adjusted to 7 with Amberlite IR-120® (H+-form) and acidified by addition of 1 ml acetic acid. Then 543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H+-form). The acidic eluate is freeze-dried.
- Yield: 1.82 g (71% of theory) of a colorless powder
- Water content (Karl-Fischer): 8.9%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 44.72; H, 5.31; Gd, 20.19; N, 7.19.
- Fnd.: C, 44.88; H, 5.21; Gd, 20.01; N, 6.95.
- 2.32 g (8.11 mmol) 2-bromoacetylglycin-benzyl ester (Teger-Nilsson et al., WO 93/11152, page 38) is added to 4.53 g (7 mmol) of that in example 31c described 1,7-α-α′-diisopropyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-methyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, dissolved in 50 ml of chloroform, and it is stirred over night at 50° C. 50 ml of water is added, the organic phase is separated and washed twice in each case with 20 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on a silica gel (mobile solvent: dichloromethane/methanol: 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 4.8 g (81% of theory) of a colorless powder.
- Elementary analysis:
- Cld.: C, 66.25; H, 8.64; N, 8.22.
- Fnd.: C, 66.00; H, 8.56; N, 8.31.
- 2.55 g (3 mmol) of the title compound of example 34a is dissolved in 100 ml of isopropanol, 5 ml of water is added and after addition of a spatula tip palladium catalyst (10% Pd/C) it is hydrogenated for 8 hours a room temperature. Catalyst is filtered off, and the filtrate is evaporated to the dry state in a vacuum. The residue is dissolved in 25 ml of trifluoroacetic acid without further purification and it is stirred for 2 hours at room temperature. The deprotected product is precipitated by addition of diethylether, exhausted and dried in a vacuum. The residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5. 543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). Fractions that contain the product are combined and added via an IR-120®-cation exchange column (H+-form). The acidic eluate is freeze-dried.
- Yield: 1.51 g (64% of theory) of a colorless powder.
- Water content (Karl-Fischer): 9.0%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 42.06; H, 5.93; Gd, 22.03; N, 9.81.
- Fnd.: C, 41.95; H, 5.99; Gd, 21.77; N, 9.62.
- 2.32 g (8.11 mmol) 2-bromoacetylglycin-benzyl ester (Teger-Nilsson et al., WO 93/11152, page 38) is added to 4.61 g (7 mmol) of that in example 32a described 1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-cyclohexyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, dissolved in 50 ml of chloroform, and it is stirred over night at 50° C. 50 ml of water is added, the organic phase is separated and washed twice in each case with 20 ml of water. The organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20/1). The fractions that contain the product are combined and concentrated by evaporation.
- Yield: 4.35 g (72% of theory) of a colorless powder.
- Elementary analysis:
- Cld.: C, 66.72; H, 8.51; N, 8.10.
- Fnd.: C, 66.43; H, 8.77; N, 8.02.
- 2.6 g (3 mmol) of the title compound of example 35a is dissolved in 100 ml of isopropanol, 5 ml of water is added and after the addition of a spatula tip of palladium catalyst (10% Pd/C) it is hydrogenated for 8 hours at room temperature. Catalyst is filtered out, the filtrate is evaporated to the dry state in a vacuum. The residue is dissolved in 25 ml of trifluoroacetic acid without further purification and it is stirred for 2 hours at room temperature. The deprotected product is precipitated by the addition of diethylether, exhausted and dried in a vacuum. The residue is dissolved in 20 ml of water and 2 ml of isopropanol and the pH is adjusted to 5.543 mg (1.5 mmol) gadolinium oxide is added and it is refluxed for 3 hours. After the complexation is finished, the pH is adjusted to 7.4 with ammonia and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and added via an IR-120®-cation exchange column (H+-form). The acidic eluate is freeze-dried.
- Yield: 1.74 g (73% of theory) of a colorless powder.
- Water content (Karl-Fischer): 8.8%
- Elementary analysis (referenced to the anhydrous substance):
- Cld.: C, 43.02; H, 5.83; Gd, 21.66; N, 9.65.
- Fnd.: C, 42.87; H, 6.05; Gd, 21.29; N, 9.55.
- Examples 36-108 describe conjugates of the above-described gadolinium complexes with biomolecules. The conjugates were produced according to the following general operating instructions I-IV. The results are summarized in Table 1. Here, “AAV” stands for general operating instructions, “ACTH” stands for adrenocorticotropic hormone, and “RP-18” refers to a “reversed phase” stationary chromatography phase. The number of complexes per biomolecule was determined by means of ICP (inductively coupled plasma atomic emission spectroscopy).
- General Operating Instructions (AAV) I: Albumin-Amide Conjugates
- 3 mmol of the Gd complex acid is dissolved in 15 ml of DMF, mixed with 380 mg (3.3 mmol) of N-hydroxysuccinimide and 681 mg of dicyclohexylcarbodiimide while being cooled with ice, and preactivated for 1 hour in ice. The active ester mixture is added in drops within 30 minutes in a solution of 16.75 g (0.25 mmol) of bovine serum albumin (BSA) or human serum albumin (HSA) in 150 ml of phosphate buffer (pH 7.4) and stirred for 2 hours at room temperature. The batch solution is filtered, the filtrate is ultrafiltered with an AMICON® YM30 (cut-off 30,000 Da), the retentate is chromatographed on a Sephadex® G50-column, and the product fractions are freeze-dried.
- General Operating Instructions (AAV) II: Albumin-Maleimide Conjugates
- 0.0438 mmol of the Gd-complex maleimide in 1 ml of DMF is added to 0.84 g (0.0125 mmol) of bovine serum albumin (BSA), dissolved in 15 ml of phosphate buffer (pH 7.4), and it is stirred for one hour at room temperature. The batch solution is filtered, the filtrate is ultrafiltered with an AMICON® YM30 (cut-off 30,000 Da), the retentate is chromatographed on a Sephadex® G50 column, and the product fractions are freeze-dried.
- General Operating Instructions (AAV) III: Production of Amide Conjugates
- 3 mmol of the Gd-complex acid is dissolved in 15 ml of DMF, mixed with 380 mg (3.3 mmol) of N-hydroxysuccinimide and 681 mg of dicyclohexylcarbodiimide while being cooled with ice, and preactivated for 1 hour in ice. The active ester mixture is added in drops to a solution of 2.5 mmol of amine components in 15-150 ml of DMF and stirred overnight at room temperature. The batch solution is filtered and chromatographed on silica gel.
- General Operating Instructions (AAV) IV: Production of Maleimido-SH Conjugates
- 3 mmol of the Gd-complex maleimide in 15 ml of DMF is added in drops to 2.5 mmol of SH components in 15-150 ml of DMF, and it is stirred for one hour at room temperature. The batch solution is chromatographed on silica gel.
TABLE 1 Edukt Gd- Anzahl Komplexe Komplex pro Biomolekül Ausbeute Beispiel (Beispiel Nr.) konjugiert mit (Herkunft) AAV (ICP) Bemerkungen (%) 36 1 BSA Sigma I 3.7 — quant. 37 2 BSA Sigma I 6.1 — quant. 38 3 BSA Sigma I 2.9 — quant. 39 4 BSA Sigma I 3.5 — quant. 40 5 BSA Sigma I 4.2 — quant. 41 6 BSA Sigma I 6.5 — quant. 42 7 BSA Sigma I 5.0 — quant. 43 16 BSA Sigma II 0.71 — quant. 44 17 BSA Sigma II 0.55 — quant. 45 8 BSA Sigma I 3.0 — quant. 46 9 BSA Sigma I 4.7 — quant. 47 10 BSA Sigma I 5.1 — quant. 48 11 BSA Sigma I 2.7 — quant. 49 12 BSA Sigma I 4.0 — quant. 50 13 BSA Sigma I 3.3 — quant. 51 14 BSA Sigma I 5.8 — quant. 52 15 BSA Sigma I 4.6 — quant. 53 18 BSA Sigma I 3.7 — quant. 54 19 BSA Sigma I 4.1 — quant. 55 20 BSA Sigma I 2.8 — quant. 56 21 BSA Sigma I 3.5 — quant. 57 22 BSA Sigma I 3.3 — quant. 58 23 BSA Sigma I 2.9 — 59 24 BSA Sigma I 4.0 — quant. 60 25 BSA Sigma I 3.5 — quant. 61 26 BSA Sigma I 3.0 — quant. 62 27 BSA Sigma I 3.9 — quant. 63 28 BSA Sigma I 3.1 — quant. 64 29 BSA Sigma I 3.4 — quant. 65 11 (D-Lys16)-ACTH (1-24 human) BACHEM I 2.0 — quant. 66 12 ACTH (1-17) BACHEM I 1.7 — quant. 67 14 H-β-Ala-Phe BACHEM III 1.0 wurde an RP-18 95 gereinigt 68 8 Anti-Inflamatory Peptide 2 BACHEM I 1.0 — quant. 69 9 L-Carnosin BACHEM III 1.0 wurde an RP-18 97 gereinigt 70 16 Homoglutathion BACHEM IV 1.0 wurde an RP-18 94 gereinigt 71 17 Guanyl-Cys-OH BACHEM IV 1.0 wurde an RP-18 93 gereinigt 72 8 H-DL-d-Hydroxy-DL-Lys-OH BACHEM III 1.0 wurde an RP-18 85 gereinigt 73 7 H-β-Ala-Lys-OH BACHEM III 1.0 wurde an RP-18 87 gereinigt 74 16 H-Arg-Gly-Asp-Cys-OH BACHEM III 1.0 wurde an RP-18 91 gereinigt 75 9 H-Asp-Leu-Trp-Gln-Lys-OH BACHEM III 1.0 wurde an RP-18 94 gereinigt 76 12 H-Ala-His-Lys-OH BACHEM III 2.0 wurde an RP-18 91 gereinigt 77 13 Endothelin-2 (Human) BACHEM I 0.87 — quant. 78 14 Human Serumalbumin BACHEM I 5.1 — quant. 79 7 Human Serumalbumin BACHEM I 3.1 — quant. 80 8 Human Serumalbumin BACHEM I 2.3 — quant. 81 17 Thioguanosin Aldrich IV 1.0 wurde an RP-18 96 gereinigt 82 5 6-Aminopenicilinsäure Aldrich III 1.0 wurde an RP-18 92 gereinigt 83 11 4-Aminopteroylglutaminsäure Aldrich III 1.0 wurde an RP-18 65 gereinigt 84 4 2-Amino-purinthiol Aldrich IV 1.0 wurde an RP-18 94 gereinigt 85 12 5-Azacytidin Aldrich III 1.0 wurde an RP-18 96 gereinigt 86 17 4,5-Diamino-2,6- Aldrich IV 1.0 wurde an RP-18 71 dimercaptopyrimidin gereinigt 87 13 Mitomycin C Aldrich III 1.0 wurde an RP-18 81 gereinigt 88 12 Muraminsäure Aldrich III 1.0 wurde an RP-18 92 gereinigt 89 6 Puromycin SIGMA III 1.0 wurde an RP-18 90 gereinigt 90 11 Doxorubicin SIGMA III 1.0 wurde an RP-18 89 gereinigt 91 12 Spectinomycin SIGMA III 1.0 wurde an RP-18 88 gereinigt 92 4 Streptomycin SIGMA III 1.0 wurde an RP-18 62 gereinigt 93 14 Neomycin B SIGMA III 1.0 wurde an RP-18 52 gereinigt 94 8 Nystatin SIGMA III 1.0 wurde an RP-18 72 gereinigt 95 3 Hygromycin SIGMA III 1.0 wurde an RP-18 71 gereinigt 96 2 Ampicillin SIGMA III 1.0 wurde an RP-18 42 gereinigt 97 30 BSA Sigma I 2.1 — quant. 98 31 BSA Sigma I 1.8 — quant 99 32 BSA Sigma I 2.7 — quant 100 33 BSA Sigma I 1.2 — quant 101 34 BSA Sigma I 1.6 — quant 102 35 BSA Sigma I 2.5 — quant 103 30 HSA Sigma I 1.9 — quant 104 31 HSA Sigma I 2.5 — quant 105 32 HSA Sigma I 2.2 — quant 106 33 HSA Sigma I 1.5 — Quant 107 34 HSA Sigma I 1.7 — quant 108 35 HSA Sigma I 2.4 — quant
#[Key to Table 1:]
Beispiel = Example
Edukt Gd-Komplex (Beispiel Nr.) = Gd-Complex Educt (Example No.)
konjugiert mit = Conjugated with
(Herkunft) = (Origin)
Anzahl Komplexe pro Biomolekül = Number of complexes per biomolecule
Bemerkungen = Remarks
Ausbeute (%) = Yield (%)
L-Carnosin = L-Carnosine
Homoglutathion = Homoglutathione
wurde an RP-18 gereinigt = was purified on RP-18
Thioguanosin = Thioguanosine
6-Aminopenicilinsäure = 6-Aminopenicillic acid
4-Aminopteroylglutaminsäure = 4-Aminopteroylglutamic acid
2-Amino-purinthiol = 2-amino-purinethiol
5-Azacytidin = 5-Azacytidine
4,5-Diamino-2,6-dimercaptopyrimidin = 4,5-Diamino-2,6-dimercaptopyridimidine
Muraminsäure = Muramic acid
- In this example, the relaxivities of the conjugates from Examples 36-38 and 97-108 were compared with the relaxivities of two comparison substances. As comparison substances, Gd-DTPA (1) with the formula:
and Gd-GlyMeDOTA (2) with the formula:
which were reacted in each case with bovine serum albumin (BSA), were used. - The measurements were made in each case in aqueous solution and in plasma at +37° C. and a frequency of 20 MHz. The results are summarized in Table 2 below, whereby the indicated relaxivities per mol of gadolinium were calculated from the measured values:
TABLE 2 Gd-Komplex Anzahl Gd/BSA R1 (H2O) R1 (Plasma) Beispiel (aus Beispiel) or HSA (L/mmol * s) (L/mmol * s) 36 1 3.7 22.1 25.3 37 2 6.1 29.8 35.7 38 3 2.9 38.2 51.5 39 4 3.5 27.1 29.7 40 5 4.2 20.0 22.4 41 6 6.5 23.2 25.8 42 7 5.0 31.1 37.4 43 16 0.71 38.0 38.3 44 17 0.55 40.6 41.4 97 30 2.1 35.3 39.1 98 31 1.8 32.2 36.5 99 32 2.7 36.5 40.1 100 33 1.2 40.0 44.6 101 34 1.6 31.8 34.8 102 35 2.5 40.1 45.7 103 30 1.9 34.6 39.9 104 31 2.5 31.7 36.1 105 32 2.2 35.4 40.3 106 33 1.5 41.6 46.7 107 34 1.7 33.6 37.0 108 35 2.4 39.1 44.9 Vergleichssubstanz 1 Gd-DTPA 36 13.39 13.97 Vergleichssubstanz 2 Gd-GlyMeDOTA 4.7 18.3 20.8
[Key:]
Beispiel = Example
Gd-Komplex (aus Beispiel) = Gd complex (from Example)
Anzahl Gd/BSA = Gd/BSA number
Vergleichssubstanz = Comparison substance
- This example shows that the conjugates that are produced with the compounds according to the invention have, surprisingly enough, a higher relaxivity than the comparison substances despite their low number of gadolinium atoms per biomolecule. Compared to comparison substance 2, it was possible to increase the relaxivity by the special liganding of the macrocyclic ring.
- The entire disclosures of all applications, patents and publications, cited herein and of corresponding German application No. 10135356.1, filed Jul. 20, 2001 is incorporated by reference herein.
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (15)
1. Compounds of formula I
in which
Z represents a hydrogen atom or at least two Z's represent a metal ion equivalent,
B1, B2, B3, B4 are independently selected from the group consisting of hydrogen atoms and C1-4-alkyl radicals,
R1, R2, R3 are independently selected from the group consisting of hydrogen atoms and straight, branched or cyclic, saturated or unsaturated C1-10-alkyl or aryl radicals, which optionally are substituted with a carboxyl group —SO3H or —PO3H2, and whereby the alkyl chains of the C1-10-alkyl radicals optionally contain an aryl group and/or 1-2 oxygen atoms, provided that at least one of the radicals B1, B2, B3, B4, R1, R2 and R3 does not represent a hydrogen atom,
A represents a straight or branched, saturated or unsaturated C1-30-hydrocarbon chain that optionally contains 1-5 oxygen atoms, 1-5 nitrogen atoms and/or 1-5 —NR′ radicals, in which R′ is defined as R1, R2 and R3 but can be selected independently, which optionally is substituted with 1-3 carboxyl groups, 1-3 —SO3H, 1-3 —PO3H2 and/or 1-3 halogen atoms, in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically, and which is configured in such a way that X is connected via at least 3 atoms to the nitrogen to which A is bonded, and
X represents a group that can participate in a reaction with a biomolecule, as well as their salts, provided that
a) If B1, B2, B3 and B4 are hydrogen atoms and R1, R2 and R3 are —CH2CH2CO2H, A-X together are not —CH(CO2H)CH2CH2CO2H,
b) If B1, B2, B3 and B4 are hydrogen atoms and R1, R2 and R3 are methyl or R1, R2 and R3 are ethyl radicals, which optionally are substituted with a carboxy group, A does not represent the radical —CH(R7)—CO—NR5U6—, in which R5 stands for a hydrogen atom, a methyl or an ethyl radical, which optionally is substituted with 1 carboxy group, R7 stands for a straight-chain, branched, saturated or unsaturated C1-C30-alkyl chain, which optionally is interrupted by 1-10 oxygen atoms, I phenylene group, or 1-phenylenoxy group, and/or optionally is substituted by 1-5 hydroxy groups, 1-3 carboxy groups or 1 phenyl group, and U6 stands for a straight-chain, branched, saturated or unsaturated C1-C20-alkylene group that contains 1-5 imino groups, 1-3 phenylene groups, 1-3 phenylenoxy groups, 1-3 phenylenimino groups, 1-5 amide groups, 1-2 hydrazide groups, 1-5 carbonyl groups, 1-5 ethylenoxy groups, 1 urea group, 1 thiourea group, 1-2 carboxyalkylimino groups, 1-2 ester groups, 1-10 oxygen atoms, 1-5 sulfur atoms and/or 1-5 nitrogen atoms and/or is optionally substituted by 1-5 hydroxy groups, 1-2 mercapto groups, 1-5 oxo groups, 1-5 thioxo groups, 1-3 carboxy groups, 1-5 carboxyalkyl groups, 1-5 ester groups and/or 1-3 amino groups, whereby the optionally contained phenylene groups can be substituted by 1-2 carboxy groups, 1-2 sulfone groups or 1-2 hydroxy groups, and
c) If B1, B2, B3 and B4 are hydrogen atoms and R1, R2 and R3 represent the same C1-4-alkyl radical, A does not represent the radical
in which R6 is a hydrogen atom or a C1-4-alkyl radical, D is a saturated or unsaturated, straight-chain or branched C1-4-alkylene group, which optionally can be interrupted or substituted with a carbonyl group, and D is bonded to X.
2. Compounds according to claim 1 , in which R1, R2 and R3 are independently selected from the group consisting of hydrogen atoms, straight-chain or branched C1-10-alkyl radicals, cyclohexyl radicals, —CH2—COOH, —C(CH3)2—COOH, phenyl radicals or radicals of formula —(CH2)m—(O)n-(phenylene)p-Y, in which m is an integer from 1 to 5, n is 0 or 1, p is 0 or 1, and y represents a hydrogen atom, a methoxy radical, a carboxyl group, —SO3H or —PO3H2.
3. Compounds according to claim 2 , in which if B1, B2, B3 and B4 are hydrogen atoms, R1, R2 and R3 are independently selected from the group consisting of hydrogen atoms, isopropyl radicals, isobutyl radicals, tert-butyl radicals, straight-chain or branched C5-10-alkyl radicals, cyclohexyl radicals, —CH2—COOH, —C(CH3)2—COOH, phenyl radicals or radicals of formula —(CH2)m—(O)n-(phenylene)p-Y, in which m is an integer from 1 to 5, n is 0 or 1, p is 0 or 1, and Y represents a hydrogen atom, a methoxy radical, a carboxyl group, —SO3H or —PO3H2, provided that at least one of the radicals R1, R2 and R3 does not represent a hydrogen atom.
4. Compounds according to claim 3 , in which if B1, B2, B3 and B4 are hydrogen atoms, R1, R2 and R3 are independently selected from the group consisting of hydrogen atoms, isopropyl, cyclohexyl or phenyl radicals, provided that at least one of the radicals R1, R2 and R3 does not represent a hydrogen atom.
5. Compounds according to claim 1 , in which A represents a radical A′-U, in which A′ is bonded to the nitrogen atom of the macrocyclic ring and U is bonded to X, and whereby A′ represents
a) A bond,
b) —CH(CO2H)—,
c) a group of formula
in which Q represents a hydrogen atom, a C1-10-alkyl radical, which optionally is substituted with a carboxyl group, or an aryl radical, which optionally is substituted with a carboxyl group, a C1-15-alkoxy group, an aryloxy group or a halogen atom, and R′ is defined as R1, R2 and R3 in claim 1 , but can be selected independently, or
d) a group of formula
in which o is 0 or 1, and the ring optionally is annellated with a benzene ring, whereby this benzene ring, if present, can be substituted with a methoxy or carboxyl group, —SO3H or —PO3H2, whereby in the groups under c) and d), the positions that are marked
are bonded to the adjacent groups, and in which position α is bonded to a nitrogen atom of the macrocyclic ring and position β is bonded to U, and
U represents a straight or branched, saturated or unsaturated C1-30-hydrocarbon chain that optionally contains 1-3 oxygen atoms, 1-3 nitrogen atoms and/or 1-3 —NR″ radicals, in which R″ is defined as R1, R2 and R3 in claim 1 but can be selected independently, and in which optionally 1-3 carbon atoms are present as carbonyl groups, whereby the chain or a portion of the chain can be arranged concentrically, provided that A′ and U together are configured in such a way that X is bonded via at least 3 atoms with the nitrogen atom to which A′ is bonded.
8. Compounds according to claim 5 , in which U is selected from
—CH2—, —(CH2)5—, —(CH2)10—, -phenylene-O—CH2—, -phenylene-O—(CH2)3—, -phenylene-O—(CH2)10—, —CH2-phenylene-, -cyclohexylene-O—CH2—, -phenylene-, —C(phenyl)H—, —CH2-pyridylene-O—CH2—, —CH2-pyridylene- and —CH2—CO—NH—CH2—CH2—
9. Compounds according to claim 1 , in which X is selected from the group that consists of carboxyl, activated carboxyl, amino, isocyanate, isothiocyanate, hydrazine, semicarbazide, thiosemicarbazide, chloroacetamide, bromoacetamide, iodoacetamide, acylamino, mixed anhydrides, azide, hydroxide, sulfonyl chloride, carbodiimide and radicals of formulas
in which Hal is a halogen atom.
11. 10-(4-Carboxy-1-methyl-2-oxo-3-azabutyl)-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-carboxy-1-methyl-2-oxo-3-azabutyl) 1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-carboxy-1-methyl-2-oxo-3-azabutyl)-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-(t-butoxycarbonyl-1-phenyl-2-oxo-3-azabutyl)-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[α-(4-(ethoxycarbonylmethoxy)phenyl)-methoxycarbonylmethyl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[α-(4-(ethoxycarbonylpropoxy)phenyl)-methoxycarbonylmethyl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[α-(4-ethoxycarbonyldecyloxy)phenyl)-methoxycarbonylmethyl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(p-carboxybenzyl)-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(p-carboxybenzyl)-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(p-carboxybenzyl)-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(p-carboxybenzyl)-1,4,7-α,α′,α″-triphenyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-(t-butoxycarbony-1-phenyl-2-oxo-3-azabutyl)-1,4,7-α,α′,α″-triphenyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-carboxy-2-oxo-3-azabutyl)-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-carboxy-2-oxo-3-azabutyl)-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-(4-carboxy-1-methyl-2-oxo-3-azabutyl)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid-tri-tert-butyl ester, 10-[8-(N-maleimido)-1-methyl-2,5-dioxo-3,6-diazaoctyl]-1,4,7-α,α′,α″-tris-(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane and 10-[8-(N-maleimido)-1-methyl-2,5-dioxo-3,6-diazaoctyl]-1,4,7-α,α′,α″-tris(cyclohexyl) 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(carboxymethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(carboxymethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(carboxymethyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(4-carboxyphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(4-carboxyphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(4-carboxyphenyl)-2-oxo-pyrrolidin-3-yl]-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(carboxymethyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(carboxymethyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(carboxymethyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(4-carboxyphenyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-trimethyl-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(4-carboxyphenyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-tris(isopropyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[1-(4-carboxyphenyl)-2-oxo-piperidin-3-yl]-1,4,7-α,α′,α″-tris(cyclohexyl)-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 10-[4-(benzyloxycarbonyl)-1-methyl-2-oxo-3-azabutyl]-1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-isopropyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, 10-[4-(Benzyloxycarbonyl)-1-methyl-2-oxo-3-azabutyl]-1,7-α,α′-diisopropyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-methyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, 10-[4-(benzyloxycarbonyl)-1-methyl-2-oxo-3-azabutyl]-1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-cyclohexyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, 10-[α-(4-(ethoxycarbonylmethoxy)phenyl)-methoxycarbonylmethyl]-1,7-α,α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-isopropyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, 10-[4-(benzyloxycarbonyl)-2-oxo-3-azabutyl]-1,7-α-α′-diisopropyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-methyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane, 10-[4-(benzyloxycarbonyl)-2-oxo-3-azabutyl]-1,7-α-α′-dimethyl-1,7-bis(t-butoxycarbonylmethyl)-4-α-cyclohexyl-4-benzyloxycarbonylmethyl-1,4,7,10-tetraazacyclododecane.
12. Compounds according to claim 1 , in which at least two of radicals Z stand for a metal ion equivalent of a radioactive or paramagnetic element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 46, 47, 49, 58-71, 75, 77, 82 or 83.
13. Use of the compounds of formula I
in which Z, B1, B2, B3, B4, R1, R2, R3, A and X are defined as in claim 1 , provided that at least one of the B1, B2, B3, B4, R1, R2 and R3 does not represent a hydrogen atom and if B1, B2, B3, B4 are hydrogen atoms and R1, R2, R3 represent the same C1-4-alkyl radicals, A does not represent the radical
in which R6 is a hydrogen atom or a C1-4-alkyl radical, D is a saturated or unsaturated, straight-chain or branched C1-4-alkylene group, which optionally is interrupted or substituted with a carbonyl group, and D is bonded to X, for the production of a conjugate with a biomolecule.
14. Use according to claim 13 , in which the biomolecule is selected from the group that consists of biopolymers, proteins, synthetically modified biopolymers, carbohydrates, antibodies, DNA and RNA fragments, β-amino acids, vector amines for transfer into the cell, biogenic amines, pharmaceutical agents, oncological preparations, synthetic polymers, which are directed to a biological target, steroids, prostaglandins, taxol and derivatives thereof, endothelins, alkaloids, folic acid and derivatives thereof, bioactive lipids, fats, fatty acid esters, synthetically modified mono-, di- and triglycerides, liposomes, which are derivatized on the surface, micelles that consist of natural fatty acids or perfluoroalkyl compounds, porphyrins, texaphrines, expanded porphyrins, cytochromes, inhibitors, neuramidases, neuropeptides, immunomodulators, endoglycosidases, substrates that are attacked by the enzymes calmodulin kinase, casein-kinase II, glutathione-S-transferase, heparinase, matrix-metalloproteases, β-insulin-receptor-kinase, UDP-galactose 4-epimerase, fucosidases, G-proteins, galactosidases, glycosidases, glycosyltransferases and xylosidase, antibiotics, vitamins and vitamin analogs, hormones, DNA intercalators, nucleosides, nucleotides, lectins, vitamin B12, Lewis-X and related substances, psoralens, dienetriene antibiotics, carbacyclins, VEGF, somatostatin and derivatives thereof, biotin derivatives, antihormones, tumor-specific proteins and synthetic agents, polymers that accumulate in acidic or basic areas of the body, myoglobins, apomyoglobins, neurotransmitter peptides, tumor necrosis factors, peptides that accumulate in inflamed tissues, blood-pool reagents, anion and cation-transporter proteins, polyesters, polyamides and polyphosphates.
15. Process for the production of compounds of formula I
in which Z, B1, B2, B3, B4, R1, R2, R3, A and X are defined as in claim 1 , provided that at least one of the B1, B2, B3, B4, R1, R2 and R3 does not represent a hydrogen atom and if B1, B2, B3, B4 are hydrogen atoms and R1, R2, R3 represent the same C1-4-alkyl radicals, A does not represent the radical
in which R6 is a hydrogen atom or a C1-4-alkyl radical, D is a saturated or unsaturated, straight-chain or branched C1-4-alkylene group, which optionally is interrupted or substituted with a carbonyl group, and D is bonded to X, in which a compound of formula II
in which B1, B2, B3 and B4 are defined as in claim 1 , is optionally reacted with Nu-A-X′, Nu-CH(R1)—CO2-Z′, Nu-CH(R2)—CO2-Z′ and Nu-CH(R3)—CO2-Z′ optionally after protective groups for the nitrogen atoms are introduced, whereby A and R1, R2 and R3 are defined as in claim 1 , and Nu is a nucleofuge, X′ stands for X or a protected form of X, and X is defined as in claim 1 , and Z′ stands for a hydrogen atom, a metal ion equivalent or a protective group for carboxyl, then the optionally present protective groups are removed, and, if desired, reacted in a way that is known in the art with at least one metal oxide or metal salt of a desired element and optionally then still present acid hydrogen atoms are completely or partially substituted in the thus obtained complexes by cations of inorgnaic and/or organic bases, amino acids or amino acid amides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10135356.1 | 2001-07-20 | ||
DE10135356A DE10135356C1 (en) | 2001-07-20 | 2001-07-20 | Macrocyclic metal complexes and their use for the preparation of conjugates with biomolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070009442A1 true US20070009442A1 (en) | 2007-01-11 |
Family
ID=7692471
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/198,046 Expired - Fee Related US7164016B2 (en) | 2001-07-20 | 2002-07-19 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules |
US11/390,472 Abandoned US20070009442A1 (en) | 2001-07-20 | 2006-03-28 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/198,046 Expired - Fee Related US7164016B2 (en) | 2001-07-20 | 2002-07-19 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules |
Country Status (19)
Country | Link |
---|---|
US (2) | US7164016B2 (en) |
EP (1) | EP1409024B1 (en) |
JP (1) | JP2005504745A (en) |
KR (1) | KR20040030826A (en) |
CN (1) | CN1533286A (en) |
AR (1) | AR036183A1 (en) |
AT (1) | ATE403442T1 (en) |
AU (1) | AU2002321236B2 (en) |
BR (1) | BR0211273A (en) |
CA (1) | CA2453106A1 (en) |
DE (2) | DE10135356C1 (en) |
IL (1) | IL159290A0 (en) |
MX (1) | MXPA04000401A (en) |
NO (1) | NO20040238L (en) |
PE (1) | PE20030322A1 (en) |
PL (1) | PL366426A1 (en) |
RU (1) | RU2305096C2 (en) |
UY (1) | UY27390A1 (en) |
WO (1) | WO2003009874A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193384A1 (en) * | 2005-04-26 | 2008-08-14 | Koninklijke Philips Electronics, N.V. | Responsive Mri Contrast Agents |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
US11191854B2 (en) | 2017-05-05 | 2021-12-07 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
US11433148B2 (en) | 2017-05-05 | 2022-09-06 | Centre For Probe Development And Commercialization | IGF-1R monoclonal antibodies and uses thereof |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
DE10135356C1 (en) * | 2001-07-20 | 2003-04-17 | Schering Ag | Macrocyclic metal complexes and their use for the preparation of conjugates with biomolecules |
DE10325752A1 (en) * | 2003-06-06 | 2004-12-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Lectin conjugates |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
FI20055712A0 (en) * | 2005-12-29 | 2005-12-29 | Wallac Oy | Moacrocyclic oligonucleotide labeling reagents and conjugates derived therefrom |
KR101653182B1 (en) * | 2006-04-19 | 2016-09-01 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Compositions and methods for cellular imaging and therapy |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
WO2010011367A2 (en) * | 2008-02-22 | 2010-01-28 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US10556873B2 (en) | 2008-02-22 | 2020-02-11 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
KR101253100B1 (en) * | 2010-02-16 | 2013-04-10 | 경북대학교 산학협력단 | Polyazamacrocyclic compounds, producing method and biomedical application thereof |
KR101236142B1 (en) * | 2010-09-30 | 2013-02-21 | 경북대학교 산학협력단 | MRI contrast agents comprising Gd-complexes |
WO2015051362A1 (en) | 2013-10-04 | 2015-04-09 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
EP3544964B1 (en) | 2016-11-28 | 2020-06-17 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
FR3069245B1 (en) * | 2017-07-21 | 2019-07-26 | Guerbet | LIPOPHILIC MACROCYCLIC LIGANDS, THEIR COMPLEXES AND THEIR MEDICAL USES |
CN109810140B (en) * | 2017-11-22 | 2021-06-29 | 湖南科技大学 | Heme ligand simulant and synthesis method thereof |
JOP20210114A1 (en) | 2018-11-23 | 2023-01-30 | Bayer Ag | Formulation of contrast media and process of preparation thereof |
CN110396122B (en) * | 2019-08-13 | 2020-10-27 | 牡丹江医学院 | Nuclear magnetic resonance contrast agent, preparation method and application thereof in tumor diagnosis |
KR102203368B1 (en) * | 2020-10-30 | 2021-01-14 | 경북대학교 산학협력단 | Novel compound and mri contrast agent comprising the same |
EP4059925A1 (en) * | 2021-03-15 | 2022-09-21 | Bayer Aktiengesellschaft | New contrast agent for use in magnetic resonance imaging |
CN115364684B (en) * | 2022-10-25 | 2023-01-03 | 天津大学 | High-flux positively-charged nanofiltration membrane and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739323A (en) * | 1992-04-24 | 1998-04-14 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
US6019959A (en) * | 1997-07-31 | 2000-02-01 | Schering Aktiengesellschaft | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis |
US7164016B2 (en) * | 2001-07-20 | 2007-01-16 | Schering Ag | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132409A (en) * | 1987-01-12 | 1992-07-21 | Bracco Industria Chimica S.P.A. | Macrocyclic chelating agents and chelates thereof |
US5049667A (en) * | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
US5006643A (en) * | 1987-06-24 | 1991-04-09 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
DE353450T1 (en) * | 1988-06-24 | 1990-09-06 | The Dow Chemical Co., Midland, Mich., Us | MACROCYCLIC BIFUNCTIONAL CHELATORS, COMPLEXES OF THEM AND THEIR CONJUGATED ANTIBODIES. |
US5972307A (en) * | 1989-10-23 | 1999-10-26 | Nycomed Salutar, Inc. | Dichelants |
JPH04154729A (en) * | 1990-10-16 | 1992-05-27 | Nippon Mejifuijitsukusu Kk | Contrast medium for nuclear magnetic resonance |
US5133956A (en) * | 1991-05-30 | 1992-07-28 | The Dow Chemical Company | Radiolabeled metal-binding protein for the treatment of arthritis |
JPH0656802A (en) * | 1992-03-27 | 1994-03-01 | Nippon Mejifuijitsukusu Kk | Tetraazacyclododecane derivative and its use |
EP0565930A1 (en) | 1992-03-27 | 1993-10-20 | Nihon Medi-Physics Co., Ltd. | Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents |
FR2689739B1 (en) * | 1992-04-10 | 1994-07-08 | Europ Sieges Automobiles | PERFECTED SEAT WITH MULTIPLE POSITIONS. |
IT1265440B1 (en) * | 1993-12-24 | 1996-11-22 | Bracco Spa | PARAMAGNETIC DIAGNOSTIC FORMULATIONS AND METHOD OF USE OF THEM |
DE69426811T2 (en) * | 1993-12-30 | 2001-09-13 | Guerbet Villepinte | Polyaminated ligands, metal complexes, manufacturing processes and diagnostic and therapeutic uses |
US6693190B1 (en) * | 1994-05-11 | 2004-02-17 | Bracco International B.V. | Enhanced relaxivity monomeric and multimeric compounds |
DE19525924A1 (en) | 1995-07-04 | 1997-01-09 | Schering Ag | Cascade polymer complexes, processes for their preparation and pharmaceutical compositions containing them |
DE19603033A1 (en) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics |
US5977313A (en) * | 1996-10-10 | 1999-11-02 | Quadrant Healthcare Limited | Platelet substitutes and conjugation methods suitable for their preparation |
IT1291624B1 (en) * | 1997-04-18 | 1999-01-11 | Bracco Spa | COMPLEX CHELATES OF PARAMAGNETIC METALS WITH LOW TOXICITY |
IT1293777B1 (en) * | 1997-07-25 | 1999-03-10 | Bracco Spa | PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES |
IT1293778B1 (en) * | 1997-07-25 | 1999-03-10 | Bracco Spa | 1,4,7,10-TETRAAZABICICLO (8.2.2.)TETRADECAN-2 ONE, ITS PREPARATION AND USE FOR THE PREPARATION OF TETRAAZAMACROCYCLES |
WO2001052900A2 (en) * | 2000-01-21 | 2001-07-26 | Mallinckrodt Inc. | Novel orthogonally protected amino acid chelators for biomedical applications |
DE10135355C1 (en) * | 2001-07-20 | 2003-04-17 | Schering Ag | Conjugates of macrocyclic metal complexes with biomolecules and their use in the preparation of NMR and radiodiagnostic agents and radiotherapy |
-
2001
- 2001-07-20 DE DE10135356A patent/DE10135356C1/en not_active Expired - Fee Related
-
2002
- 2002-07-17 UY UY27390A patent/UY27390A1/en not_active Application Discontinuation
- 2002-07-18 JP JP2003515266A patent/JP2005504745A/en active Pending
- 2002-07-18 MX MXPA04000401A patent/MXPA04000401A/en unknown
- 2002-07-18 AT AT02754904T patent/ATE403442T1/en not_active IP Right Cessation
- 2002-07-18 BR BR0211273-6A patent/BR0211273A/en not_active IP Right Cessation
- 2002-07-18 WO PCT/EP2002/007999 patent/WO2003009874A1/en active IP Right Grant
- 2002-07-18 PL PL02366426A patent/PL366426A1/en not_active Application Discontinuation
- 2002-07-18 KR KR10-2004-7000906A patent/KR20040030826A/en not_active Application Discontinuation
- 2002-07-18 IL IL15929002A patent/IL159290A0/en unknown
- 2002-07-18 RU RU2004105261/04A patent/RU2305096C2/en not_active IP Right Cessation
- 2002-07-18 CA CA002453106A patent/CA2453106A1/en not_active Abandoned
- 2002-07-18 EP EP02754904A patent/EP1409024B1/en not_active Expired - Lifetime
- 2002-07-18 DE DE50212604T patent/DE50212604D1/en not_active Expired - Fee Related
- 2002-07-18 AU AU2002321236A patent/AU2002321236B2/en not_active Ceased
- 2002-07-18 CN CNA028145704A patent/CN1533286A/en active Pending
- 2002-07-19 AR ARP020102719A patent/AR036183A1/en unknown
- 2002-07-19 US US10/198,046 patent/US7164016B2/en not_active Expired - Fee Related
- 2002-07-19 PE PE2002000642A patent/PE20030322A1/en not_active Application Discontinuation
-
2004
- 2004-01-19 NO NO20040238A patent/NO20040238L/en not_active Application Discontinuation
-
2006
- 2006-03-28 US US11/390,472 patent/US20070009442A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739323A (en) * | 1992-04-24 | 1998-04-14 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
US6019959A (en) * | 1997-07-31 | 2000-02-01 | Schering Aktiengesellschaft | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis |
US7164016B2 (en) * | 2001-07-20 | 2007-01-16 | Schering Ag | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193384A1 (en) * | 2005-04-26 | 2008-08-14 | Koninklijke Philips Electronics, N.V. | Responsive Mri Contrast Agents |
US8734761B2 (en) | 2005-04-26 | 2014-05-27 | Koninklijke Philips N.V. | Responsive MRI contrast agents |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
US11191854B2 (en) | 2017-05-05 | 2021-12-07 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
US11433148B2 (en) | 2017-05-05 | 2022-09-06 | Centre For Probe Development And Commercialization | IGF-1R monoclonal antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
RU2004105261A (en) | 2005-07-10 |
DE50212604D1 (en) | 2008-09-18 |
EP1409024A1 (en) | 2004-04-21 |
DE10135356C1 (en) | 2003-04-17 |
AU2002321236B2 (en) | 2006-11-02 |
RU2305096C2 (en) | 2007-08-27 |
MXPA04000401A (en) | 2004-03-18 |
UY27390A1 (en) | 2003-02-28 |
US7164016B2 (en) | 2007-01-16 |
US20030108486A1 (en) | 2003-06-12 |
BR0211273A (en) | 2004-08-03 |
PE20030322A1 (en) | 2003-04-13 |
CN1533286A (en) | 2004-09-29 |
ATE403442T1 (en) | 2008-08-15 |
KR20040030826A (en) | 2004-04-09 |
IL159290A0 (en) | 2004-06-01 |
NO20040238L (en) | 2004-01-19 |
WO2003009874A1 (en) | 2003-02-06 |
EP1409024B1 (en) | 2008-08-06 |
JP2005504745A (en) | 2005-02-17 |
AR036183A1 (en) | 2004-08-18 |
PL366426A1 (en) | 2005-01-24 |
CA2453106A1 (en) | 2003-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070009442A1 (en) | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | |
US20070014725A1 (en) | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | |
US6177060B1 (en) | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | |
JP3701678B2 (en) | Cascade polymer complex, process for producing the same, and medicament containing the same | |
US8961927B2 (en) | Agents for magnetic imaging method | |
BR112012001260B1 (en) | Epsilon-polylysine conjugates, their use, macromolecule conjugate, and kit | |
JP2001518471A (en) | Contrast agents for infarction and necrosis imaging | |
US6019959A (en) | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis | |
US20060292079A1 (en) | Conjugates of hydroxypyridinone derivative metal complexes with biomolecules and their use for MRI diagnosis | |
US20030194371A1 (en) | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | |
JP4878119B2 (en) | Enantiomerically pure (4S, 8S)-and (4R, 8R) -4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N, 6N, 9N-tricarboxymethyl-1,11-undecane Diacids and their derivatives, processes for their production and their use for the production of pharmaceuticals | |
US20120064002A1 (en) | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | |
US20040258620A1 (en) | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | |
JP5162081B2 (en) | Enantiomerically pure (4S, 8S)-and (4R, 8R) -4-p-benzyl-8-methyl-3,6,9-triaza-3N, 6N, 9N-tricarboxymethyl-1,11-undecane Conjugates of acids and biomolecules, methods for producing salts thereof and their use for the production of pharmaceuticals | |
US20070003484A1 (en) | Hydroxypyridinone derivatives, metal complexes thereof and the use thereof for preparing conjugates with biomolecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCHERING AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLATZEK, JOHANNES;SCHMITT-WILLICH, HERIBERT;MICHL, GUNTHER;AND OTHERS;REEL/FRAME:018321/0287;SIGNING DATES FROM 20060709 TO 20060827 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |